P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
3.692e-08 | -17.11 | nervous system development | biological process | GO:0007399 | 2185 | 21 | 18204 | 48 |
LSAMP,SLC1A2,MEIS2,PARD3,MSI2,RORA,NTM,TNIK,ATP1A2,RFX4,NFIA,GPM6A,SOX5,SLC1A3,PCDH9,CAMK2G,BMPR1B,LRIG1,CTNND2,CTNNA2,NRXN1 |
4.239e-07 | -14.67 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 18 | 16828 | 48 |
CTNND2,LSAMP,GPC5,CAMK2G,PCDH9,PARD3,ATP13A4,SFXN5,SLC1A3,TNIK,GPM6A,FGFR3,PARD3B,SOX5,RYR3,ACSS1,DTNA,MEIS2 |
5.049e-07 | -14.50 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 15 | 16828 | 48 |
FGFR3,NPAS3,RYR3,SOX5,SLC1A2,TNIK,NKAIN3,COL5A3,FBXL7,CAMK2G,NFIA,LSAMP,BMPR1B,PARD3,ATP1A2 |
5.049e-07 | -14.50 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 15 | 16828 | 48 |
BMPR1B,PARD3,ATP1A2,FBXL7,COL5A3,CAMK2G,NFIA,LSAMP,NKAIN3,FGFR3,NPAS3,SLC1A2,RYR3,SOX5,TNIK |
5.483e-07 | -14.42 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 42 | 16828 | 48 |
SLC25A18,CTNND2,ZNRF3,GPC5,FBXL7,COL5A3,NHSL1,BMPR1B,PARD3,LRIG1,NTM,RORA,HIF3A,GPM6A,FGFR3,RFX4,SOX5,SLC4A4,MEIS2,NKAIN3,NFIA,GLIS3,PITPNC1,LSAMP,CDH20,MSI2,ZBTB20,PCDH9,SORBS1,NRXN1,ATP13A4,SFXN5,SPARCL1,TNIK,SLC1A3,NPAS3,PARD3B,SLC1A2,RYR3,AHCYL2,ABLIM1,DTNA |
2.102e-06 | -13.07 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 10 | 16828 | 48 |
NKAIN3,SFXN5,PCDH9,AHCYL2,RYR3,SOX5,GPC5,LSAMP,GPM6A,CTNND2 |
2.238e-06 | -13.01 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 19 | 16828 | 48 |
PCDH9,NHSL1,ATP13A4,LRIG1,PARD3,BMPR1B,LSAMP,CTNND2,GPC5,FBXL7,AHCYL2,NKAIN3,GPM6A,SLC1A3,SLC1A2,RFX4,RYR3,SOX5,NPAS3 |
2.238e-06 | -13.01 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 19 | 16828 | 48 |
LSAMP,CTNND2,FBXL7,GPC5,PCDH9,NHSL1,LRIG1,ATP13A4,PARD3,BMPR1B,SLC1A3,GPM6A,SOX5,RYR3,RFX4,SLC1A2,NPAS3,AHCYL2,NKAIN3 |
2.248e-06 | -13.01 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 48 |
RYR3,SLC1A2,SLC1A3,TNIK,ZBTB20,LSAMP,GLIS3,NFIA,ATP13A4,NRXN1,PCDH9,SOX5,GPM6A,HIF3A,RORA,NTM,NKAIN3,MEIS2,SLC4A4,COL5A3,GPC5,FBXL7,CTNND2,PARD3,BMPR1B,PAMR1 |
2.248e-06 | -13.01 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 26 | 16828 | 48 |
RYR3,SLC1A2,SLC1A3,TNIK,ZBTB20,NFIA,LSAMP,GLIS3,ATP13A4,PCDH9,NRXN1,SOX5,RORA,HIF3A,NTM,GPM6A,SLC4A4,NKAIN3,MEIS2,COL5A3,FBXL7,GPC5,CTNND2,BMPR1B,PARD3,PAMR1 |
2.797e-06 | -12.79 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 3 | 18204 | 48 |
SLC25A18,SLC1A2,SLC1A3 |
3.052e-06 | -12.70 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 23 | 16828 | 48 |
PARD3,GPC5,FBXL7,ZNRF3,CTNND2,NKAIN3,MEIS2,SOX5,FGFR3,GPM6A,RORA,ATP13A4,SFXN5,PCDH9,ZBTB20,LSAMP,CDH20,AHCYL2,RYR3,SLC1A2,NPAS3,SLC1A3,TNIK |
3.778e-06 | -12.49 | multicellular organism development | biological process | GO:0007275 | 3957 | 25 | 18204 | 48 |
SLC1A3,NFIA,NRXN1,CTNNA2,CAMK2G,LRIG1,BMPR1B,PARD3,LSAMP,MEIS2,FGFR3,RFX4,ATP1A2,HIF3A,MSI2,TNIK,GPM6A,SOX5,CTNND2,PCDH9,ZNRF3,SLC1A2,CDH20,RORA,NTM |
4.189e-06 | -12.38 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 47 | 16828 | 48 |
SLC1A2,RYR3,PARD3B,ACSS1,AHCYL2,LSAMP,PITPNC1,NFIA,SORBS1,PRODH,SFXN5,SPARCL1,GPM6A,SOX5,RFX4,MEIS2,NKAIN3,SLC4A4,ZNRF3,SLC25A18,CTNND2,CAMK2G,LRIG1,ATP1A2,BMPR1B,TNIK,SLC1A3,NPAS3,ABLIM1,DTNA,GLIS3,CDH20,MSI2,ZBTB20,NRXN1,PCDH9,ATP13A4,NTM,HIF3A,RORA,FGFR3,FBXL7,GPC5,COL5A3,PAMR1,NHSL1,PARD3 |
4.251e-06 | -12.37 | cell adhesion | biological process | GO:0007155 | 942 | 12 | 18204 | 48 |
PCDH9,NTM,SORBS1,CDH20,CTNNA2,CTNND2,NRXN1,LSAMP,COL5A3,PARD3,PARD3B,SPARCL1 |
5.860e-06 | -12.05 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 3 | 18094 | 47 |
SLC1A3,SLC25A18,SLC1A2 |
5.917e-06 | -12.04 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 48 |
NFIA,GLIS3,PITPNC1,LSAMP,ZBTB20,SORBS1,PCDH9,NRXN1,ATP13A4,SFXN5,TNIK,SLC1A3,PARD3B,NPAS3,SLC1A2,RYR3,AHCYL2,ACSS1,ABLIM1,CTNND2,GPC5,FBXL7,COL5A3,NHSL1,PAMR1,PARD3,LRIG1,NTM,RORA,GPM6A,FGFR3,SOX5,RFX4,SLC4A4,MEIS2,NKAIN3 |
6.757e-06 | -11.90 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 9 | 16828 | 48 |
LSAMP,GPM6A,CTNND2,RYR3,GPC5,PCDH9,MEIS2,ATP13A4,SFXN5 |
6.857e-06 | -11.89 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 2 | 18521 | 49 |
PARD3B,PARD3 |
7.290e-06 | -11.83 | adherens junction | cellular component | GO:0005912 | 188 | 6 | 19108 | 48 |
CTNND2,CTNNA2,CDH20,SORBS1,PARD3,PARD3B |
7.428e-06 | -11.81 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 2 | 17795 | 49 |
PARD3B,PARD3 |
7.580e-06 | -11.79 | system development | biological process | GO:0048731 | 3533 | 23 | 18204 | 48 |
NFIA,SLC1A3,CTNNA2,NRXN1,CAMK2G,LRIG1,BMPR1B,PARD3,LSAMP,MEIS2,HIF3A,ATP1A2,FGFR3,RFX4,MSI2,TNIK,GPM6A,SOX5,CTNND2,PCDH9,SLC1A2,NTM,RORA |
7.613e-06 | -11.79 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 11 | 16828 | 48 |
LSAMP,COL5A3,GPC5,FBXL7,PCDH9,ATP1A2,PARD3,SOX5,RYR3,SLC1A2,NKAIN3 |
7.671e-06 | -11.78 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 20 | 16828 | 48 |
RORA,TNIK,GPM6A,SLC1A3,SOX5,RYR3,AHCYL2,MEIS2,NKAIN3,CTNND2,CDH20,LSAMP,ZNRF3,GPC5,FBXL7,ZBTB20,PCDH9,PARD3,ATP13A4,SFXN5 |
8.945e-06 | -11.62 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 35 | 16828 | 48 |
TNIK,PARD3B,RYR3,SLC1A2,ABLIM1,ACSS1,DTNA,PITPNC1,CDH20,LSAMP,ZBTB20,NRXN1,PCDH9,SORBS1,ATP13A4,SFXN5,HIF3A,RORA,NTM,GPM6A,FGFR3,RFX4,SOX5,SLC4A4,CTNND2,SLC25A18,ZNRF3,GPC5,FBXL7,CAMK2G,NHSL1,PAMR1,PARD3,LRIG1,ATP1A2 |
9.792e-06 | -11.53 | cell morphogenesis | biological process | GO:0000902 | 687 | 10 | 18204 | 48 |
CDH20,BMPR1B,TNIK,NRXN1,CTNND2,CTNNA2,GPM6A,SLC1A3,NFIA,PARD3 |
1.209e-05 | -11.32 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 21 | 16828 | 48 |
FBXL7,GPC5,CTNND2,ZNRF3,LSAMP,PARD3,LRIG1,ATP13A4,SFXN5,PRODH,PCDH9,PARD3B,SOX5,RYR3,RFX4,SLC1A2,HIF3A,SLC1A3,GPM6A,NKAIN3,MEIS2 |
1.285e-05 | -11.26 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 5 | 10285 | 30 |
SLC1A2,AHCYL2,SLC4A4,SLC1A3,SLC25A18 |
1.304e-05 | -11.25 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 3 | 18094 | 47 |
SLC25A18,SLC1A2,SLC1A3 |
1.506e-05 | -11.10 | cell junction | cellular component | GO:0030054 | 2224 | 17 | 19108 | 48 |
SLC1A3,CTNND2,GPM6A,SORBS1,NRXN1,CTNNA2,SLC1A2,ATP1A2,CDH20,PARD3,DTNA,FGFR3,TNIK,NFIA,SPARCL1,PARD3B,PCDH9 |
1.557e-05 | -11.07 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 12 | 19454 | 49 |
MSI2,SPARCL1,ABLIM1,SLC1A3,LSAMP,GPM6A,SORBS1,SLC4A4,CAMK2G,AHCYL2,ATP1A2,NHSL1 |
1.589e-05 | -11.05 | anatomical structure development | biological process | GO:0048856 | 5207 | 28 | 18204 | 48 |
CAMK2G,BMPR1B,LRIG1,CTNNA2,NRXN1,COL5A3,NFIA,SLC1A3,MSI2,TNIK,ATP1A2,HIF3A,FGFR3,RFX4,LSAMP,MEIS2,PARD3,PCDH9,CTNND2,SPARCL1,ABLIM1,GPM6A,SOX5,CDH20,NTM,RORA,ZNRF3,SLC1A2 |
1.601e-05 | -11.04 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 7 | 19454 | 49 |
DTNA,SORBS1,CTNNA2,NHSL1,ABLIM1,TNIK,PARD3 |
1.840e-05 | -10.90 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 11 | 19454 | 49 |
SLC1A2,CTNNA2,ATP1A2,ABLIM1,SORBS1,LSAMP,GPM6A,SLC1A3,CTNND2,TNIK,NTM |
1.901e-05 | -10.87 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 3 | 18204 | 48 |
SLC1A3,SLC1A2,SLC25A18 |
2.528e-05 | -10.59 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 20 | 16828 | 48 |
PARD3,SFXN5,LRIG1,PCDH9,PRODH,FBXL7,GPC5,CTNND2,ZNRF3,LSAMP,MEIS2,NKAIN3,PARD3B,SLC1A2,RFX4,RYR3,SOX5,HIF3A,GPM6A,SLC1A3 |
2.865e-05 | -10.46 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 17 | 18204 | 48 |
LRIG1,BMPR1B,NRXN1,CTNND2,CTNNA2,GPM6A,SOX5,SLC1A3,NFIA,ABLIM1,CDH20,TNIK,RORA,FGFR3,HIF3A,MEIS2,PARD3 |
3.134e-05 | -10.37 | developmental process | biological process | GO:0032502 | 5716 | 29 | 18204 | 48 |
ZNRF3,SLC1A2,CDH20,NTM,RORA,ABLIM1,SPARCL1,SOX5,GPM6A,CTNND2,NHSL1,PCDH9,PARD3,LSAMP,MEIS2,HIF3A,ATP1A2,FGFR3,RFX4,MSI2,TNIK,NFIA,SLC1A3,COL5A3,CTNNA2,NRXN1,CAMK2G,LRIG1,BMPR1B |
3.401e-05 | -10.29 | generation of neurons | biological process | GO:0048699 | 1158 | 12 | 18204 | 48 |
PARD3,NFIA,SLC1A3,GPM6A,SOX5,CTNNA2,CTNND2,NRXN1,TNIK,NTM,BMPR1B,RORA |
3.748e-05 | -10.19 | cell-cell junction | cellular component | GO:0005911 | 513 | 8 | 19108 | 48 |
PARD3B,PCDH9,CDH20,ATP1A2,CTNNA2,PARD3,SORBS1,CTNND2 |
3.799e-05 | -10.18 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
4.287e-05 | -10.06 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
4.787e-05 | -9.95 | multicellular organismal process | biological process | GO:0032501 | 6177 | 30 | 18204 | 48 |
TNIK,MSI2,HIF3A,ATP1A2,RFX4,FGFR3,RYR3,MEIS2,LSAMP,PARD3,LRIG1,BMPR1B,CAMK2G,CTNNA2,NRXN1,NFIA,SLC1A3,NTM,RORA,SLC4A4,CDH20,DTNA,SLC1A2,ZNRF3,PTGDS,PCDH9,CTNND2,ABLIM1,SOX5,GPM6A |
4.917e-05 | -9.92 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
4.917e-05 | -9.92 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
5.048e-05 | -9.89 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 10 | 16828 | 48 |
ABLIM1,PCDH9,NRXN1,MEIS2,PARD3,CTNND2,RYR3,PARD3B,NPAS3,GPC5 |
5.724e-05 | -9.77 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC25A18 |
5.769e-05 | -9.76 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 16 | 16828 | 48 |
PCDH9,NRXN1,BMPR1B,ZNRF3,COL5A3,ZBTB20,AHCYL2,SLC4A4,RORA,GPM6A,TNIK,NPAS3,PARD3B,FGFR3,RYR3,SOX5 |
5.842e-05 | -9.75 | larynx | COSMIC cancer mutations | larynx | 1948 | 16 | 16828 | 48 |
AHCYL2,SLC4A4,GPM6A,TNIK,RORA,SOX5,RYR3,PARD3B,FGFR3,NPAS3,PCDH9,NRXN1,BMPR1B,ZNRF3,COL5A3,ZBTB20 |
5.891e-05 | -9.74 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 48 |
COL5A3,GPC5,FBXL7,LSAMP,CTNND2,PARD3,PCDH9,RYR3,SOX5,SLC1A3,RORA,NKAIN3,MEIS2,ACSS1 |
5.891e-05 | -9.74 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 14 | 16828 | 48 |
SLC1A3,RORA,RYR3,SOX5,ACSS1,MEIS2,NKAIN3,LSAMP,CTNND2,FBXL7,GPC5,COL5A3,PCDH9,PARD3 |
6.518e-05 | -9.64 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 25 | 16828 | 48 |
TNIK,RYR3,PARD3B,ACSS1,CDH20,NFIA,ZBTB20,PRODH,PCDH9,SORBS1,ATP13A4,GPM6A,HIF3A,NTM,SOX5,RFX4,FGFR3,SLC4A4,CTNND2,COL5A3,FBXL7,PTGDS,NHSL1,LRIG1,PARD3 |
6.571e-05 | -9.63 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
6.571e-05 | -9.63 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
6.644e-05 | -9.62 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 3 | 18204 | 48 |
SLC1A3,ATP1A2,SLC1A2 |
6.644e-05 | -9.62 | L-glutamate import | biological process | GO:0051938 | 30 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
6.774e-05 | -9.60 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
6.774e-05 | -9.60 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
6.801e-05 | -9.60 | cell junction organization | biological process | GO:0034330 | 532 | 8 | 18204 | 48 |
SORBS1,CDH20,NRXN1,CTNND2,GPM6A,PARD3,SPARCL1,NFIA |
7.279e-05 | -9.53 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 6 | 18094 | 47 |
ATP13A4,SLC1A3,SLC25A18,SLC1A2,ATP1A2,SLC4A4 |
7.360e-05 | -9.52 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 42 | 16828 | 48 |
ZBTB20,LSAMP,PITPNC1,CDH20,GLIS3,NFIA,ATP13A4,SFXN5,PRODH,NRXN1,PCDH9,SORBS1,RYR3,SLC1A2,NPAS3,PARD3B,SLC1A3,TNIK,DTNA,ABLIM1,AHCYL2,COL5A3,FBXL7,GPC5,ZNRF3,CTNND2,SLC25A18,LRIG1,ATP1A2,PARD3,BMPR1B,PAMR1,SOX5,RFX4,FGFR3,GPM6A,RORA,HIF3A,NTM,NKAIN3,MEIS2,SLC4A4 |
7.360e-05 | -9.52 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 42 | 16828 | 48 |
TNIK,SLC1A3,NPAS3,PARD3B,SLC1A2,RYR3,AHCYL2,ABLIM1,DTNA,NFIA,GLIS3,LSAMP,CDH20,PITPNC1,ZBTB20,SORBS1,NRXN1,PCDH9,PRODH,ATP13A4,SFXN5,NTM,RORA,HIF3A,GPM6A,FGFR3,RFX4,SOX5,SLC4A4,MEIS2,NKAIN3,SLC25A18,CTNND2,ZNRF3,GPC5,FBXL7,COL5A3,PAMR1,BMPR1B,PARD3,ATP1A2,LRIG1 |
7.526e-05 | -9.49 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 19 | 16828 | 48 |
ATP13A4,SFXN5,ATP1A2,NHSL1,SORBS1,PCDH9,PRODH,GPC5,CTNND2,NFIA,PITPNC1,DTNA,SLC4A4,PARD3B,NPAS3,FGFR3,SLC1A2,RFX4,RYR3 |
7.709e-05 | -9.47 | vascular transport | biological process | GO:0010232 | 86 | 4 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2,SLC4A4 |
7.709e-05 | -9.47 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 4 | 18204 | 48 |
SLC1A2,SLC4A4,ATP1A2,SLC1A3 |
7.769e-05 | -9.46 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 49 |
GPM6A,LSAMP,NTM |
8.151e-05 | -9.41 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 9 | 16828 | 48 |
ABLIM1,NRXN1,PCDH9,PARD3,MEIS2,CTNND2,PARD3B,NPAS3,RYR3 |
8.239e-05 | -9.40 | neuron projection | cellular component | GO:0043005 | 1331 | 12 | 19108 | 48 |
CTNNA2,AHCYL2,ATP1A2,CAMK2G,SLC1A2,SLC1A3,GPM6A,CTNND2,PCDH9,DTNA,PARD3,BMPR1B |
8.247e-05 | -9.40 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 9 | 16828 | 48 |
MEIS2,PARD3,ABLIM1,PCDH9,NRXN1,RYR3,NPAS3,PARD3B,CTNND2 |
8.880e-05 | -9.33 | response to auditory stimulus | biological process | GO:0010996 | 33 | 3 | 18204 | 48 |
ATP1A2,NRXN1,SLC1A3 |
8.970e-05 | -9.32 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 9 | 10285 | 30 |
ATP13A4,SLC1A2,RYR3,SLC25A18,ATP1A2,AHCYL2,CAMK2G,SLC4A4,SLC1A3 |
9.104e-05 | -9.30 | neuron differentiation | biological process | GO:0030182 | 1081 | 11 | 18204 | 48 |
BMPR1B,CTNNA2,CTNND2,NRXN1,NFIA,SLC1A3,GPM6A,NTM,RORA,TNIK,PARD3 |
1.014e-04 | -9.20 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
1.014e-04 | -9.20 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
1.101e-04 | -9.11 | cell periphery | cellular component | GO:0071944 | 6020 | 28 | 19108 | 48 |
SLC4A4,PARD3,DTNA,LRIG1,TNIK,SPARCL1,PCDH9,SLC1A3,CTNND2,NRXN1,ZNRF3,NKAIN3,FGFR3,BMPR1B,PARD3B,RYR3,GPC5,HIF3A,SORBS1,GPM6A,NTM,CDH20,ATP1A2,SLC1A2,COL5A3,ATP13A4,CTNNA2,LSAMP |
1.162e-04 | -9.06 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 9 | 18094 | 47 |
ATP13A4,SLC25A18,ATP1A2,RYR3,GPM6A,SFXN5,SLC1A2,SLC1A3,SLC4A4 |
1.336e-04 | -8.92 | neurogenesis | biological process | GO:0022008 | 1334 | 12 | 18204 | 48 |
PARD3,RORA,TNIK,NTM,NFIA,SLC1A3,GPM6A,SOX5,CTNNA2,CTNND2,NRXN1,BMPR1B |
1.402e-04 | -8.87 | humerus | COSMIC cancer mutations | humerus | 546 | 8 | 16828 | 48 |
GPM6A,HIF3A,SOX5,PARD3B,GPC5,AHCYL2,NKAIN3,SFXN5 |
1.428e-04 | -8.85 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 49 |
SLC1A2,SLC1A3 |
1.428e-04 | -8.85 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 49 |
SLC1A2,SLC1A3 |
1.428e-04 | -8.85 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 49 |
SLC1A3,SLC1A2 |
1.471e-04 | -8.82 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 48 |
SLC1A2,SLC1A3,RYR3 |
1.477e-04 | -8.82 | TIAM1 (TIAM Rac1 associated GEF 1) | protein interactions | 7074 | 201 | 5 | 19454 | 49 |
RYR3,PARD3,CAMK2G,ATP1A2,DTNA |
1.546e-04 | -8.77 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 49 |
SLC1A2,SLC1A3 |
1.695e-04 | -8.68 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 47 |
RORA,CTNNA2,CDH20,CTNND2 |
1.729e-04 | -8.66 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 48 |
NKAIN3,CTNND2,LSAMP,GPM6A |
1.794e-04 | -8.63 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 43 |
SLC1A2,SLC1A3 |
1.955e-04 | -8.54 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 8 | 18094 | 47 |
SLC4A4,GPM6A,SLC1A2,SLC1A3,ATP1A2,RYR3,ATP13A4,SLC25A18 |
2.018e-04 | -8.51 | mouth | COSMIC cancer mutations | mouth | 9004 | 38 | 16828 | 48 |
DTNA,ACSS1,ABLIM1,SLC1A2,RYR3,NPAS3,PARD3B,TNIK,SLC1A3,SFXN5,ATP13A4,PCDH9,SORBS1,NRXN1,ZBTB20,LSAMP,PITPNC1,CDH20,SLC4A4,SOX5,RFX4,FGFR3,GPM6A,NTM,RORA,HIF3A,LRIG1,ATP1A2,PARD3,PAMR1,NHSL1,CAMK2G,GPC5,FBXL7,COL5A3,ZNRF3,SLC25A18,CTNND2 |
2.033e-04 | -8.50 | bone-humerus-other-chondroblastoma | COSMIC cancer mutations | bone-humerus-other-chondroblastoma | 301 | 6 | 16828 | 48 |
SOX5,GPC5,GPM6A,NKAIN3,SFXN5,AHCYL2 |
2.175e-04 | -8.43 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 9 | 18204 | 48 |
SFXN5,SLC4A4,ATP1A2,ATP13A4,RYR3,SLC1A2,SLC25A18,SLC1A3,GPM6A |
2.204e-04 | -8.42 | plasma membrane | cellular component | GO:0005886 | 5538 | 26 | 19108 | 48 |
SORBS1,GPM6A,ATP1A2,NTM,CDH20,ATP13A4,SLC1A2,LSAMP,CTNNA2,NKAIN3,FGFR3,BMPR1B,PARD3B,RYR3,HIF3A,GPC5,SLC1A3,CTNND2,NRXN1,ZNRF3,SLC4A4,PARD3,DTNA,LRIG1,TNIK,PCDH9 |
2.212e-04 | -8.42 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 49 |
NTM,LSAMP |
2.212e-04 | -8.42 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 49 |
NTM,LSAMP |
2.259e-04 | -8.40 | acidic amino acid transport | biological process | GO:0015800 | 45 | 3 | 18204 | 48 |
SLC1A3,SLC1A2,SLC25A18 |
2.267e-04 | -8.39 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 23 | 16828 | 48 |
GPM6A,HIF3A,RFX4,FGFR3,SLC4A4,ZNRF3,CTNND2,CAMK2G,COL5A3,FBXL7,NHSL1,ATP1A2,PARD3,TNIK,RYR3,SLC1A2,PARD3B,NPAS3,ACSS1,PITPNC1,GLIS3,NFIA,PCDH9 |
2.329e-04 | -8.37 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 18 |
SLC1A3,SLC1A2 |
2.390e-04 | -8.34 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 4 | 18094 | 47 |
SLC4A4,SLC1A3,SLC25A18,SLC1A2 |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 43 |
SLC1A2,SLC1A3 |
2.526e-04 | -8.28 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 43 |
SLC1A2,SLC1A3 |
2.642e-04 | -8.24 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 7 | 18204 | 48 |
GPM6A,PARD3,BMPR1B,TNIK,NRXN1,CTNNA2,CTNND2 |
2.647e-04 | -8.24 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 16 | 16828 | 48 |
FBXL7,GPC5,COL5A3,CTNND2,LSAMP,CDH20,PARD3,PCDH9,FGFR3,SLC1A2,SOX5,RYR3,GPM6A,SLC1A3,MEIS2,NKAIN3 |
2.812e-04 | -8.18 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 7 | 18204 | 48 |
GPM6A,PARD3,NRXN1,CTNND2,CTNNA2,BMPR1B,TNIK |
2.990e-04 | -8.12 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 7 | 18204 | 48 |
NRXN1,CTNND2,CTNNA2,BMPR1B,TNIK,GPM6A,PARD3 |
3.023e-04 | -8.10 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 2 | 18204 | 48 |
PARD3,PARD3B |
3.023e-04 | -8.10 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
3.550e-04 | -7.94 | neuron development | biological process | GO:0048666 | 859 | 9 | 18204 | 48 |
SLC1A3,GPM6A,PARD3,NTM,BMPR1B,TNIK,NRXN1,CTNNA2,CTNND2 |
3.564e-04 | -7.94 | anchoring junction | cellular component | GO:0070161 | 902 | 9 | 19108 | 48 |
FGFR3,PARD3,SORBS1,CTNND2,PARD3B,CDH20,ATP1A2,PCDH9,CTNNA2 |
3.648e-04 | -7.92 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 2 | 10285 | 30 |
SLC4A4,AHCYL2 |
3.688e-04 | -7.91 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
3.972e-04 | -7.83 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 23 | 16828 | 48 |
RYR3,SLC1A2,SLC1A3,TNIK,DTNA,ACSS1,AHCYL2,LSAMP,CDH20,SPARCL1,ATP13A4,PCDH9,SOX5,FGFR3,GPM6A,RORA,NKAIN3,MEIS2,FBXL7,GPC5,CTNND2,ATP1A2,PARD3 |
3.975e-04 | -7.83 | NAKATPASE | prints domains | PR00121 | 9 | 2 | 5227 | 18 |
ATP13A4,ATP1A2 |
4.014e-04 | -7.82 | amino acid transport | biological process | GO:0006865 | 132 | 4 | 18204 | 48 |
SLC1A2,SLC25A18,SFXN5,SLC1A3 |
4.074e-04 | -7.81 | Ig_I-set | interpro domains | IPR013098 | 132 | 4 | 18521 | 49 |
LRIG1,FGFR3,LSAMP,NTM |
4.325e-04 | -7.75 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 21 | 16828 | 48 |
PCDH9,ATP13A4,ATP1A2,SPARCL1,PARD3,CDH20,LSAMP,CTNND2,GPC5,FBXL7,ACSS1,AHCYL2,MEIS2,NKAIN3,GPM6A,TNIK,RORA,SLC1A2,RYR3,SOX5,FGFR3 |
4.418e-04 | -7.72 | auditory behavior | biological process | GO:0031223 | 12 | 2 | 18204 | 48 |
NRXN1,SLC1A3 |
4.447e-04 | -7.72 | cell body | cellular component | GO:0044297 | 556 | 7 | 19108 | 48 |
SLC1A3,NRXN1,SLC1A2,ATP1A2,BMPR1B,GPM6A,CTNND2 |
4.456e-04 | -7.72 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 34 | 16828 | 48 |
SLC25A18,CTNND2,GPC5,FBXL7,COL5A3,CAMK2G,NHSL1,PAMR1,BMPR1B,PARD3,ATP1A2,LRIG1,RORA,GPM6A,FGFR3,SOX5,RFX4,SLC4A4,MEIS2,NKAIN3,GLIS3,CDH20,LSAMP,PCDH9,PRODH,ATP13A4,SFXN5,TNIK,SLC1A3,SLC1A2,RYR3,AHCYL2,ACSS1,ABLIM1 |
4.555e-04 | -7.69 | visual behavior | biological process | GO:0007632 | 57 | 3 | 18204 | 48 |
SLC1A2,MEIS2,ATP1A2 |
4.733e-04 | -7.66 | I-set | pfam domains | PF07679 | 132 | 4 | 17795 | 49 |
LSAMP,NTM,FGFR3,LRIG1 |
4.983e-04 | -7.60 | bone | COSMIC cancer mutations | bone | 8157 | 35 | 16828 | 48 |
PARD3,LRIG1,ATP1A2,PTGDS,PAMR1,GPC5,COL5A3,CAMK2G,CTNND2,SLC4A4,NKAIN3,FGFR3,SOX5,RORA,HIF3A,GPM6A,SFXN5,ATP13A4,SPARCL1,NRXN1,PCDH9,SORBS1,PRODH,ZBTB20,GLIS3,LSAMP,DTNA,AHCYL2,ACSS1,ABLIM1,NPAS3,PARD3B,RYR3,TNIK,SLC1A3 |
5.015e-04 | -7.60 | neurotransmitter transport | biological process | GO:0006836 | 140 | 4 | 18204 | 48 |
SLC1A2,NRXN1,SLC1A3,ATP1A2 |
5.547e-04 | -7.50 | DACT2 (dishevelled binding antagonist of beta catenin 2) | protein interactions | 168002 | 14 | 2 | 19454 | 49 |
CAMK2G,ZBTB20 |
5.593e-04 | -7.49 | Ion homeostasis | REACTOME pathways | R-HSA-5578775 | 56 | 3 | 10285 | 30 |
CAMK2G,RYR3,ATP1A2 |
5.833e-04 | -7.45 | symporter activity | molecular function | GO:0015293 | 148 | 4 | 18094 | 47 |
SLC4A4,SLC1A2,SLC25A18,SLC1A3 |
5.887e-04 | -7.44 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 22 | 16828 | 48 |
PARD3,ATP1A2,PCDH9,COL5A3,FBXL7,CAMK2G,CTNND2,NFIA,PITPNC1,ZNRF3,GLIS3,SLC4A4,ACSS1,PARD3B,FGFR3,NPAS3,RYR3,RFX4,SLC1A2,HIF3A,TNIK,GPM6A |
5.909e-04 | -7.43 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 22 | 16828 | 48 |
ACSS1,TNIK,PARD3B,NPAS3,RYR3,SLC1A2,PCDH9,NFIA,PITPNC1,GLIS3,SLC4A4,HIF3A,GPM6A,FGFR3,RFX4,PARD3,ATP1A2,CTNND2,ZNRF3,COL5A3,FBXL7,CAMK2G |
6.069e-04 | -7.41 | Ig_3 | pfam domains | PF13927 | 141 | 4 | 17795 | 49 |
LRIG1,FGFR3,NTM,LSAMP |
6.071e-04 | -7.41 | mechanosensory behavior | biological process | GO:0007638 | 14 | 2 | 18204 | 48 |
NRXN1,SLC1A3 |
6.071e-04 | -7.41 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 2 | 18204 | 48 |
SLC4A4,ATP1A2 |
6.202e-04 | -7.39 | Ion transport by P-type ATPases | REACTOME pathways | R-HSA-936837 | 58 | 3 | 10285 | 30 |
CAMK2G,ATP13A4,ATP1A2 |
6.337e-04 | -7.36 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 5 | 18094 | 47 |
SLC1A3,SLC1A2,SLC25A18,SFXN5,SLC4A4 |
6.391e-04 | -7.36 | TIAM2 (TIAM Rac1 associated GEF 2) | protein interactions | 26230 | 15 | 2 | 19454 | 49 |
PARD3,TNIK |
6.702e-04 | -7.31 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 3 | 18094 | 47 |
SLC25A18,SLC1A2,SLC1A3 |
7.006e-04 | -7.26 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
7.454e-04 | -7.20 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 4 | 18094 | 47 |
SLC4A4,ATP1A2,SLC1A2,SLC1A3 |
7.583e-04 | -7.18 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 7 | 18094 | 47 |
SLC25A18,SLC1A2,SLC1A3,GPM6A,RYR3,SLC4A4,ATP1A2 |
7.767e-04 | -7.16 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 2 | 26134 | 49 |
ZBTB20,LSAMP |
7.955e-04 | -7.14 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 7 | 19454 | 49 |
TNIK,PARD3,FGFR3,DTNA,AHCYL2,NHSL1,ABLIM1 |
7.979e-04 | -7.13 | asymmetric cell division | biological process | GO:0008356 | 16 | 2 | 18204 | 48 |
SOX5,PARD3 |
8.042e-04 | -7.13 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 46 | 16828 | 48 |
HIF3A,RORA,NTM,FGFR3,PAMR1,NHSL1,PARD3,COL5A3,FBXL7,GPC5,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3,PCDH9,NRXN1,ATP13A4,CDH20,GLIS3,ZBTB20,MSI2,NKAIN3,SLC4A4,GPM6A,SOX5,RFX4,PTGDS,LRIG1,ATP1A2,BMPR1B,ZNRF3,CTNND2,SLC25A18,CAMK2G,ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,PRODH,SORBS1,SFXN5,PITPNC1,LSAMP,NFIA |
8.060e-04 | -7.12 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 15 | 16828 | 48 |
PARD3,PCDH9,FBXL7,GPC5,COL5A3,CTNND2,CDH20,LSAMP,MEIS2,NKAIN3,SLC1A2,SOX5,RYR3,GPM6A,SLC1A3 |
8.060e-04 | -7.12 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 15 | 16828 | 48 |
CTNND2,CDH20,LSAMP,FBXL7,GPC5,COL5A3,PCDH9,PARD3,GPM6A,SLC1A3,SLC1A2,RYR3,SOX5,MEIS2,NKAIN3 |
8.180e-04 | -7.11 | monoatomic ion transport | biological process | GO:0006811 | 964 | 9 | 18204 | 48 |
ATP13A4,RYR3,ATP1A2,SFXN5,SLC4A4,SLC1A3,GPM6A,SLC25A18,SLC1A2 |
8.233e-04 | -7.10 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 32 | 16828 | 48 |
ATP1A2,LRIG1,BMPR1B,PARD3,PAMR1,NHSL1,COL5A3,GPC5,FBXL7,CTNND2,SLC25A18,NKAIN3,MEIS2,SLC4A4,SOX5,RFX4,FGFR3,GPM6A,RORA,SFXN5,ATP13A4,PRODH,PCDH9,CDH20,LSAMP,GLIS3,ABLIM1,ACSS1,AHCYL2,RYR3,SLC1A2,SLC1A3 |
8.536e-04 | -7.07 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 39 | 16828 | 48 |
PCDH9,SORBS1,NRXN1,PRODH,ATP13A4,SPARCL1,PITPNC1,CDH20,NFIA,MSI2,ABLIM1,AHCYL2,DTNA,TNIK,RYR3,PARD3B,NPAS3,PAMR1,ATP1A2,LRIG1,PARD3,BMPR1B,ZNRF3,SLC25A18,CTNND2,CAMK2G,FBXL7,GPC5,COL5A3,MEIS2,NKAIN3,SLC4A4,GPM6A,NTM,RORA,HIF3A,SOX5,RFX4,FGFR3 |
8.608e-04 | -7.06 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 11 | 18204 | 48 |
SOX5,SLC1A3,NFIA,BMPR1B,SORBS1,PTGDS,SLC1A2,MEIS2,FGFR3,RYR3,ATP1A2 |
8.653e-04 | -7.05 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 39 | 16828 | 48 |
SLC4A4,NKAIN3,MEIS2,HIF3A,RORA,NTM,GPM6A,FGFR3,RFX4,SOX5,PAMR1,BMPR1B,PARD3,ATP1A2,LRIG1,CTNND2,SLC25A18,ZNRF3,COL5A3,FBXL7,GPC5,CAMK2G,AHCYL2,ABLIM1,DTNA,TNIK,NPAS3,PARD3B,RYR3,PRODH,NRXN1,SORBS1,PCDH9,SPARCL1,ATP13A4,NFIA,PITPNC1,CDH20,MSI2 |
8.967e-04 | -7.02 | cell junction assembly | biological process | GO:0034329 | 285 | 5 | 18204 | 48 |
SORBS1,CDH20,PARD3,NRXN1,GPM6A |
9.218e-04 | -6.99 | transporter activity | molecular function | GO:0005215 | 1211 | 10 | 18094 | 47 |
SLC25A18,ATP13A4,RYR3,ATP1A2,SLC1A3,SLC1A2,SFXN5,GPM6A,PITPNC1,SLC4A4 |
9.267e-04 | -6.98 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 2 | 19454 | 49 |
FGFR3,PARD3 |
9.444e-04 | -6.96 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 6 | 18094 | 47 |
SLC4A4,RYR3,ATP1A2,SLC1A3,SLC1A2,GPM6A |
9.636e-04 | -6.94 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 49 |
NTM,LSAMP,GPM6A |
9.667e-04 | -6.94 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 6 | 18094 | 47 |
SLC25A18,SLC1A2,SLC1A3,ATP13A4,SLC4A4,ATP1A2 |
9.828e-04 | -6.93 | Adherens junction | KEGG pathways | hsa04520 | 72 | 3 | 7161 | 20 |
SORBS1,CTNNA2,PARD3 |
9.828e-04 | -6.93 | Adherens junction | KEGG pathways | ko04520 | 72 | 3 | 7161 | 20 |
SORBS1,CTNNA2,PARD3 |
1.000e-03 | -6.91 | ANKRD40 (ankyrin repeat domain 40) | protein interactions | 91369 | 78 | 3 | 19454 | 49 |
SOX5,SLC25A18,MSI2 |
1.021e-03 | -6.89 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
1.024e-03 | -6.88 | central nervous system development | biological process | GO:0007417 | 995 | 9 | 18204 | 48 |
MEIS2,SLC1A2,PCDH9,MSI2,BMPR1B,RORA,ATP1A2,CTNNA2,RFX4 |
1.037e-03 | -6.87 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 6 | 18204 | 48 |
BMPR1B,NRXN1,CTNND2,CTNNA2,SLC1A3,PARD3 |
1.068e-03 | -6.84 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 5 | 19454 | 49 |
ABLIM1,TNIK,DTNA,AHCYL2,PARD3 |
1.085e-03 | -6.83 | EPHA4 (EPH receptor A4) | protein interactions | 2043 | 180 | 4 | 19454 | 49 |
FGFR3,CTNNA2,PARD3,AHCYL2 |
1.091e-03 | -6.82 | plasma membrane region | cellular component | GO:0098590 | 1278 | 10 | 19108 | 48 |
SORBS1,GPM6A,TNIK,SLC1A3,SLC4A4,PARD3,SLC1A2,ATP1A2,PARD3B,NRXN1 |
1.105e-03 | -6.81 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
1.107e-03 | -6.81 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 48 |
BMPR1B,FGFR3,SOX5,NFIA |
1.131e-03 | -6.78 | cartilage condensation | biological process | GO:0001502 | 19 | 2 | 18204 | 48 |
SOX5,BMPR1B |
1.139e-03 | -6.78 | PAS_fold | interpro domains | IPR013767 | 19 | 2 | 18521 | 49 |
HIF3A,NPAS3 |
1.139e-03 | -6.78 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 3 | 18204 | 48 |
ZBTB20,SLC4A4,SORBS1 |
1.139e-03 | -6.78 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
1.147e-03 | -6.77 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 49 |
NRXN1,CTNND2 |
1.160e-03 | -6.76 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 27 | 16828 | 48 |
SLC1A3,NPAS3,PARD3B,RYR3,AHCYL2,DTNA,LSAMP,CDH20,SORBS1,PRODH,ATP13A4,NTM,GPM6A,SOX5,SLC4A4,MEIS2,NKAIN3,SLC25A18,CTNND2,ZNRF3,GPC5,FBXL7,COL5A3,PAMR1,PARD3,ATP1A2,LRIG1 |
1.160e-03 | -6.76 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 27 | 16828 | 48 |
SLC1A3,RYR3,PARD3B,NPAS3,AHCYL2,DTNA,LSAMP,CDH20,SORBS1,PRODH,ATP13A4,GPM6A,NTM,SOX5,MEIS2,NKAIN3,SLC4A4,ZNRF3,SLC25A18,CTNND2,GPC5,FBXL7,COL5A3,PAMR1,ATP1A2,LRIG1,PARD3 |
1.173e-03 | -6.75 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 47 |
SLC1A3,SLC1A2,SLC4A4 |
1.203e-03 | -6.72 | Axon guidance | KEGG pathways | hsa04360 | 174 | 4 | 7161 | 20 |
ABLIM1,CAMK2G,PARD3,BMPR1B |
1.203e-03 | -6.72 | Axon guidance | KEGG pathways | ko04360 | 174 | 4 | 7161 | 20 |
ABLIM1,BMPR1B,PARD3,CAMK2G |
1.224e-03 | -6.71 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 43 | 16828 | 48 |
NPAS3,PARD3B,SLC1A2,RYR3,TNIK,SLC1A3,DTNA,ACSS1,ABLIM1,ZBTB20,NFIA,GLIS3,CDH20,LSAMP,PITPNC1,ATP13A4,SFXN5,SPARCL1,NRXN1,SORBS1,PCDH9,PRODH,FGFR3,SOX5,RFX4,NTM,RORA,HIF3A,GPM6A,SLC4A4,MEIS2,FBXL7,GPC5,COL5A3,SLC25A18,CTNND2,ZNRF3,BMPR1B,PARD3,LRIG1,ATP1A2,NHSL1,PAMR1 |
1.233e-03 | -6.70 | PAS | pfam domains | PF00989 | 19 | 2 | 17795 | 49 |
NPAS3,HIF3A |
1.238e-03 | -6.69 | cervix | COSMIC cancer mutations | cervix | 11793 | 43 | 16828 | 48 |
FBXL7,GPC5,COL5A3,PAMR1,NHSL1,PARD3,NTM,RORA,HIF3A,FGFR3,GLIS3,CDH20,ZBTB20,NRXN1,PCDH9,ATP13A4,TNIK,SLC1A3,NPAS3,ABLIM1,DTNA,ZNRF3,SLC25A18,CTNND2,ATP1A2,LRIG1,BMPR1B,GPM6A,RFX4,SOX5,MEIS2,SLC4A4,LSAMP,PITPNC1,NFIA,SORBS1,PRODH,SFXN5,SPARCL1,SLC1A2,RYR3,PARD3B,ACSS1 |
1.255e-03 | -6.68 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 48 |
BMPR1B,SOX5 |
1.302e-03 | -6.64 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 7 | 18204 | 48 |
SLC4A4,RYR3,ATP13A4,ATP1A2,SLC25A18,GPM6A,SLC1A3 |
1.313e-03 | -6.64 | SLC-mediated transmembrane transport | REACTOME pathways | R-HSA-425407 | 287 | 5 | 10285 | 30 |
SLC1A3,SLC25A18,SLC4A4,AHCYL2,SLC1A2 |
1.337e-03 | -6.62 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 48 | 16828 | 48 |
FBXL7,GPC5,COL5A3,PARD3,PAMR1,NHSL1,FGFR3,NTM,HIF3A,RORA,MSI2,ZBTB20,GLIS3,CDH20,ATP13A4,NRXN1,PCDH9,NPAS3,TNIK,SLC1A3,DTNA,ABLIM1,CAMK2G,ZNRF3,SLC25A18,CTNND2,LRIG1,ATP1A2,BMPR1B,PTGDS,RFX4,SOX5,GPM6A,MEIS2,NKAIN3,SLC4A4,PITPNC1,LSAMP,NFIA,SFXN5,SPARCL1,SORBS1,PRODH,SLC1A2,RYR3,PARD3B,ACSS1,AHCYL2 |
1.344e-03 | -6.61 | neuronal cell body | cellular component | GO:0043025 | 489 | 6 | 19108 | 48 |
GPM6A,CTNND2,BMPR1B,SLC1A3,ATP1A2,NRXN1 |
1.362e-03 | -6.60 | regulation of carbohydrate metabolic process | biological process | GO:0006109 | 183 | 4 | 18204 | 48 |
SLC4A4,RORA,SORBS1,ZBTB20 |
1.366e-03 | -6.60 | carboxylic acid transmembrane transporter activity | molecular function | GO:0046943 | 186 | 4 | 18094 | 47 |
SLC1A2,SLC25A18,SLC1A3,SFXN5 |
1.385e-03 | -6.58 | cell aggregation | biological process | GO:0098743 | 21 | 2 | 18204 | 48 |
SOX5,BMPR1B |
1.385e-03 | -6.58 | positive regulation of nucleotide catabolic process | biological process | GO:0030813 | 21 | 2 | 18204 | 48 |
SLC4A4,ZBTB20 |
1.385e-03 | -6.58 | positive regulation of glycolytic process | biological process | GO:0045821 | 21 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
1.385e-03 | -6.58 | positive regulation of purine nucleotide catabolic process | biological process | GO:0033123 | 21 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
1.393e-03 | -6.58 | organic acid transmembrane transporter activity | molecular function | GO:0005342 | 187 | 4 | 18094 | 47 |
SLC1A3,SLC25A18,SLC1A2,SFXN5 |
1.411e-03 | -6.56 | L-amino acid transport | biological process | GO:0015807 | 84 | 3 | 18204 | 48 |
SLC25A18,SLC1A2,SLC1A3 |
1.460e-03 | -6.53 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 48 |
FGFR3,SOX5,BMPR1B |
1.465e-03 | -6.53 | Cation_ATPase_N | smart domains | SM00831 | 16 | 2 | 9717 | 35 |
ATP13A4,ATP1A2 |
1.520e-03 | -6.49 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 49 |
MSI2,MEIS2 |
1.521e-03 | -6.49 | intracellular sodium ion homeostasis | biological process | GO:0006883 | 22 | 2 | 18204 | 48 |
ATP1A2,SLC1A3 |
1.614e-03 | -6.43 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
1.720e-03 | -6.37 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 4 | 19454 | 49 |
ABLIM1,NRXN1,DTNA,PARD3B |
1.724e-03 | -6.36 | scalp | COSMIC cancer mutations | scalp | 2110 | 14 | 16828 | 48 |
ATP1A2,ATP13A4,SORBS1,NRXN1,COL5A3,GPC5,CAMK2G,NFIA,LSAMP,SLC4A4,FGFR3,SOX5,RORA,NTM |
1.731e-03 | -6.36 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 29 | 16828 | 48 |
SLC4A4,MEIS2,FGFR3,SOX5,HIF3A,GPM6A,PARD3,BMPR1B,ATP1A2,GPC5,FBXL7,COL5A3,SLC25A18,CTNND2,ABLIM1,NPAS3,PARD3B,RYR3,TNIK,SFXN5,ATP13A4,SPARCL1,NRXN1,SORBS1,PCDH9,PRODH,ZBTB20,GLIS3,PITPNC1 |
1.732e-03 | -6.36 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 27 | 16828 | 48 |
SLC1A2,RYR3,PARD3B,NPAS3,SLC1A3,GLIS3,LSAMP,CDH20,NFIA,SPARCL1,PCDH9,SORBS1,SOX5,FGFR3,GPM6A,RORA,MEIS2,NKAIN3,CAMK2G,FBXL7,GPC5,COL5A3,ZNRF3,CTNND2,PARD3,PAMR1,NHSL1 |
1.742e-03 | -6.35 | cell projection | cellular component | GO:0042995 | 2398 | 14 | 19108 | 48 |
GPM6A,CTNND2,ABLIM1,SLC1A3,CTNNA2,AHCYL2,ATP1A2,CAMK2G,SLC1A2,NRXN1,BMPR1B,PARD3,DTNA,PCDH9 |
1.757e-03 | -6.34 | P-type transmembrane transporter activity | molecular function | GO:0140358 | 24 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
1.757e-03 | -6.34 | P-type ion transporter activity | molecular function | GO:0015662 | 24 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
1.786e-03 | -6.33 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 48 |
SPARCL1,NFIA,CTNND2,GPM6A,NRXN1 |
1.810e-03 | -6.31 | Proximal tubule bicarbonate reclamation | KEGG pathways | hsa04964 | 23 | 2 | 7161 | 20 |
SLC4A4,ATP1A2 |
1.810e-03 | -6.31 | Proximal tubule bicarbonate reclamation | KEGG pathways | ko04964 | 23 | 2 | 7161 | 20 |
ATP1A2,SLC4A4 |
1.863e-03 | -6.29 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 48 |
NHSL1,ATP1A2,SFXN5,ATP13A4,SLC4A4,PITPNC1,NFIA,CTNND2,RFX4,SLC1A2,FGFR3 |
1.863e-03 | -6.29 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 11 | 16828 | 48 |
NFIA,CTNND2,PITPNC1,NHSL1,SFXN5,ATP13A4,ATP1A2,FGFR3,SLC1A2,RFX4,SLC4A4 |
1.875e-03 | -6.28 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 49 |
RYR3 |
1.875e-03 | -6.28 | human chr10p11.22-p11.21 | chromosome location | human chr10p11.22-p11.21 | 1 | 1 | 26134 | 49 |
PARD3 |
1.875e-03 | -6.28 | human chr3q26.2-q26.31 | chromosome location | human chr3q26.2-q26.31 | 1 | 1 | 26134 | 49 |
TNIK |
1.931e-03 | -6.25 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 3 | 19454 | 49 |
FGFR3,PARD3,SORBS1 |
1.959e-03 | -6.24 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 9 | 18094 | 47 |
ATP13A4,SLC25A18,ATP1A2,RYR3,SFXN5,GPM6A,SLC1A2,SLC1A3,SLC4A4 |
2.028e-03 | -6.20 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 48 |
CTNNA2,CDH20,DTNA |
2.055e-03 | -6.19 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 41 | 16828 | 48 |
DTNA,AHCYL2,ABLIM1,ACSS1,PARD3B,NPAS3,RYR3,SLC1A2,SLC1A3,TNIK,SPARCL1,ATP13A4,SFXN5,PRODH,NRXN1,PCDH9,MSI2,NFIA,LSAMP,CDH20,GLIS3,SLC4A4,NKAIN3,MEIS2,FGFR3,RFX4,SOX5,RORA,HIF3A,NTM,BMPR1B,PARD3,ATP1A2,LRIG1,NHSL1,PAMR1,COL5A3,FBXL7,GPC5,CAMK2G,CTNND2 |
2.095e-03 | -6.17 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 49 |
ABLIM1,DTNA |
2.126e-03 | -6.15 | neuron projection development | biological process | GO:0031175 | 693 | 7 | 18204 | 48 |
PARD3,GPM6A,CTNNA2,CTNND2,NRXN1,BMPR1B,TNIK |
2.132e-03 | -6.15 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
2.164e-03 | -6.14 | KRTAP6-1 (keratin associated protein 6-1) | protein interactions | 337966 | 102 | 3 | 19454 | 49 |
GLIS3,CAMK2G,MEIS2 |
2.181e-03 | -6.13 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
2.227e-03 | -6.11 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 3 | 18094 | 47 |
SLC1A2,SLC25A18,SLC1A3 |
2.253e-03 | -6.10 | LRRC7 (leucine rich repeat containing 7) | protein interactions | 57554 | 28 | 2 | 19454 | 49 |
CAMK2G,CTNND2 |
2.287e-03 | -6.08 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 3 | 19454 | 49 |
SORBS1,SPARCL1,ABLIM1 |
2.299e-03 | -6.08 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 7 | 18094 | 47 |
ATP1A2,RYR3,SLC25A18,SLC4A4,GPM6A,SLC1A2,SLC1A3 |
2.312e-03 | -6.07 | tibia | COSMIC cancer mutations | tibia | 836 | 8 | 16828 | 48 |
FGFR3,CTNND2,LSAMP,TNIK,GPM6A,NKAIN3,ABLIM1,ACSS1 |
2.325e-03 | -6.06 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 48 |
SLC1A3,RYR3,SLC1A2 |
2.375e-03 | -6.04 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 19 | 16828 | 48 |
DTNA,SLC4A4,MEIS2,NPAS3,PARD3B,RYR3,TNIK,SLC1A3,BMPR1B,PARD3,PCDH9,PAMR1,GPC5,FBXL7,MSI2,CTNND2,LSAMP,PITPNC1,ZNRF3 |
2.375e-03 | -6.04 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 19 | 16828 | 48 |
BMPR1B,PARD3,PAMR1,PCDH9,GPC5,FBXL7,MSI2,CTNND2,ZNRF3,LSAMP,PITPNC1,SLC4A4,DTNA,MEIS2,PARD3B,NPAS3,RYR3,SLC1A3,TNIK |
2.416e-03 | -6.03 | INSC (INSC spindle orientation adaptor protein) | protein interactions | 387755 | 29 | 2 | 19454 | 49 |
PARD3B,PARD3 |
2.478e-03 | -6.00 | Calcium-transporting ATPase, transmembrane domain | gene3d domains | 1.20.1110.10 | 25 | 2 | 14470 | 43 |
ATP1A2,ATP13A4 |
2.519e-03 | -5.98 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 49 |
PITPNC1 |
2.519e-03 | -5.98 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 49 |
BMPR1B |
2.519e-03 | -5.98 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 49 |
BMPR1B |
2.519e-03 | -5.98 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 49 |
GLIS3 |
2.519e-03 | -5.98 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 49 |
FGFR3 |
2.519e-03 | -5.98 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 49 |
FGFR3 |
2.519e-03 | -5.98 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 49 |
BMPR1B |
2.519e-03 | -5.98 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 49 |
GLIS3 |
2.519e-03 | -5.98 | Sytl1 (synaptotagmin-like 1) | protein interactions | 269589 | 1 | 1 | 19454 | 49 |
NRXN1 |
2.548e-03 | -5.97 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 9 | 18204 | 48 |
SLC1A2,NFIA,SOX5,SLC1A3,BMPR1B,SORBS1,ATP1A2,FGFR3,RYR3 |
2.626e-03 | -5.94 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 8 | 19454 | 49 |
PARD3,PITPNC1,FGFR3,PARD3B,CAMK2G,SORBS1,NHSL1,ABLIM1 |
2.637e-03 | -5.94 | negative regulation of calcium:sodium antiporter activity | biological process | GO:1903280 | 1 | 1 | 18204 | 48 |
ATP1A2 |
2.637e-03 | -5.94 | olfactory cortex development | biological process | GO:0021989 | 1 | 1 | 18204 | 48 |
ATP1A2 |
2.646e-03 | -5.93 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 49 |
SORBS1 |
2.646e-03 | -5.93 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 49 |
SORBS1 |
2.646e-03 | -5.93 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 49 |
SPARCL1 |
2.646e-03 | -5.93 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 49 |
SORBS1 |
2.646e-03 | -5.93 | ZNRF3_Znf_RING | interpro domains | IPR045903 | 1 | 1 | 18521 | 49 |
ZNRF3 |
2.664e-03 | -5.93 | response to mechanical stimulus | biological process | GO:0009612 | 220 | 4 | 18204 | 48 |
MEIS2,SLC1A3,NRXN1,ATP1A2 |
2.671e-03 | -5.93 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 3 | 18204 | 48 |
NFIA,SOX5,RORA |
2.706e-03 | -5.91 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 21 | 16828 | 48 |
TNIK,HIF3A,SOX5,RYR3,FGFR3,ACSS1,DTNA,GLIS3,LSAMP,ZNRF3,CTNND2,NFIA,GPC5,COL5A3,NRXN1,PCDH9,ATP13A4,LRIG1,SPARCL1,ATP1A2,PARD3 |
2.719e-03 | -5.91 | brain development | biological process | GO:0007420 | 724 | 7 | 18204 | 48 |
RFX4,CTNNA2,ATP1A2,RORA,PCDH9,MEIS2,SLC1A2 |
2.743e-03 | -5.90 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 48 |
CDH20,CTNNA2 |
2.749e-03 | -5.90 | Muscle contraction | REACTOME pathways | R-HSA-397014 | 204 | 4 | 10285 | 30 |
ATP1A2,CAMK2G,SORBS1,RYR3 |
2.754e-03 | -5.89 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 49 |
FGFR3 |
2.817e-03 | -5.87 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 48 |
GPM6A,ABLIM1,PARD3,RFX4,NRXN1,CTNND2,CTNNA2,TNIK,BMPR1B |
2.917e-03 | -5.84 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 30 |
FGFR3 |
2.937e-03 | -5.83 | NXPH2 (neurexophilin 2) | protein interactions | 11249 | 32 | 2 | 19454 | 49 |
PCDH9,NRXN1 |
2.972e-03 | -5.82 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 43 |
FGFR3 |
2.983e-03 | -5.81 | cell-cell adhesion | biological process | GO:0098609 | 546 | 6 | 18204 | 48 |
CDH20,PCDH9,NRXN1,CTNNA2,CTNND2,SPARCL1 |
2.985e-03 | -5.81 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 48 |
NTM,ATP13A4,SLC4A4,COL5A3 |
3.000e-03 | -5.81 | Ion channel transport | REACTOME pathways | R-HSA-983712 | 209 | 4 | 10285 | 30 |
ATP13A4,ATP1A2,CAMK2G,RYR3 |
3.024e-03 | -5.80 | nodular | COSMIC cancer mutations | nodular | 1515 | 11 | 16828 | 48 |
SPARCL1,ATP1A2,ATP13A4,CTNND2,CDH20,GLIS3,SLC4A4,ABLIM1,NPAS3,FGFR3,HIF3A |
3.042e-03 | -5.80 | SMAD7 (SMAD family member 7) | protein interactions | 4092 | 115 | 3 | 19454 | 49 |
SOX5,PARD3,BMPR1B |
3.098e-03 | -5.78 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 49 |
PAMR1,SLC1A2 |
3.127e-03 | -5.77 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 27 | 16828 | 48 |
ZBTB20,GLIS3,CDH20,NFIA,SFXN5,ATP13A4,SPARCL1,PCDH9,NRXN1,SORBS1,PRODH,PARD3B,SLC1A3,DTNA,ACSS1,ABLIM1,CAMK2G,GPC5,COL5A3,ATP1A2,LRIG1,PARD3,RFX4,FGFR3,GPM6A,HIF3A,SLC4A4 |
3.143e-03 | -5.76 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 27 | 16828 | 48 |
ZBTB20,GLIS3,CDH20,NFIA,ATP13A4,SFXN5,SPARCL1,PCDH9,NRXN1,SORBS1,PRODH,PARD3B,SLC1A3,DTNA,ACSS1,ABLIM1,CAMK2G,GPC5,COL5A3,LRIG1,ATP1A2,PARD3,RFX4,FGFR3,GPM6A,HIF3A,SLC4A4 |
3.145e-03 | -5.76 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 47 | 16828 | 48 |
PARD3B,RYR3,SLC1A2,AHCYL2,ACSS1,NFIA,LSAMP,PITPNC1,SPARCL1,SFXN5,PRODH,SORBS1,SOX5,RFX4,GPM6A,SLC4A4,NKAIN3,MEIS2,CAMK2G,CTNND2,SLC25A18,ZNRF3,BMPR1B,ATP1A2,LRIG1,PTGDS,NPAS3,SLC1A3,TNIK,DTNA,ABLIM1,ZBTB20,CDH20,GLIS3,ATP13A4,NRXN1,PCDH9,FGFR3,HIF3A,RORA,NTM,COL5A3,FBXL7,GPC5,PARD3,NHSL1,PAMR1 |
3.175e-03 | -5.75 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 8 | 16828 | 48 |
HIF3A,NFIA,GLIS3,FGFR3,PAMR1,ACSS1,PCDH9,LRIG1 |
3.211e-03 | -5.74 | microtubule organizing center localization | biological process | GO:0061842 | 32 | 2 | 18204 | 48 |
PARD3B,PARD3 |
3.211e-03 | -5.74 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 48 |
BMPR1B,SOX5 |
3.211e-03 | -5.74 | positive regulation of ATP metabolic process | biological process | GO:1903580 | 32 | 2 | 18204 | 48 |
SLC4A4,ZBTB20 |
3.211e-03 | -5.74 | centrosome localization | biological process | GO:0051642 | 32 | 2 | 18204 | 48 |
PARD3,PARD3B |
3.211e-03 | -5.74 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
3.224e-03 | -5.74 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 48 |
NFIA,SOX5,FGFR3,BMPR1B |
3.259e-03 | -5.73 | caecum | COSMIC cancer mutations | caecum | 14248 | 47 | 16828 | 48 |
GLIS3,CDH20,ZBTB20,PCDH9,NRXN1,ATP13A4,TNIK,SLC1A3,NPAS3,ABLIM1,DTNA,GPC5,FBXL7,COL5A3,NHSL1,PAMR1,PARD3,NTM,RORA,HIF3A,FGFR3,NFIA,PITPNC1,LSAMP,SORBS1,PRODH,SFXN5,SPARCL1,PARD3B,SLC1A2,RYR3,AHCYL2,ACSS1,SLC25A18,CTNND2,ZNRF3,CAMK2G,PTGDS,BMPR1B,ATP1A2,LRIG1,GPM6A,SOX5,RFX4,SLC4A4,MEIS2,NKAIN3 |
3.282e-03 | -5.72 | E1-E2_ATPase | pfam domains | PF00122 | 31 | 2 | 17795 | 49 |
ATP1A2,ATP13A4 |
3.350e-03 | -5.70 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 13 | 19108 | 48 |
DTNA,PARD3,BMPR1B,PCDH9,SLC1A3,CTNND2,GPM6A,ABLIM1,CTNNA2,AHCYL2,ATP1A2,CAMK2G,SLC1A2 |
3.495e-03 | -5.66 | Cation_ATPase | pfam domains | PF13246 | 32 | 2 | 17795 | 49 |
ATP13A4,ATP1A2 |
3.590e-03 | -5.63 | PAS | smart domains | SM00091 | 25 | 2 | 9717 | 35 |
NPAS3,HIF3A |
3.622e-03 | -5.62 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 28 | 16828 | 48 |
ABLIM1,ACSS1,PARD3B,NPAS3,RYR3,SLC1A2,SLC1A3,SFXN5,SORBS1,ZBTB20,PITPNC1,CDH20,SLC4A4,FGFR3,SOX5,RFX4,RORA,HIF3A,NTM,GPM6A,PARD3,NHSL1,PAMR1,COL5A3,GPC5,FBXL7,CTNND2,SLC25A18 |
3.635e-03 | -5.62 | Ig_sub2 | interpro domains | IPR003598 | 239 | 4 | 18521 | 49 |
LRIG1,FGFR3,NTM,LSAMP |
3.644e-03 | -5.61 | PAS-like_dom_sf | interpro domains | IPR035965 | 34 | 2 | 18521 | 49 |
NPAS3,HIF3A |
3.644e-03 | -5.61 | PAS | interpro domains | IPR000014 | 34 | 2 | 18521 | 49 |
HIF3A,NPAS3 |
3.702e-03 | -5.60 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 48 |
BMPR1B,TNIK,CTNNA2,CTNND2,RFX4,NRXN1,PARD3,ABLIM1,GPM6A |
3.707e-03 | -5.60 | SLC5A5 (solute carrier family 5 member 5) | protein interactions | 6528 | 36 | 2 | 19454 | 49 |
SFXN5,CAMK2G |
3.717e-03 | -5.59 | monoatomic cation transport | biological process | GO:0006812 | 766 | 7 | 18204 | 48 |
SLC25A18,SLC1A3,GPM6A,SLC4A4,ATP1A2,ATP13A4,RYR3 |
3.721e-03 | -5.59 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 47 |
SLC1A2,SLC1A3 |
3.854e-03 | -5.56 | organic anion transport | biological process | GO:0015711 | 398 | 5 | 18204 | 48 |
SLC1A3,SFXN5,SLC4A4,SLC25A18,SLC1A2 |
3.893e-03 | -5.55 | striated muscle contraction | biological process | GO:0006941 | 120 | 3 | 18204 | 48 |
RYR3,ATP1A2,DTNA |
3.913e-03 | -5.54 | BCAT2 (branched chain amino acid transaminase 2) | protein interactions | 587 | 37 | 2 | 19454 | 49 |
PRODH,PTGDS |
3.936e-03 | -5.54 | head development | biological process | GO:0060322 | 774 | 7 | 18204 | 48 |
MEIS2,SLC1A2,RFX4,ATP1A2,CTNNA2,RORA,PCDH9 |
4.021e-03 | -5.52 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 49 |
ABLIM1,PARD3,DTNA |
4.048e-03 | -5.51 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 48 |
ATP1A2,ATP13A4,RYR3,ZBTB20,SLC4A4,SLC1A3 |
4.079e-03 | -5.50 | ATPase_P-typ_cyto_dom_N | interpro domains | IPR023299 | 36 | 2 | 18521 | 49 |
ATP13A4,ATP1A2 |
4.079e-03 | -5.50 | P_typ_ATPase | interpro domains | IPR001757 | 36 | 2 | 18521 | 49 |
ATP13A4,ATP1A2 |
4.079e-03 | -5.50 | ATPase_P-typ_P_site | interpro domains | IPR018303 | 36 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
4.079e-03 | -5.50 | ATPase_P-typ_transduc_dom_A_sf | interpro domains | IPR008250 | 36 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
4.079e-03 | -5.50 | P_typ_ATPase_HD_dom | interpro domains | IPR044492 | 36 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
4.196e-03 | -5.47 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 3 | 16828 | 48 |
SLC1A2,SOX5,RYR3 |
4.275e-03 | -5.45 | positive regulation of purine nucleotide metabolic process | biological process | GO:1900544 | 37 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
4.275e-03 | -5.45 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 48 |
SORBS1,SLC1A2 |
4.275e-03 | -5.45 | positive regulation of nucleotide metabolic process | biological process | GO:0045981 | 37 | 2 | 18204 | 48 |
SLC4A4,ZBTB20 |
4.305e-03 | -5.45 | ATPase_P-typ_TM_dom_sf | interpro domains | IPR023298 | 37 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
4.432e-03 | -5.42 | L-proline degradation | BIOCYC pathways | META_PROUT-PWY | 2 | 1 | 902 | 2 |
PRODH |
4.505e-03 | -5.40 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
4.561e-03 | -5.39 | DZIP1 (DAZ interacting zinc finger protein 1) | protein interactions | 22873 | 40 | 2 | 19454 | 49 |
CAMK2G,PARD3 |
4.574e-03 | -5.39 | RHOB (ras homolog family member B) | protein interactions | 388 | 832 | 7 | 19454 | 49 |
ABLIM1,AHCYL2,DTNA,PARD3B,SLC1A3,PARD3,TNIK |
4.639e-03 | -5.37 | haematopoietic_and_lymphoid_tissue | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue | 14368 | 47 | 16828 | 48 |
NRXN1,PCDH9,ATP13A4,CDH20,GLIS3,ZBTB20,MSI2,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3,NHSL1,PAMR1,PARD3,COL5A3,GPC5,FBXL7,HIF3A,RORA,NTM,FGFR3,PRODH,SORBS1,SPARCL1,SFXN5,NFIA,LSAMP,PITPNC1,AHCYL2,ACSS1,PARD3B,RYR3,SLC1A2,BMPR1B,ATP1A2,LRIG1,CTNND2,SLC25A18,ZNRF3,CAMK2G,SLC4A4,NKAIN3,MEIS2,GPM6A,RFX4,SOX5 |
4.741e-03 | -5.35 | sodium ion homeostasis | biological process | GO:0055078 | 39 | 2 | 18204 | 48 |
ATP1A2,SLC1A3 |
4.770e-03 | -5.35 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 3 | 19454 | 49 |
ABLIM1,PARD3,DTNA |
4.896e-03 | -5.32 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 30 | 16828 | 48 |
ACSS1,NPAS3,PARD3B,SLC1A2,RYR3,NRXN1,PCDH9,PRODH,SFXN5,ATP13A4,NFIA,LSAMP,PITPNC1,CDH20,ZBTB20,SLC4A4,MEIS2,NTM,RORA,FGFR3,RFX4,SOX5,NHSL1,PARD3,ATP1A2,LRIG1,CTNND2,ZNRF3,FBXL7,COL5A3 |
4.896e-03 | -5.32 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 30 | 16828 | 48 |
NFIA,PITPNC1,LSAMP,CDH20,ZBTB20,PCDH9,NRXN1,PRODH,ATP13A4,SFXN5,NPAS3,PARD3B,SLC1A2,RYR3,ACSS1,CTNND2,ZNRF3,FBXL7,COL5A3,NHSL1,PARD3,ATP1A2,LRIG1,NTM,RORA,FGFR3,RFX4,SOX5,SLC4A4,MEIS2 |
4.955e-03 | -5.31 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 48 |
FGFR3,DTNA,CDH20 |
4.969e-03 | -5.30 | PAS | prosite domains | PS50112 | 30 | 2 | 12186 | 43 |
NPAS3,HIF3A |
4.974e-03 | -5.30 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 3 | 18204 | 48 |
SLC1A3,SLC25A18,SLC1A2 |
5.031e-03 | -5.29 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 49 |
GLIS3 |
5.031e-03 | -5.29 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 49 |
GLIS3 |
5.031e-03 | -5.29 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | SLC23A3 (solute carrier family 23 member 3) | protein interactions | 151295 | 2 | 1 | 19454 | 49 |
PRODH |
5.031e-03 | -5.29 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.031e-03 | -5.29 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 49 |
BMPR1B |
5.078e-03 | -5.28 | animal organ development | biological process | GO:0048513 | 2846 | 15 | 18204 | 48 |
MEIS2,SLC1A2,RFX4,FGFR3,ATP1A2,RORA,SOX5,GPM6A,NFIA,ABLIM1,COL5A3,CTNNA2,BMPR1B,LRIG1,PCDH9 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic domain N | gene3d domains | 3.40.1110.10 | 36 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
5.097e-03 | -5.28 | Calcium-transporting ATPase, cytoplasmic transduction domain A | gene3d domains | 2.70.150.10 | 36 | 2 | 14470 | 43 |
ATP1A2,ATP13A4 |
5.188e-03 | -5.26 | proline dehydrogenase activity | molecular function | GO:0004657 | 2 | 1 | 18094 | 47 |
PRODH |
5.210e-03 | -5.26 | transmembrane transport | biological process | GO:0055085 | 1264 | 9 | 18204 | 48 |
SLC1A2,SLC25A18,GPM6A,SLC1A3,SLC4A4,SFXN5,ATP1A2,RYR3,ATP13A4 |
5.225e-03 | -5.25 | sarcoplasmic reticulum membrane | cellular component | GO:0033017 | 43 | 2 | 19108 | 48 |
RYR3,CAMK2G |
5.236e-03 | -5.25 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 48 |
SLC4A4,RYR3,SLC1A3,ATP13A4,ATP1A2 |
5.267e-03 | -5.25 | acetate biosynthetic process | biological process | GO:0019413 | 2 | 1 | 18204 | 48 |
ACSS1 |
5.267e-03 | -5.25 | acetyl-CoA biosynthetic process from acetate | biological process | GO:0019427 | 2 | 1 | 18204 | 48 |
ACSS1 |
5.267e-03 | -5.25 | Wnt receptor catabolic process | biological process | GO:0038018 | 2 | 1 | 18204 | 48 |
ZNRF3 |
5.267e-03 | -5.25 | propionate biosynthetic process | biological process | GO:0019542 | 2 | 1 | 18204 | 48 |
ACSS1 |
5.267e-03 | -5.25 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 48 |
FGFR3 |
5.284e-03 | -5.24 | Ac_CoA_lig | interpro domains | IPR011904 | 2 | 1 | 18521 | 49 |
ACSS1 |
5.284e-03 | -5.24 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 49 |
MSI2 |
5.284e-03 | -5.24 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 49 |
SPARCL1 |
5.284e-03 | -5.24 | Proline_oxidase | interpro domains | IPR015659 | 2 | 1 | 18521 | 49 |
PRODH |
5.284e-03 | -5.24 | ZNRF-3_ecto | interpro domains | IPR040700 | 2 | 1 | 18521 | 49 |
ZNRF3 |
5.284e-03 | -5.24 | Proline_DH_dom | interpro domains | IPR002872 | 2 | 1 | 18521 | 49 |
PRODH |
5.284e-03 | -5.24 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 49 |
DTNA |
5.322e-03 | -5.24 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 47 |
SLC1A3,SLC1A2 |
5.390e-03 | -5.22 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 4 | 16828 | 48 |
NPAS3,GPC5,PCDH9,NFIA |
5.390e-03 | -5.22 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 4 | 16828 | 48 |
PCDH9,NFIA,NPAS3,GPC5 |
5.407e-03 | -5.22 | organic acid transmembrane transport | biological process | GO:1903825 | 135 | 3 | 18204 | 48 |
SLC1A3,SLC1A2,SLC25A18 |
5.443e-03 | -5.21 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 48 |
DTNA,RYR3,ATP1A2 |
5.457e-03 | -5.21 | inorganic cation transmembrane transport | biological process | GO:0098662 | 618 | 6 | 18204 | 48 |
SLC1A3,GPM6A,SLC25A18,ATP1A2,RYR3,SLC4A4 |
5.500e-03 | -5.20 | ZNRF_3_ecto | pfam domains | PF18212 | 2 | 1 | 17795 | 49 |
ZNRF3 |
5.500e-03 | -5.20 | Pro_dh | pfam domains | PF01619 | 2 | 1 | 17795 | 49 |
PRODH |
5.501e-03 | -5.20 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 5 | 19454 | 49 |
ABLIM1,SOX5,PARD3,SORBS1,DTNA |
5.514e-03 | -5.20 | axon | cellular component | GO:0030424 | 650 | 6 | 19108 | 48 |
DTNA,PARD3,GPM6A,CTNNA2,PCDH9,SLC1A2 |
5.603e-03 | -5.18 | LCK (LCK proto-oncogene, Src family tyrosine kinase) | protein interactions | 3932 | 455 | 5 | 19454 | 49 |
SLC25A18,CTNND2,DTNA,CAMK2G,PARD3 |
5.706e-03 | -5.17 | Calml3 (calmodulin-like 3) | protein interactions | 70405 | 144 | 3 | 19454 | 49 |
CAMK2G,ZBTB20,ABLIM1 |
5.712e-03 | -5.17 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 48 |
ATP1A2,RYR3,SLC1A3,ATP13A4,SLC4A4 |
5.737e-03 | -5.16 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 48 |
SLC1A3,ATP1A2,SLC4A4,SLC1A2 |
5.747e-03 | -5.16 | regulation of generation of precursor metabolites and energy | biological process | GO:0043467 | 138 | 3 | 18204 | 48 |
ZBTB20,SLC4A4,SORBS1 |
5.826e-03 | -5.15 | Proline catabolism | REACTOME pathways | R-HSA-70688 | 2 | 1 | 10285 | 30 |
PRODH |
5.836e-03 | -5.14 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 4 | 19454 | 49 |
PARD3B,DTNA,PARD3,SORBS1 |
5.935e-03 | -5.13 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 43 |
CTNNA2 |
5.935e-03 | -5.13 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 43 |
RYR3 |
5.946e-03 | -5.12 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 48 |
PARD3B,MEIS2,NTM,SORBS1,TNIK |
5.967e-03 | -5.12 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 30 | 16828 | 48 |
AHCYL2,ABLIM1,ACSS1,SLC1A3,TNIK,PARD3B,RYR3,SLC1A2,PCDH9,SPARCL1,ATP13A4,SFXN5,CDH20,LSAMP,GLIS3,NKAIN3,MEIS2,RORA,GPM6A,RFX4,SOX5,NHSL1,PAMR1,BMPR1B,PARD3,LRIG1,CTNND2,COL5A3,FBXL7,GPC5 |
5.997e-03 | -5.12 | prostate | COSMIC cancer mutations | prostate | 13883 | 46 | 16828 | 48 |
ZNRF3,SLC25A18,CTNND2,LRIG1,ATP1A2,BMPR1B,GPM6A,SOX5,RFX4,MEIS2,NKAIN3,SLC4A4,PITPNC1,LSAMP,NFIA,SORBS1,PRODH,SFXN5,SPARCL1,SLC1A2,RYR3,PARD3B,ACSS1,AHCYL2,FBXL7,GPC5,COL5A3,PAMR1,NHSL1,PARD3,NTM,HIF3A,RORA,FGFR3,GLIS3,CDH20,MSI2,ZBTB20,PCDH9,NRXN1,ATP13A4,TNIK,SLC1A3,NPAS3,ABLIM1,DTNA |
6.002e-03 | -5.12 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 48 |
SLC1A2,SORBS1 |
6.041e-03 | -5.11 | MOB4 (MOB family member 4, phocein) | protein interactions | 25843 | 147 | 3 | 19454 | 49 |
ABLIM1,CAMK2G,TNIK |
6.075e-03 | -5.10 | lung-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-adenocarcinoma | 15133 | 48 | 16828 | 48 |
RORA,HIF3A,NTM,FGFR3,COL5A3,GPC5,FBXL7,NHSL1,PAMR1,PARD3,SLC1A3,TNIK,NPAS3,ABLIM1,DTNA,CDH20,GLIS3,ZBTB20,MSI2,NRXN1,PCDH9,ATP13A4,GPM6A,RFX4,SOX5,SLC4A4,NKAIN3,MEIS2,CTNND2,SLC25A18,ZNRF3,CAMK2G,PTGDS,BMPR1B,ATP1A2,LRIG1,PARD3B,RYR3,SLC1A2,AHCYL2,ACSS1,NFIA,PITPNC1,LSAMP,PRODH,SORBS1,SPARCL1,SFXN5 |
6.110e-03 | -5.10 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-follicular_lymphoma | 981 | 8 | 16828 | 48 |
PCDH9,PARD3,NKAIN3,CTNND2,RORA,LSAMP,GPC5,SOX5 |
6.132e-03 | -5.09 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 20 | 16828 | 48 |
CTNND2,CDH20,GPC5,COL5A3,PCDH9,PAMR1,PARD3,ATP13A4,ATP1A2,LRIG1,RORA,PARD3B,FGFR3,SLC1A2,RFX4,AHCYL2,ACSS1,ABLIM1,SLC4A4,MEIS2 |
6.219e-03 | -5.08 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 48 |
ZBTB20,SORBS1,SLC4A4 |
6.219e-03 | -5.08 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
6.231e-03 | -5.08 | CATATPASE | prints domains | PR00119 | 35 | 2 | 5227 | 18 |
ATP1A2,ATP13A4 |
6.263e-03 | -5.07 | PAS domain | gene3d domains | 3.30.450.20 | 40 | 2 | 14470 | 43 |
HIF3A,NPAS3 |
6.270e-03 | -5.07 | GSE1 (Gse1 coiled-coil protein) | protein interactions | 23199 | 149 | 3 | 19454 | 49 |
TNIK,NFIA,SOX5 |
6.334e-03 | -5.06 | apical junction complex | cellular component | GO:0043296 | 150 | 3 | 19108 | 48 |
PARD3,PARD3B,SORBS1 |
6.490e-03 | -5.04 | follicular_lymphoma | COSMIC cancer mutations | follicular_lymphoma | 1209 | 9 | 16828 | 48 |
GPC5,SOX5,CTNND2,RORA,TNIK,LSAMP,PARD3,NKAIN3,PCDH9 |
6.524e-03 | -5.03 | SFN (stratifin) | protein interactions | 2810 | 671 | 6 | 19454 | 49 |
NFIA,ABLIM1,PARD3B,TNIK,PARD3,SORBS1 |
6.618e-03 | -5.02 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 4 | 16828 | 48 |
FGFR3,RYR3,SOX5,SLC1A2 |
6.630e-03 | -5.02 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 4 | 18094 | 47 |
SLC1A3,SLC1A2,SLC25A18,SLC4A4 |
6.687e-03 | -5.01 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 48 |
SLC1A2,ATP1A2,GPC5,NRXN1,FGFR3,SLC1A3,SLC4A4 |
6.702e-03 | -5.01 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
ZNRF3,CTNND2,SLC25A18,CAMK2G,PTGDS,ATP1A2,LRIG1,BMPR1B,GPM6A,SOX5,NKAIN3,MEIS2,SLC4A4,PITPNC1,LSAMP,NFIA,PRODH,SORBS1,SPARCL1,SFXN5,RYR3,SLC1A2,PARD3B,ACSS1,AHCYL2,COL5A3,GPC5,FBXL7,PAMR1,NHSL1,PARD3,RORA,HIF3A,FGFR3,CDH20,GLIS3,ZBTB20,MSI2,NRXN1,PCDH9,ATP13A4,SLC1A3,TNIK,NPAS3,ABLIM1,DTNA |
6.702e-03 | -5.01 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 48 |
LRIG1,ATP1A2,BMPR1B,PARD3,PAMR1,PTGDS,NHSL1,CAMK2G,COL5A3,FBXL7,GPC5,ZNRF3,CTNND2,SLC25A18,NKAIN3,MEIS2,SLC4A4,SOX5,FGFR3,GPM6A,HIF3A,RORA,SPARCL1,SFXN5,ATP13A4,PRODH,NRXN1,SORBS1,PCDH9,ZBTB20,MSI2,LSAMP,CDH20,PITPNC1,GLIS3,NFIA,DTNA,ABLIM1,ACSS1,AHCYL2,RYR3,SLC1A2,NPAS3,PARD3B,SLC1A3,TNIK |
6.715e-03 | -5.00 | adult behavior | biological process | GO:0030534 | 146 | 3 | 18204 | 48 |
SLC1A2,ATP1A2,NRXN1 |
6.856e-03 | -4.98 | trunk | COSMIC cancer mutations | trunk | 3554 | 18 | 16828 | 48 |
NPAS3,FGFR3,SOX5,RYR3,HIF3A,SLC1A3,MEIS2,ABLIM1,CTNND2,GLIS3,CDH20,LSAMP,PARD3,ATP13A4,ATP1A2,SPARCL1,NRXN1,PCDH9 |
7.045e-03 | -4.96 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.045e-03 | -4.96 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 43 |
SPARCL1 |
7.101e-03 | -4.95 | neuromuscular process | biological process | GO:0050905 | 149 | 3 | 18204 | 48 |
SLC1A3,NRXN1,CTNNA2 |
7.101e-03 | -4.95 | ATPASE_E1_E2 | prosite domains | PS00154 | 36 | 2 | 12186 | 43 |
ATP1A2,ATP13A4 |
7.272e-03 | -4.92 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 48 |
GPC5,PARD3,FGFR3 |
7.322e-03 | -4.92 | cellular response to organic cyclic compound | biological process | GO:0071407 | 464 | 5 | 18204 | 48 |
ATP1A2,RYR3,SLC1A3,SLC1A2,RORA |
7.349e-03 | -4.91 | DNA-binding transcription factor activity, RNA polymerase II-specific | molecular function | GO:0000981 | 1355 | 9 | 18094 | 47 |
RORA,SOX5,NFIA,GLIS3,RFX4,NPAS3,HIF3A,MEIS2,ZBTB20 |
7.399e-03 | -4.91 | visual learning | biological process | GO:0008542 | 49 | 2 | 18204 | 48 |
MEIS2,ATP1A2 |
7.538e-03 | -4.89 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Lrrc7 (leucine rich repeat containing 7) | protein interactions | 117284 | 3 | 1 | 19454 | 49 |
CAMK2G |
7.538e-03 | -4.89 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 49 |
NTM |
7.538e-03 | -4.89 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 49 |
ABLIM1 |
7.538e-03 | -4.89 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 49 |
PTGDS |
7.538e-03 | -4.89 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | PIGL (phosphatidylinositol glycan anchor biosynthesis class L) | protein interactions | 9487 | 3 | 1 | 19454 | 49 |
MEIS2 |
7.538e-03 | -4.89 | TULP1 (TUB like protein 1) | protein interactions | 7287 | 3 | 1 | 19454 | 49 |
NRXN1 |
7.538e-03 | -4.89 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 49 |
GLIS3 |
7.538e-03 | -4.89 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.538e-03 | -4.89 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 49 |
BMPR1B |
7.544e-03 | -4.89 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 4 | 19454 | 49 |
DTNA,SORBS1,PARD3,NRXN1 |
7.689e-03 | -4.87 | carboxylic acid transport | biological process | GO:0046942 | 297 | 4 | 18204 | 48 |
SLC1A3,SLC1A2,SFXN5,SLC25A18 |
7.773e-03 | -4.86 | adenosylhomocysteinase activity | molecular function | GO:0004013 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | hydrolase activity, acting on carbon-sulfur bonds | molecular function | GO:0046508 | 3 | 1 | 18094 | 47 |
AHCYL2 |
7.773e-03 | -4.86 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 47 |
SLC1A2 |
7.773e-03 | -4.86 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 47 |
PTGDS |
7.774e-03 | -4.86 | learning | biological process | GO:0007612 | 154 | 3 | 18204 | 48 |
MEIS2,NRXN1,ATP1A2 |
7.779e-03 | -4.86 | organic acid transport | biological process | GO:0015849 | 298 | 4 | 18204 | 48 |
SLC1A3,SLC1A2,SFXN5,SLC25A18 |
7.890e-03 | -4.84 | acetate metabolic process | biological process | GO:0006083 | 3 | 1 | 18204 | 48 |
ACSS1 |
7.890e-03 | -4.84 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 48 |
CTNNA2 |
7.890e-03 | -4.84 | proline catabolic process to glutamate | biological process | GO:0010133 | 3 | 1 | 18204 | 48 |
PRODH |
7.890e-03 | -4.84 | neuroligin clustering involved in postsynaptic membrane assembly | biological process | GO:0097118 | 3 | 1 | 18204 | 48 |
NRXN1 |
7.890e-03 | -4.84 | regulation of calcium:sodium antiporter activity | biological process | GO:1903279 | 3 | 1 | 18204 | 48 |
ATP1A2 |
7.890e-03 | -4.84 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 48 |
SLC1A2 |
7.890e-03 | -4.84 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 48 |
SLC1A2 |
7.891e-03 | -4.84 | FOXF2 (forkhead box F2) | protein interactions | 2295 | 53 | 2 | 19454 | 49 |
AHCYL2,ZBTB20 |
7.916e-03 | -4.84 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 49 |
CTNNA2 |
7.916e-03 | -4.84 | HIF_alpha-like | interpro domains | IPR021537 | 3 | 1 | 18521 | 49 |
HIF3A |
7.916e-03 | -4.84 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 49 |
GPM6A |
7.916e-03 | -4.84 | Adenosylhomocysteinase-like | interpro domains | IPR000043 | 3 | 1 | 18521 | 49 |
AHCYL2 |
7.916e-03 | -4.84 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 49 |
SORBS1 |
7.916e-03 | -4.84 | NR_DBD_ROR | interpro domains | IPR044101 | 3 | 1 | 18521 | 49 |
RORA |
7.916e-03 | -4.84 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | Ado_hCys_hydrolase_NAD-bd | interpro domains | IPR015878 | 3 | 1 | 18521 | 49 |
AHCYL2 |
7.916e-03 | -4.84 | FAD-linked_oxidoreductase-like | interpro domains | IPR029041 | 3 | 1 | 18521 | 49 |
PRODH |
7.916e-03 | -4.84 | ROR_rcpt | interpro domains | IPR003079 | 3 | 1 | 18521 | 49 |
RORA |
7.916e-03 | -4.84 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 49 |
GPM6A |
7.916e-03 | -4.84 | Adenosylhomocyst_ase-like_sf | interpro domains | IPR042172 | 3 | 1 | 18521 | 49 |
AHCYL2 |
7.916e-03 | -4.84 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | S-Ado-L-homoCys_hydrolase_CS | interpro domains | IPR020082 | 3 | 1 | 18521 | 49 |
AHCYL2 |
7.916e-03 | -4.84 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 49 |
RYR3 |
7.916e-03 | -4.84 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 49 |
RYR3 |
7.964e-03 | -4.83 | Cardiac conduction | REACTOME pathways | R-HSA-5576891 | 142 | 3 | 10285 | 30 |
RYR3,CAMK2G,ATP1A2 |
7.995e-03 | -4.83 | neuromuscular process controlling balance | biological process | GO:0050885 | 51 | 2 | 18204 | 48 |
SLC1A3,NRXN1 |
8.053e-03 | -4.82 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 48 |
BMPR1B,GPM6A,NFIA |
8.111e-03 | -4.81 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 7 | 19454 | 49 |
SORBS1,DTNA,PARD3B,NHSL1,CTNNA2,PARD3,CTNND2 |
8.238e-03 | -4.80 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 49 |
SORBS1 |
8.238e-03 | -4.80 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 49 |
GPM6A |
8.238e-03 | -4.80 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | HIF-1 | pfam domains | PF11413 | 3 | 1 | 17795 | 49 |
HIF3A |
8.238e-03 | -4.80 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 49 |
RYR3 |
8.238e-03 | -4.80 | AdoHcyase_NAD | pfam domains | PF00670 | 3 | 1 | 17795 | 49 |
AHCYL2 |
8.238e-03 | -4.80 | AdoHcyase | pfam domains | PF05221 | 3 | 1 | 17795 | 49 |
AHCYL2 |
8.266e-03 | -4.80 | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-temporoparietal-glioma-astrocytoma_Grade_IV | 48 | 2 | 16828 | 48 |
RYR3,PARD3 |
8.301e-03 | -4.79 | regulation of purine nucleotide catabolic process | biological process | GO:0033121 | 52 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
8.301e-03 | -4.79 | regulation of nucleotide catabolic process | biological process | GO:0030811 | 52 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
8.301e-03 | -4.79 | regulation of glycolytic process | biological process | GO:0006110 | 52 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
8.316e-03 | -4.79 | acute_myeloid_leukaemia | COSMIC cancer mutations | acute_myeloid_leukaemia | 10418 | 38 | 16828 | 48 |
PRODH,PCDH9,NRXN1,SPARCL1,ATP13A4,SFXN5,NFIA,CDH20,LSAMP,GLIS3,MSI2,AHCYL2,ABLIM1,ACSS1,SLC1A3,TNIK,PARD3B,NPAS3,RYR3,SLC1A2,NHSL1,PAMR1,PARD3,ATP1A2,LRIG1,CTNND2,COL5A3,FBXL7,GPC5,CAMK2G,SLC4A4,NKAIN3,MEIS2,HIF3A,RORA,NTM,SOX5,RFX4 |
8.316e-03 | -4.79 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia | 10418 | 38 | 16828 | 48 |
RORA,HIF3A,NTM,SOX5,RFX4,SLC4A4,NKAIN3,MEIS2,CTNND2,COL5A3,FBXL7,GPC5,CAMK2G,NHSL1,PAMR1,PARD3,ATP1A2,LRIG1,SLC1A3,TNIK,NPAS3,PARD3B,RYR3,SLC1A2,AHCYL2,ABLIM1,ACSS1,NFIA,CDH20,LSAMP,GLIS3,MSI2,PRODH,PCDH9,NRXN1,SPARCL1,ATP13A4,SFXN5 |
8.365e-03 | -4.78 | ATPase-coupled monoatomic cation transmembrane transporter activity | molecular function | GO:0019829 | 53 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
8.444e-03 | -4.77 | RNA polymerase II transcription regulatory region sequence-specific DNA binding | molecular function | GO:0000977 | 1385 | 9 | 18094 | 47 |
HIF3A,RFX4,NPAS3,ZBTB20,MEIS2,SOX5,RORA,GLIS3,NFIA |
8.447e-03 | -4.77 | ion binding | molecular function | GO:0043167 | 6007 | 24 | 18094 | 47 |
PCDH9,PITPNC1,SLC1A2,ACSS1,ATP13A4,CAMK2G,SPARCL1,RORA,DTNA,SLC1A3,PRODH,NRXN1,PAMR1,ATP1A2,ABLIM1,RYR3,ZBTB20,PTGDS,PARD3,GLIS3,FGFR3,BMPR1B,ZNRF3,TNIK |
8.477e-03 | -4.77 | SYN1 (synapsin I) | protein interactions | 6853 | 55 | 2 | 19454 | 49 |
CAMK2G,GPM6A |
8.483e-03 | -4.77 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 48 |
SLC1A2,SLC4A4,SLC1A3 |
8.500e-03 | -4.77 | Hippo signaling pathway | KEGG pathways | ko04390 | 154 | 3 | 7161 | 20 |
BMPR1B,PARD3,CTNNA2 |
8.500e-03 | -4.77 | Hippo signaling pathway | KEGG pathways | hsa04390 | 154 | 3 | 7161 | 20 |
CTNNA2,BMPR1B,PARD3 |
8.533e-03 | -4.76 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 48 |
FGFR3 |
8.533e-03 | -4.76 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 48 |
FGFR3 |
8.571e-03 | -4.76 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 9 | 16828 | 48 |
RYR3,FGFR3,TNIK,GPM6A,NTM,CTNND2,ATP13A4,ABLIM1,PAMR1 |
8.571e-03 | -4.76 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 9 | 16828 | 48 |
PAMR1,ABLIM1,ATP13A4,NTM,CTNND2,GPM6A,TNIK,FGFR3,RYR3 |
8.612e-03 | -4.75 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 2 | 18204 | 48 |
BMPR1B,SOX5 |
8.612e-03 | -4.75 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 48 |
SLC1A2,SLC1A3 |
8.642e-03 | -4.75 | presynaptic membrane | cellular component | GO:0042734 | 168 | 3 | 19108 | 48 |
NRXN1,SLC1A2,GPM6A |
8.685e-03 | -4.75 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 6 | 19454 | 49 |
DTNA,SLC1A3,ABLIM1,PARD3,TNIK,MSI2 |
8.776e-03 | -4.74 | export from cell | biological process | GO:0140352 | 485 | 5 | 18204 | 48 |
ATP1A2,NRXN1,SLC4A4,CAMK2G,PTGDS |
8.889e-03 | -4.72 | - | gene3d domains | 3.20.20.220 | 3 | 1 | 14470 | 43 |
PRODH |
8.889e-03 | -4.72 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 43 |
RYR3 |
8.889e-03 | -4.72 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 43 |
CTNNA2 |
8.889e-03 | -4.72 | Adenosylhomocysteinase-like | gene3d domains | 3.40.50.1480 | 3 | 1 | 14470 | 43 |
AHCYL2 |
9.081e-03 | -4.70 | NXPH3 (neurexophilin 3) | protein interactions | 11248 | 57 | 2 | 19454 | 49 |
CTNNA2,NRXN1 |
9.109e-03 | -4.70 | response to light stimulus | biological process | GO:0009416 | 312 | 4 | 18204 | 48 |
ATP1A2,SLC1A3,MEIS2,SLC1A2 |
9.129e-03 | -4.70 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 48 |
SLC1A3,SLC4A4,ATP13A4,ZBTB20,RYR3,ATP1A2 |
9.165e-03 | -4.69 | ROR2 (receptor tyrosine kinase like orphan receptor 2) | protein interactions | 4920 | 327 | 4 | 19454 | 49 |
PARD3,SORBS1,DTNA,TNIK |
9.249e-03 | -4.68 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 48 |
SLC1A3,SLC1A2 |
9.249e-03 | -4.68 | establishment or maintenance of epithelial cell apical/basal polarity | biological process | GO:0045197 | 55 | 2 | 18204 | 48 |
PARD3,PARD3B |
9.253e-03 | -4.68 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 12 | 16828 | 48 |
RORA,FGFR3,ABLIM1,CTNND2,COL5A3,SORBS1,PCDH9,ATP1A2,SPARCL1,ATP13A4,PARD3,BMPR1B |
9.253e-03 | -4.68 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 12 | 16828 | 48 |
COL5A3,CTNND2,PARD3,BMPR1B,ATP13A4,SPARCL1,ATP1A2,PCDH9,SORBS1,FGFR3,RORA,ABLIM1 |
9.383e-03 | -4.67 | import across plasma membrane | biological process | GO:0098739 | 165 | 3 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2 |
9.390e-03 | -4.67 | CILK1 (ciliogenesis associated kinase 1) | protein interactions | 22858 | 58 | 2 | 19454 | 49 |
CAMK2G,MSI2 |
9.391e-03 | -4.67 | urinary_tract-bladder-carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma | 14050 | 46 | 16828 | 48 |
DTNA,ABLIM1,NPAS3,SLC1A3,TNIK,ATP13A4,NRXN1,PCDH9,ZBTB20,MSI2,CDH20,GLIS3,FGFR3,HIF3A,RORA,NTM,PARD3,PAMR1,COL5A3,GPC5,FBXL7,ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,SPARCL1,SFXN5,PRODH,SORBS1,PITPNC1,LSAMP,NFIA,MEIS2,SLC4A4,RFX4,SOX5,GPM6A,ATP1A2,LRIG1,BMPR1B,PTGDS,CAMK2G,ZNRF3,CTNND2,SLC25A18 |
9.578e-03 | -4.65 | chemical homeostasis | biological process | GO:0048878 | 914 | 7 | 18204 | 48 |
SLC1A3,ZBTB20,RYR3,ATP13A4,ATP1A2,SLC4A4,RORA |
9.597e-03 | -4.65 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
9.657e-03 | -4.64 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 48 |
DTNA,CDH20,CTNNA2 |
9.687e-03 | -4.64 | ACTB (actin beta) | protein interactions | 60 | 958 | 7 | 19454 | 49 |
NHSL1,ABLIM1,DTNA,SORBS1,AHCYL2,SFXN5,MEIS2 |
9.733e-03 | -4.63 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 15 | 16828 | 48 |
COL5A3,CTNND2,ZNRF3,PITPNC1,PARD3,SPARCL1,LRIG1,NHSL1,PCDH9,PRODH,FGFR3,RYR3,TNIK,SLC4A4,NKAIN3 |
9.733e-03 | -4.63 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 15 | 16828 | 48 |
NKAIN3,SLC4A4,TNIK,RYR3,FGFR3,PCDH9,PRODH,NHSL1,SPARCL1,LRIG1,PARD3,ZNRF3,PITPNC1,CTNND2,COL5A3 |
9.834e-03 | -4.62 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 9 | 16828 | 48 |
ATP13A4,SPARCL1,ATP1A2,ABLIM1,NPAS3,GLIS3,CDH20,HIF3A,CTNND2 |
9.873e-03 | -4.62 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 7 | 16828 | 48 |
LRIG1,PAMR1,PCDH9,ACSS1,NFIA,HIF3A,GLIS3 |
1.001e-02 | -4.60 | internode region of axon | cellular component | GO:0033269 | 4 | 1 | 19108 | 48 |
PARD3 |
1.001e-02 | -4.60 | collagen type V trimer | cellular component | GO:0005588 | 4 | 1 | 19108 | 48 |
COL5A3 |
1.002e-02 | -4.60 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 49 |
DTNA,FGFR3 |
1.004e-02 | -4.60 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 49 |
GPM6A |
1.004e-02 | -4.60 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | CALML4 (calmodulin like 4) | protein interactions | 91860 | 4 | 1 | 19454 | 49 |
CAMK2G |
1.004e-02 | -4.60 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 49 |
GLIS3 |
1.004e-02 | -4.60 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 49 |
BMPR1B |
1.004e-02 | -4.60 | Nme2 (NME/NM23 nucleoside diphosphate kinase 2) | protein interactions | 18103 | 4 | 1 | 19454 | 49 |
RORA |
1.004e-02 | -4.60 | SYNPO (synaptopodin) | protein interactions | 11346 | 177 | 3 | 19454 | 49 |
ABLIM1,CAMK2G,ZBTB20 |
1.015e-02 | -4.59 | synapse | cellular component | GO:0045202 | 1473 | 9 | 19108 | 48 |
CTNND2,TNIK,GPM6A,SLC1A3,DTNA,SLC1A2,ATP1A2,NRXN1,SPARCL1 |
1.016e-02 | -4.59 | EZR (ezrin) | protein interactions | 7430 | 526 | 5 | 19454 | 49 |
AHCYL2,SORBS1,DTNA,TNIK,ABLIM1 |
1.027e-02 | -4.58 | IGc2 | smart domains | SM00408 | 239 | 4 | 9717 | 35 |
LRIG1,NTM,LSAMP,FGFR3 |
1.030e-02 | -4.58 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 18 |
RYR3 |
1.030e-02 | -4.58 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 18 |
GPM6A |
1.030e-02 | -4.58 | RORNUCRECPTR | prints domains | PR01293 | 3 | 1 | 5227 | 18 |
RORA |
1.030e-02 | -4.58 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 18 |
PTGDS |
1.033e-02 | -4.57 | RNA polymerase II cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000978 | 1180 | 8 | 18094 | 47 |
NFIA,GLIS3,RORA,SOX5,MEIS2,ZBTB20,RFX4,HIF3A |
1.034e-02 | -4.57 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 48 |
ATP1A2,ATP13A4,SLC1A3,RYR3,SLC4A4 |
1.034e-02 | -4.57 | Synaptic Vesicle Pathway | WikiPathways | WP2267 | 52 | 2 | 5310 | 16 |
SLC1A3,ATP1A2 |
1.035e-02 | -4.57 | propionate-CoA ligase activity | molecular function | GO:0050218 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.035e-02 | -4.57 | short-chain fatty acid-CoA ligase activity | molecular function | GO:0031955 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.035e-02 | -4.57 | oxidoreductase activity, acting on the CH-NH group of donors, quinone or similar compound as acceptor | molecular function | GO:0016649 | 4 | 1 | 18094 | 47 |
PRODH |
1.035e-02 | -4.57 | acetate-CoA ligase activity | molecular function | GO:0003987 | 4 | 1 | 18094 | 47 |
ACSS1 |
1.035e-02 | -4.57 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 47 |
RYR3 |
1.035e-02 | -4.57 | tricarboxylic acid transmembrane transporter activity | molecular function | GO:0015142 | 4 | 1 | 18094 | 47 |
SFXN5 |
1.035e-02 | -4.57 | citrate transmembrane transporter activity | molecular function | GO:0015137 | 4 | 1 | 18094 | 47 |
SFXN5 |
1.043e-02 | -4.56 | binding | molecular function | GO:0005488 | 16422 | 47 | 18094 | 47 |
ABLIM1,RYR3,ZBTB20,PTGDS,CTNNA2,GPC5,COL5A3,ZNRF3,CDH20,TNIK,LRIG1,PARD3,SFXN5,SOX5,MEIS2,ACSS1,ATP13A4,HIF3A,PCDH9,GPM6A,AHCYL2,FBXL7,CTNND2,SORBS1,SLC1A3,ATP1A2,PARD3B,RFX4,NRXN1,SLC4A4,PAMR1,GLIS3,FGFR3,NTM,BMPR1B,SLC25A18,MSI2,LSAMP,CAMK2G,NFIA,PITPNC1,SLC1A2,PRODH,NPAS3,SPARCL1,DTNA,RORA |
1.051e-02 | -4.56 | 4-hydroxyproline catabolic process | biological process | GO:0019470 | 4 | 1 | 18204 | 48 |
PRODH |
1.051e-02 | -4.56 | positive regulation of cardiac muscle myoblast proliferation | biological process | GO:0110024 | 4 | 1 | 18204 | 48 |
MEIS2 |
1.051e-02 | -4.56 | response to glycoside | biological process | GO:1903416 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.051e-02 | -4.56 | short-chain fatty acid biosynthetic process | biological process | GO:0051790 | 4 | 1 | 18204 | 48 |
ACSS1 |
1.051e-02 | -4.56 | regulation of amino acid uptake involved in synaptic transmission | biological process | GO:0051941 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.051e-02 | -4.56 | malate-aspartate shuttle | biological process | GO:0043490 | 4 | 1 | 18204 | 48 |
SLC25A18 |
1.051e-02 | -4.56 | proline catabolic process | biological process | GO:0006562 | 4 | 1 | 18204 | 48 |
PRODH |
1.051e-02 | -4.56 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 48 |
BMPR1B |
1.051e-02 | -4.56 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 48 |
PTGDS |
1.051e-02 | -4.56 | positive regulation of mesenchymal stem cell differentiation | biological process | GO:2000741 | 4 | 1 | 18204 | 48 |
SOX5 |
1.051e-02 | -4.56 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 48 |
PTGDS |
1.051e-02 | -4.56 | regulation of glutamate uptake involved in transmission of nerve impulse | biological process | GO:0051946 | 4 | 1 | 18204 | 48 |
ATP1A2 |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 49 |
ABLIM1 |
1.054e-02 | -4.55 | Ca/CaM-dep_prot_kinase-assoc | interpro domains | IPR013543 | 4 | 1 | 18521 | 49 |
CAMK2G |
1.054e-02 | -4.55 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 49 |
FGFR3 |
1.054e-02 | -4.55 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 49 |
CTNNA2 |
1.054e-02 | -4.55 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 49 |
ATP13A4 |
1.054e-02 | -4.55 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 49 |
NKAIN3 |
1.054e-02 | -4.55 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 49 |
NFIA |
1.054e-02 | -4.55 | PKNOX/Meis_N | interpro domains | IPR032453 | 4 | 1 | 18521 | 49 |
MEIS2 |
1.054e-02 | -4.55 | ACAS_N | interpro domains | IPR032387 | 4 | 1 | 18521 | 49 |
ACSS1 |
1.054e-02 | -4.55 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 49 |
ATP13A4 |
1.054e-02 | -4.55 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 49 |
NHSL1 |
1.055e-02 | -4.55 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 43 |
GPM6A |
1.055e-02 | -4.55 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 43 |
CTNNA2 |
1.055e-02 | -4.55 | ADOHCYASE_1 | prosite domains | PS00738 | 3 | 1 | 12186 | 43 |
AHCYL2 |
1.055e-02 | -4.55 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 43 |
GPM6A |
1.055e-02 | -4.55 | ADOHCYASE_2 | prosite domains | PS00739 | 3 | 1 | 12186 | 43 |
AHCYL2 |
1.055e-02 | -4.55 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 43 |
SORBS1 |
1.059e-02 | -4.55 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 48 |
BMPR1B,FGFR3 |
1.059e-02 | -4.55 | establishment or maintenance of apical/basal cell polarity | biological process | GO:0035088 | 59 | 2 | 18204 | 48 |
PARD3B,PARD3 |
1.059e-02 | -4.55 | establishment or maintenance of bipolar cell polarity | biological process | GO:0061245 | 59 | 2 | 18204 | 48 |
PARD3B,PARD3 |
1.059e-02 | -4.55 | biliary_tract | COSMIC cancer mutations | biliary_tract | 15309 | 48 | 16828 | 48 |
LRIG1,ATP1A2,BMPR1B,PTGDS,CAMK2G,ZNRF3,SLC25A18,CTNND2,MEIS2,NKAIN3,SLC4A4,RFX4,SOX5,GPM6A,SFXN5,SPARCL1,SORBS1,PRODH,PITPNC1,LSAMP,NFIA,ACSS1,AHCYL2,SLC1A2,RYR3,PARD3B,PARD3,PAMR1,NHSL1,FBXL7,GPC5,COL5A3,FGFR3,NTM,RORA,HIF3A,ATP13A4,NRXN1,PCDH9,MSI2,ZBTB20,GLIS3,CDH20,DTNA,ABLIM1,NPAS3,TNIK,SLC1A3 |
1.067e-02 | -4.54 | ARHGAP29 (Rho GTPase activating protein 29) | protein interactions | 9411 | 62 | 2 | 19454 | 49 |
CAMK2G,PARD3 |
1.077e-02 | -4.53 | AdoHcyase_NAD | smart domains | SM00997 | 3 | 1 | 9717 | 35 |
AHCYL2 |
1.077e-02 | -4.53 | AdoHcyase | smart domains | SM00996 | 3 | 1 | 9717 | 35 |
AHCYL2 |
1.077e-02 | -4.53 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 35 |
GPM6A |
1.077e-02 | -4.53 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 35 |
SORBS1 |
1.082e-02 | -4.53 | DNA-binding transcription factor activity | molecular function | GO:0003700 | 1441 | 9 | 18094 | 47 |
RFX4,NPAS3,HIF3A,MEIS2,ZBTB20,RORA,SOX5,NFIA,GLIS3 |
1.084e-02 | -4.52 | inorganic ion transmembrane transport | biological process | GO:0098660 | 715 | 6 | 18204 | 48 |
SLC4A4,ATP1A2,RYR3,SLC25A18,SLC1A3,GPM6A |
1.093e-02 | -4.52 | export across plasma membrane | biological process | GO:0140115 | 60 | 2 | 18204 | 48 |
ATP1A2,SLC4A4 |
1.093e-02 | -4.52 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 48 |
SORBS1,SLC1A2 |
1.097e-02 | -4.51 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 49 |
NFIA |
1.097e-02 | -4.51 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 49 |
ATP13A4 |
1.097e-02 | -4.51 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 49 |
ABLIM1 |
1.097e-02 | -4.51 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 49 |
NKAIN3 |
1.097e-02 | -4.51 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 49 |
NFIA |
1.097e-02 | -4.51 | Meis_PKNOX_N | pfam domains | PF16493 | 4 | 1 | 17795 | 49 |
MEIS2 |
1.097e-02 | -4.51 | CaMKII_AD | pfam domains | PF08332 | 4 | 1 | 17795 | 49 |
CAMK2G |
1.097e-02 | -4.51 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 49 |
NHSL1 |
1.097e-02 | -4.51 | ACAS_N | pfam domains | PF16177 | 4 | 1 | 17795 | 49 |
ACSS1 |
1.106e-02 | -4.50 | bladder | COSMIC cancer mutations | bladder | 14112 | 46 | 16828 | 48 |
SLC1A3,TNIK,NPAS3,ABLIM1,DTNA,CDH20,GLIS3,ZBTB20,MSI2,PCDH9,NRXN1,ATP13A4,HIF3A,RORA,NTM,FGFR3,COL5A3,FBXL7,GPC5,PAMR1,PARD3,RYR3,SLC1A2,PARD3B,ACSS1,AHCYL2,PITPNC1,LSAMP,NFIA,PRODH,SORBS1,SPARCL1,SFXN5,GPM6A,SOX5,RFX4,MEIS2,SLC4A4,ZNRF3,CTNND2,SLC25A18,CAMK2G,PTGDS,LRIG1,ATP1A2,BMPR1B |
1.106e-02 | -4.50 | urinary_tract | COSMIC cancer mutations | urinary_tract | 14112 | 46 | 16828 | 48 |
NRXN1,PCDH9,ATP13A4,GLIS3,CDH20,MSI2,ZBTB20,ABLIM1,DTNA,TNIK,SLC1A3,NPAS3,PAMR1,PARD3,FBXL7,GPC5,COL5A3,NTM,HIF3A,RORA,FGFR3,SORBS1,PRODH,SFXN5,SPARCL1,NFIA,PITPNC1,LSAMP,AHCYL2,ACSS1,PARD3B,SLC1A2,RYR3,PTGDS,BMPR1B,LRIG1,ATP1A2,SLC25A18,CTNND2,ZNRF3,CAMK2G,SLC4A4,MEIS2,GPM6A,SOX5,RFX4 |
1.106e-02 | -4.50 | L-citrulline biosynthesis | BIOCYC pathways | META_CITRULBIO-PWY | 5 | 1 | 902 | 2 |
PRODH |
1.114e-02 | -4.50 | regulation of small molecule metabolic process | biological process | GO:0062012 | 331 | 4 | 18204 | 48 |
SLC4A4,SORBS1,RORA,ZBTB20 |
1.119e-02 | -4.49 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 48 |
SLC4A4,RYR3,SLC1A3,ATP13A4,ATP1A2 |
1.120e-02 | -4.49 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 49 |
NPAS3 |
1.120e-02 | -4.49 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 49 |
GPM6A |
1.134e-02 | -4.48 | EVA1C (eva-1 homolog C) | protein interactions | 59271 | 64 | 2 | 19454 | 49 |
BMPR1B,PCDH9 |
1.136e-02 | -4.48 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 48 |
FGFR3 |
1.136e-02 | -4.48 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 48 |
FGFR3 |
1.136e-02 | -4.48 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 48 |
FGFR3 |
1.136e-02 | -4.48 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 48 |
FGFR3 |
1.146e-02 | -4.47 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 6 | 19454 | 49 |
PARD3,SORBS1,CTNND2,CTNNA2,NHSL1,ABLIM1 |
1.148e-02 | -4.47 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 48 |
PCDH9,BMPR1B,PARD3,CDH20,CTNND2,ZBTB20,COL5A3,GPC5,ACSS1,GPM6A,HIF3A,RYR3,SOX5,FGFR3,NPAS3 |
1.152e-02 | -4.46 | cis-regulatory region sequence-specific DNA binding | molecular function | GO:0000987 | 1203 | 8 | 18094 | 47 |
SOX5,RORA,GLIS3,NFIA,HIF3A,RFX4,ZBTB20,MEIS2 |
1.164e-02 | -4.45 | regulation of carbohydrate catabolic process | biological process | GO:0043470 | 62 | 2 | 18204 | 48 |
SLC4A4,ZBTB20 |
1.188e-02 | -4.43 | arm | COSMIC cancer mutations | arm | 1331 | 9 | 16828 | 48 |
ATP1A2,SLC4A4,SORBS1,NPAS3,FGFR3,PARD3B,ZBTB20,COL5A3,NTM |
1.204e-02 | -4.42 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 48 |
SLC4A4,RYR3,ATP13A4,LSAMP,PCDH9 |
1.204e-02 | -4.42 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 48 |
SLC4A4,RYR3,ATP13A4,LSAMP,PCDH9 |
1.205e-02 | -4.42 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 48 | 16828 | 48 |
ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,PRODH,SORBS1,SPARCL1,SFXN5,PITPNC1,LSAMP,NFIA,NKAIN3,MEIS2,SLC4A4,GPM6A,RFX4,SOX5,PTGDS,ATP1A2,LRIG1,BMPR1B,ZNRF3,CTNND2,SLC25A18,CAMK2G,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3,NRXN1,PCDH9,ATP13A4,CDH20,GLIS3,ZBTB20,MSI2,RORA,HIF3A,NTM,FGFR3,PAMR1,NHSL1,PARD3,COL5A3,FBXL7,GPC5 |
1.208e-02 | -4.42 | response to growth factor | biological process | GO:0070848 | 525 | 5 | 18204 | 48 |
BMPR1B,MEIS2,FGFR3,SOX5,NFIA |
1.237e-02 | -4.39 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 2 | 18204 | 48 |
CTNNA2,CTNND2 |
1.247e-02 | -4.38 | head_neck | COSMIC cancer mutations | head_neck | 15361 | 48 | 16828 | 48 |
SORBS1,PRODH,SFXN5,SPARCL1,LSAMP,PITPNC1,NFIA,ACSS1,AHCYL2,SLC1A2,RYR3,PARD3B,PTGDS,ATP1A2,LRIG1,BMPR1B,ZNRF3,SLC25A18,CTNND2,CAMK2G,MEIS2,NKAIN3,SLC4A4,GPM6A,SOX5,RFX4,PCDH9,NRXN1,ATP13A4,GLIS3,CDH20,MSI2,ZBTB20,ABLIM1,DTNA,TNIK,SLC1A3,NPAS3,PAMR1,NHSL1,PARD3,FBXL7,GPC5,COL5A3,NTM,HIF3A,RORA,FGFR3 |
1.250e-02 | -4.38 | calcium- and calmodulin-dependent protein kinase complex | cellular component | GO:0005954 | 5 | 1 | 19108 | 48 |
CAMK2G |
1.252e-02 | -4.38 | membrane protein complex | cellular component | GO:0098796 | 1261 | 8 | 19108 | 48 |
SLC1A3,BMPR1B,SORBS1,RYR3,CDH20,ATP1A2,SLC1A2,CTNNA2 |
1.253e-02 | -4.38 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | SYT13 (synaptotagmin 13) | protein interactions | 57586 | 5 | 1 | 19454 | 49 |
NRXN1 |
1.253e-02 | -4.38 | RFX4 (regulatory factor X4) | protein interactions | 5992 | 5 | 1 | 19454 | 49 |
RFX4 |
1.253e-02 | -4.38 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | ARSI (arylsulfatase family member I) | protein interactions | 340075 | 5 | 1 | 19454 | 49 |
AHCYL2 |
1.253e-02 | -4.38 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 49 |
GLIS3 |
1.253e-02 | -4.38 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 49 |
PTGDS |
1.253e-02 | -4.38 | CAMK2N2 (calcium/calmodulin dependent protein kinase II inhibitor 2) | protein interactions | 94032 | 5 | 1 | 19454 | 49 |
CAMK2G |
1.253e-02 | -4.38 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 49 |
BMPR1B |
1.253e-02 | -4.38 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 49 |
SORBS1 |
1.253e-02 | -4.38 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 49 |
PTGDS |
1.258e-02 | -4.38 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 7 | 16828 | 48 |
PTGDS,ABLIM1,SPARCL1,ATP1A2,LRIG1,NPAS3,FGFR3 |
1.267e-02 | -4.37 | main axon | cellular component | GO:0044304 | 68 | 2 | 19108 | 48 |
PARD3,SLC1A2 |
1.283e-02 | -4.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 24 | 18094 | 47 |
ZBTB20,RYR3,ABLIM1,ATP1A2,PTGDS,NRXN1,PAMR1,TNIK,ZNRF3,GLIS3,PARD3,BMPR1B,FGFR3,ACSS1,CAMK2G,ATP13A4,PITPNC1,PCDH9,SLC1A2,PRODH,SLC1A3,RORA,DTNA,SPARCL1 |
1.292e-02 | -4.35 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 47 |
FGFR3 |
1.292e-02 | -4.35 | neuroligin family protein binding | molecular function | GO:0097109 | 5 | 1 | 18094 | 47 |
NRXN1 |
1.292e-02 | -4.35 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 47 |
BMPR1B |
1.295e-02 | -4.35 | human chr22q11.21 | chromosome location | human chr22q11.21 | 92 | 2 | 26134 | 49 |
PRODH,SLC25A18 |
1.302e-02 | -4.34 | transcription cis-regulatory region binding | molecular function | GO:0000976 | 1485 | 9 | 18094 | 47 |
RORA,SOX5,NFIA,GLIS3,NPAS3,RFX4,HIF3A,MEIS2,ZBTB20 |
1.305e-02 | -4.34 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 49 |
PCDH9 |
1.310e-02 | -4.34 | temporoparietal | COSMIC cancer mutations | temporoparietal | 61 | 2 | 16828 | 48 |
RYR3,PARD3 |
1.312e-02 | -4.33 | tricarboxylic acid transport | biological process | GO:0006842 | 5 | 1 | 18204 | 48 |
SFXN5 |
1.312e-02 | -4.33 | otolith morphogenesis | biological process | GO:0032474 | 5 | 1 | 18204 | 48 |
LRIG1 |
1.312e-02 | -4.33 | propionate metabolic process | biological process | GO:0019541 | 5 | 1 | 18204 | 48 |
ACSS1 |
1.312e-02 | -4.33 | amygdala development | biological process | GO:0021764 | 5 | 1 | 18204 | 48 |
ATP1A2 |
1.312e-02 | -4.33 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 48 |
BMPR1B |
1.312e-02 | -4.33 | gephyrin clustering involved in postsynaptic density assembly | biological process | GO:0097116 | 5 | 1 | 18204 | 48 |
NRXN1 |
1.312e-02 | -4.33 | citrate transport | biological process | GO:0015746 | 5 | 1 | 18204 | 48 |
SFXN5 |
1.313e-02 | -4.33 | transcription regulatory region nucleic acid binding | molecular function | GO:0001067 | 1487 | 9 | 18094 | 47 |
SOX5,RORA,GLIS3,NFIA,HIF3A,RFX4,NPAS3,ZBTB20,MEIS2 |
1.316e-02 | -4.33 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 49 |
PCDH9 |
1.316e-02 | -4.33 | Mtc | interpro domains | IPR004686 | 5 | 1 | 18521 | 49 |
SFXN5 |
1.316e-02 | -4.33 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 49 |
CTNNA2 |
1.316e-02 | -4.33 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 49 |
ATP13A4 |
1.316e-02 | -4.33 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 49 |
SLC4A4 |
1.316e-02 | -4.33 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 49 |
SPARCL1 |
1.316e-02 | -4.33 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 49 |
PITPNC1 |
1.319e-02 | -4.33 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 10 | 16828 | 48 |
RORA,LSAMP,GPC5,FGFR3,COL5A3,SOX5,NRXN1,SLC4A4,ATP13A4,ATP1A2 |
1.323e-02 | -4.33 | kidney | COSMIC cancer mutations | kidney | 15380 | 48 | 16828 | 48 |
PTGDS,ATP1A2,LRIG1,BMPR1B,ZNRF3,CTNND2,SLC25A18,CAMK2G,NKAIN3,MEIS2,SLC4A4,GPM6A,SOX5,RFX4,PRODH,SORBS1,SPARCL1,SFXN5,PITPNC1,LSAMP,NFIA,ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,PAMR1,NHSL1,PARD3,COL5A3,FBXL7,GPC5,RORA,HIF3A,NTM,FGFR3,PCDH9,NRXN1,ATP13A4,CDH20,GLIS3,ZBTB20,MSI2,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3 |
1.336e-02 | -4.32 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 4 | 16828 | 48 |
MEIS2,PARD3B,SORBS1,NTM |
1.347e-02 | -4.31 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 7 | 16828 | 48 |
PTGDS,ABLIM1,ATP1A2,SPARCL1,LRIG1,NPAS3,FGFR3 |
1.349e-02 | -4.31 | collagen binding | molecular function | GO:0005518 | 68 | 2 | 18094 | 47 |
COL5A3,SPARCL1 |
1.354e-02 | -4.30 | NTRK3 (neurotrophic receptor tyrosine kinase 3) | protein interactions | 4916 | 367 | 4 | 19454 | 49 |
PARD3,AHCYL2,TNIK,ABLIM1 |
1.359e-02 | -4.30 | skin-head_neck-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-head_neck-carcinoma-squamous_cell_carcinoma | 14191 | 46 | 16828 | 48 |
PRODH,SORBS1,SPARCL1,SFXN5,NFIA,PITPNC1,LSAMP,AHCYL2,ACSS1,PARD3B,RYR3,SLC1A2,BMPR1B,LRIG1,ATP1A2,CTNND2,SLC25A18,ZNRF3,CAMK2G,SLC4A4,NKAIN3,MEIS2,GPM6A,RFX4,SOX5,NRXN1,PCDH9,ATP13A4,CDH20,GLIS3,ZBTB20,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3,NHSL1,PAMR1,PARD3,COL5A3,FBXL7,GPC5,RORA,HIF3A,NTM,FGFR3 |
1.369e-02 | -4.29 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 49 |
SPARCL1 |
1.369e-02 | -4.29 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 49 |
PITPNC1 |
1.369e-02 | -4.29 | SFXNs | pfam domains | PF03820 | 5 | 1 | 17795 | 49 |
SFXN5 |
1.369e-02 | -4.29 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 49 |
CTNNA2 |
1.369e-02 | -4.29 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 49 |
PCDH9 |
1.371e-02 | -4.29 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 18 |
CTNNA2 |
1.383e-02 | -4.28 | PAK6 (p21 (RAC1) activated kinase 6) | protein interactions | 56924 | 71 | 2 | 19454 | 49 |
CAMK2G,AHCYL2 |
1.383e-02 | -4.28 | ANK2 (ankyrin 2) | protein interactions | 287 | 71 | 2 | 19454 | 49 |
TNIK,GPM6A |
1.384e-02 | -4.28 | ORF3a (ORF3a protein) | protein interactions | 43740569 | 789 | 6 | 19454 | 49 |
ZNRF3,PCDH9,SLC4A4,PARD3,PARD3B,BMPR1B |
1.403e-02 | -4.27 | system process | biological process | GO:0003008 | 2015 | 11 | 18204 | 48 |
SLC1A3,ABLIM1,NRXN1,CTNNA2,LRIG1,SLC1A2,MEIS2,RYR3,ATP1A2,DTNA,SLC4A4 |
1.404e-02 | -4.27 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 43 |
NFIA |
1.404e-02 | -4.27 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 43 |
NFIA |
1.418e-02 | -4.26 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 48 |
FGFR3 |
1.418e-02 | -4.26 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 48 |
FGFR3 |
1.420e-02 | -4.25 | DPYSL3 (dihydropyrimidinase like 3) | protein interactions | 1809 | 72 | 2 | 19454 | 49 |
TNIK,GPM6A |
1.420e-02 | -4.25 | Ppp1cb (protein phosphatase 1 catalytic subunit beta) | protein interactions | 19046 | 72 | 2 | 19454 | 49 |
PARD3,ABLIM1 |
1.420e-02 | -4.25 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 49 |
BMPR1B,PARD3B |
1.424e-02 | -4.25 | EGF | pfam domains | PF00008 | 66 | 2 | 17795 | 49 |
NRXN1,PAMR1 |
1.428e-02 | -4.25 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 48 |
MEIS2,SOX5,ABLIM1,BMPR1B,LRIG1,FGFR3,CTNNA2 |
1.450e-02 | -4.23 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 4 | 16828 | 48 |
NTM,SORBS1,PARD3B,MEIS2 |
1.458e-02 | -4.23 | pancreas-carcinoma | COSMIC cancer mutations | pancreas-carcinoma | 14770 | 47 | 16828 | 48 |
FGFR3,HIF3A,RORA,NTM,PARD3,NHSL1,PAMR1,COL5A3,FBXL7,GPC5,ABLIM1,NPAS3,SLC1A3,TNIK,ATP13A4,PCDH9,NRXN1,ZBTB20,MSI2,CDH20,GLIS3,SLC4A4,NKAIN3,MEIS2,RFX4,SOX5,GPM6A,BMPR1B,ATP1A2,LRIG1,PTGDS,CAMK2G,CTNND2,SLC25A18,ZNRF3,AHCYL2,ACSS1,PARD3B,RYR3,SLC1A2,SPARCL1,SFXN5,PRODH,SORBS1,NFIA,PITPNC1,LSAMP |
1.477e-02 | -4.22 | - | gene3d domains | 6.10.140.620 | 5 | 1 | 14470 | 43 |
CAMK2G |
1.483e-02 | -4.21 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 17 | 16828 | 48 |
CTNND2,ZBTB20,COL5A3,GPC5,NHSL1,PAMR1,PCDH9,PARD3,SPARCL1,LRIG1,ATP1A2,TNIK,GPM6A,RYR3,SOX5,ABLIM1,SLC4A4 |
1.488e-02 | -4.21 | cell-cell contact zone | cellular component | GO:0044291 | 74 | 2 | 19108 | 48 |
PCDH9,ATP1A2 |
1.489e-02 | -4.21 | UTRN (utrophin) | protein interactions | 7402 | 205 | 3 | 19454 | 49 |
DTNA,PARD3,FGFR3 |
1.491e-02 | -4.21 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 17 | 16828 | 48 |
ZBTB20,COL5A3,GPC5,CTNND2,PARD3,SPARCL1,LRIG1,ATP1A2,NHSL1,PAMR1,PCDH9,SOX5,RYR3,GPM6A,TNIK,SLC4A4,ABLIM1 |
1.498e-02 | -4.20 | PAR polarity complex | cellular component | GO:0120157 | 6 | 1 | 19108 | 48 |
PARD3 |
1.502e-02 | -4.20 | CIBAR2 (CBY1 interacting BAR domain containing 2) | protein interactions | 339145 | 6 | 1 | 19454 | 49 |
CAMK2G |
1.502e-02 | -4.20 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 49 |
GPM6A |
1.502e-02 | -4.20 | SOX11 (SRY-box transcription factor 11) | protein interactions | 6664 | 6 | 1 | 19454 | 49 |
SOX5 |
1.502e-02 | -4.20 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 49 |
BMPR1B |
1.502e-02 | -4.20 | RSPO3 (R-spondin 3) | protein interactions | 84870 | 6 | 1 | 19454 | 49 |
ZNRF3 |
1.502e-02 | -4.20 | SYTL3 (synaptotagmin like 3) | protein interactions | 94120 | 6 | 1 | 19454 | 49 |
NRXN1 |
1.502e-02 | -4.20 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 49 |
BMPR1B |
1.502e-02 | -4.20 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 49 |
DTNA |
1.502e-02 | -4.20 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 49 |
FGFR3 |
1.502e-02 | -4.20 | SOX1 (SRY-box transcription factor 1) | protein interactions | 6656 | 6 | 1 | 19454 | 49 |
SOX5 |
1.502e-02 | -4.20 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 49 |
BMPR1B |
1.502e-02 | -4.20 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 49 |
GPM6A |
1.502e-02 | -4.20 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 49 |
GLIS3 |
1.502e-02 | -4.20 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 49 |
BMPR1B |
1.502e-02 | -4.20 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 49 |
SORBS1 |
1.502e-02 | -4.20 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 49 |
DTNA |
1.507e-02 | -4.20 | non-proteinogenic amino acid metabolic process | biological process | GO:0170041 | 71 | 2 | 18204 | 48 |
SLC1A3,PRODH |
1.528e-02 | -4.18 | MAGEA9 (MAGE family member A9) | protein interactions | 4108 | 207 | 3 | 19454 | 49 |
MEIS2,CAMK2G,NHSL1 |
1.528e-02 | -4.18 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 47 | 16828 | 48 |
DTNA,ABLIM1,NPAS3,TNIK,SLC1A3,ATP13A4,NRXN1,PCDH9,MSI2,ZBTB20,GLIS3,CDH20,FGFR3,NTM,HIF3A,RORA,PARD3,PAMR1,NHSL1,FBXL7,GPC5,COL5A3,ACSS1,AHCYL2,SLC1A2,RYR3,PARD3B,SFXN5,SPARCL1,SORBS1,PRODH,LSAMP,NFIA,MEIS2,NKAIN3,SLC4A4,RFX4,SOX5,GPM6A,ATP1A2,LRIG1,BMPR1B,PTGDS,CAMK2G,ZNRF3,SLC25A18,CTNND2 |
1.529e-02 | -4.18 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 13 | 16828 | 48 |
RYR3,FGFR3,NPAS3,PARD3B,SLC1A3,CDH20,ZNRF3,NFIA,SPARCL1,PARD3,PAMR1,SORBS1,NHSL1 |
1.529e-02 | -4.18 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 13 | 16828 | 48 |
PAMR1,SORBS1,NHSL1,SPARCL1,PARD3,SLC1A3,CDH20,ZNRF3,NFIA,RYR3,FGFR3,PARD3B,NPAS3 |
1.529e-02 | -4.18 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 48 |
RYR3,GPC5,PCDH9 |
1.547e-02 | -4.17 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 2 |
PTGDS |
1.547e-02 | -4.17 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 2 |
PTGDS |
1.548e-02 | -4.17 | regulation of ATP metabolic process | biological process | GO:1903578 | 72 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
1.549e-02 | -4.17 | amino acid:proton symporter activity | molecular function | GO:0005280 | 6 | 1 | 18094 | 47 |
SLC25A18 |
1.549e-02 | -4.17 | steroid hormone binding | molecular function | GO:1990239 | 6 | 1 | 18094 | 47 |
ATP1A2 |
1.549e-02 | -4.17 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 47 |
SLC4A4 |
1.549e-02 | -4.17 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 47 |
RYR3 |
1.560e-02 | -4.16 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 48 |
BMPR1B,PARD3,CTNNA2,NRXN1 |
1.562e-02 | -4.16 | ovary-carcinoma-serous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-serous_carcinoma | 10710 | 38 | 16828 | 48 |
ATP13A4,SFXN5,SORBS1,NRXN1,PCDH9,ZBTB20,MSI2,CDH20,LSAMP,GLIS3,DTNA,AHCYL2,ACSS1,NPAS3,PARD3B,RYR3,SLC1A2,SLC1A3,TNIK,PARD3,BMPR1B,ATP1A2,LRIG1,NHSL1,PAMR1,PTGDS,COL5A3,FBXL7,GPC5,CAMK2G,CTNND2,ZNRF3,SLC4A4,MEIS2,FGFR3,SOX5,RORA,NTM |
1.565e-02 | -4.16 | sarcoplasmic reticulum | cellular component | GO:0016529 | 76 | 2 | 19108 | 48 |
CAMK2G,RYR3 |
1.572e-02 | -4.15 | asymmetric neuroblast division | biological process | GO:0055059 | 6 | 1 | 18204 | 48 |
SOX5 |
1.572e-02 | -4.15 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 48 |
BMPR1B |
1.572e-02 | -4.15 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 48 |
SLC1A3 |
1.572e-02 | -4.15 | postsynaptic density protein 95 clustering | biological process | GO:0097119 | 6 | 1 | 18204 | 48 |
NRXN1 |
1.572e-02 | -4.15 | imitative learning | biological process | GO:0098596 | 6 | 1 | 18204 | 48 |
NRXN1 |
1.572e-02 | -4.15 | vocal learning | biological process | GO:0042297 | 6 | 1 | 18204 | 48 |
NRXN1 |
1.577e-02 | -4.15 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 49 |
RYR3 |
1.577e-02 | -4.15 | P-type_ATPase_IIC | interpro domains | IPR005775 | 6 | 1 | 18521 | 49 |
ATP1A2 |
1.577e-02 | -4.15 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 49 |
DTNA |
1.577e-02 | -4.15 | Syndecan/Neurexin_dom | interpro domains | IPR027789 | 6 | 1 | 18521 | 49 |
NRXN1 |
1.577e-02 | -4.15 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 49 |
RYR3 |
1.577e-02 | -4.15 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 49 |
DTNA |
1.577e-02 | -4.15 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 49 |
RYR3 |
1.577e-02 | -4.15 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 49 |
RYR3 |
1.577e-02 | -4.15 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 49 |
GPC5 |
1.577e-02 | -4.15 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 49 |
GPC5 |
1.577e-02 | -4.15 | GLI-like | interpro domains | IPR043359 | 6 | 1 | 18521 | 49 |
GLIS3 |
1.577e-02 | -4.15 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 49 |
RYR3 |
1.585e-02 | -4.14 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 16 |
SOX5,FGFR3 |
1.587e-02 | -4.14 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 49 |
NHSL1,SLC1A3,SORBS1 |
1.588e-02 | -4.14 | regulation of cartilage development | biological process | GO:0061035 | 73 | 2 | 18204 | 48 |
SOX5,BMPR1B |
1.607e-02 | -4.13 | CDK6 (cyclin dependent kinase 6) | protein interactions | 1021 | 211 | 3 | 19454 | 49 |
SOX5,FGFR3,SORBS1 |
1.615e-02 | -4.13 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 42 | 16828 | 48 |
SPARCL1,ATP13A4,SFXN5,PRODH,PCDH9,NRXN1,SORBS1,ZBTB20,NFIA,PITPNC1,LSAMP,CDH20,GLIS3,AHCYL2,ABLIM1,ACSS1,PARD3B,NPAS3,RYR3,SLC1A2,SLC1A3,TNIK,PARD3,BMPR1B,ATP1A2,LRIG1,NHSL1,PAMR1,COL5A3,GPC5,FBXL7,CTNND2,SLC25A18,NKAIN3,MEIS2,FGFR3,SOX5,RFX4,RORA,HIF3A,NTM,GPM6A |
1.641e-02 | -4.11 | HAD_sf | interpro domains | IPR023214 | 74 | 2 | 18521 | 49 |
ATP13A4,ATP1A2 |
1.641e-02 | -4.11 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Syndecan | pfam domains | PF01034 | 6 | 1 | 17795 | 49 |
NRXN1 |
1.641e-02 | -4.11 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 49 |
GPC5 |
1.641e-02 | -4.11 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 49 |
DTNA |
1.641e-02 | -4.11 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 49 |
RYR3 |
1.641e-02 | -4.11 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 20 |
ATP1A2,SLC4A4 |
1.641e-02 | -4.11 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 20 |
SLC4A4,ATP1A2 |
1.652e-02 | -4.10 | KRTAP19-6 (keratin associated protein 19-6) | protein interactions | 337973 | 78 | 2 | 19454 | 49 |
MEIS2,SLC25A18 |
1.660e-02 | -4.10 | membrane | cellular component | GO:0016020 | 9220 | 31 | 19108 | 48 |
PARD3,PRODH,DTNA,SLC4A4,TNIK,PTGDS,LRIG1,SLC25A18,PCDH9,SLC1A3,CTNND2,NRXN1,ZNRF3,FGFR3,NKAIN3,BMPR1B,PARD3B,RYR3,HIF3A,GPC5,GPM6A,SORBS1,SFXN5,CTNNA2,LSAMP,CAMK2G,NTM,CDH20,ATP1A2,ATP13A4,SLC1A2 |
1.668e-02 | -4.09 | sequence-specific double-stranded DNA binding | molecular function | GO:1990837 | 1547 | 9 | 18094 | 47 |
ZBTB20,MEIS2,HIF3A,RFX4,NPAS3,GLIS3,NFIA,SOX5,RORA |
1.675e-02 | -4.09 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 49 |
BMPR1B |
1.691e-02 | -4.08 | plasma membrane protein complex | cellular component | GO:0098797 | 600 | 5 | 19108 | 48 |
CTNNA2,SORBS1,BMPR1B,ATP1A2,CDH20 |
1.700e-02 | -4.07 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 48 |
FGFR3 |
1.700e-02 | -4.07 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 48 |
NHSL1 |
1.700e-02 | -4.07 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 48 |
FGFR3 |
1.711e-02 | -4.07 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 18 |
SLC4A4 |
1.711e-02 | -4.07 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 18 |
PITPNC1 |
1.715e-02 | -4.07 | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 7434 | 29 | 16828 | 48 |
SLC4A4,NKAIN3,FGFR3,SOX5,RORA,HIF3A,PARD3,ATP1A2,LRIG1,PTGDS,PAMR1,COL5A3,CAMK2G,CTNND2,DTNA,ACSS1,ABLIM1,PARD3B,NPAS3,RYR3,TNIK,SLC1A3,ATP13A4,SPARCL1,SORBS1,NRXN1,PRODH,ZBTB20,GLIS3 |
1.731e-02 | -4.06 | GFAP (glial fibrillary acidic protein) | protein interactions | 2670 | 217 | 3 | 19454 | 49 |
RORA,ABLIM1,NKAIN3 |
1.743e-02 | -4.05 | Protein_kinase_ATP_BS | interpro domains | IPR017441 | 377 | 4 | 18521 | 49 |
FGFR3,TNIK,BMPR1B,CAMK2G |
1.750e-02 | -4.05 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 49 |
BMPR1B |
1.750e-02 | -4.05 | Ahcyl1 (S-adenosylhomocysteine hydrolase-like 1) | protein interactions | 229709 | 7 | 1 | 19454 | 49 |
AHCYL2 |
1.750e-02 | -4.05 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 49 |
BMPR1B |
1.750e-02 | -4.05 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 49 |
BMPR1B |
1.750e-02 | -4.05 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 49 |
GLIS3 |
1.750e-02 | -4.05 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 49 |
FGFR3 |
1.750e-02 | -4.05 | ZBTB45 (zinc finger and BTB domain containing 45) | protein interactions | 84878 | 7 | 1 | 19454 | 49 |
ZBTB20 |
1.750e-02 | -4.05 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 49 |
NPAS3 |
1.750e-02 | -4.05 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 49 |
BMPR1B |
1.750e-02 | -4.05 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 49 |
BMPR1B |
1.757e-02 | -4.04 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 48 |
BMPR1B,NFIA |
1.757e-02 | -4.04 | regulation of synaptic transmission, glutamatergic | biological process | GO:0051966 | 77 | 2 | 18204 | 48 |
NRXN1,ATP1A2 |
1.770e-02 | -4.03 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 43 |
RYR3 |
1.774e-02 | -4.03 | ARNT2 (aryl hydrocarbon receptor nuclear translocator 2) | protein interactions | 9915 | 81 | 2 | 19454 | 49 |
MEIS2,NPAS3 |
1.779e-02 | -4.03 | Neuronal System | REACTOME pathways | R-HSA-112316 | 349 | 4 | 10285 | 30 |
SLC1A2,SLC1A3,CAMK2G,NRXN1 |
1.782e-02 | -4.03 | eye development | biological process | GO:0001654 | 381 | 4 | 18204 | 48 |
NFIA,GPM6A,MEIS2,BMPR1B |
1.783e-02 | -4.03 | other | COSMIC cancer mutations | other | 14843 | 47 | 16828 | 48 |
CDH20,GLIS3,ZBTB20,MSI2,PCDH9,NRXN1,ATP13A4,SLC1A3,TNIK,NPAS3,ABLIM1,DTNA,COL5A3,FBXL7,GPC5,NHSL1,PAMR1,PARD3,RORA,HIF3A,NTM,FGFR3,NFIA,LSAMP,PRODH,SORBS1,SPARCL1,SFXN5,PARD3B,RYR3,SLC1A2,AHCYL2,ACSS1,CTNND2,SLC25A18,ZNRF3,CAMK2G,PTGDS,BMPR1B,LRIG1,ATP1A2,GPM6A,SOX5,RFX4,SLC4A4,NKAIN3,MEIS2 |
1.795e-02 | -4.02 | anion binding | molecular function | GO:0043168 | 2412 | 12 | 18094 | 47 |
PITPNC1,ATP13A4,PTGDS,CAMK2G,ATP1A2,ACSS1,FGFR3,SLC1A3,BMPR1B,PARD3,PRODH,TNIK |
1.800e-02 | -4.02 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 48 |
SORBS1,SLC1A2 |
1.801e-02 | -4.02 | sensory organ development | biological process | GO:0007423 | 581 | 5 | 18204 | 48 |
MEIS2,BMPR1B,LRIG1,NFIA,GPM6A |
1.804e-02 | -4.01 | P-type sodium:potassium-exchanging transporter activity | molecular function | GO:0005391 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.804e-02 | -4.01 | P-type sodium transporter activity | molecular function | GO:0008554 | 7 | 1 | 18094 | 47 |
ATP1A2 |
1.804e-02 | -4.01 | calcium-dependent protein serine/threonine phosphatase activity | molecular function | GO:0004723 | 7 | 1 | 18094 | 47 |
CAMK2G |
1.804e-02 | -4.01 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 47 |
PITPNC1 |
1.806e-02 | -4.01 | YWHAH (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta) | protein interactions | 7533 | 1083 | 7 | 19454 | 49 |
PARD3,PITPNC1,ABLIM1,NHSL1,PARD3B,CAMK2G,SORBS1 |
1.812e-02 | -4.01 | HAD-like_sf | interpro domains | IPR036412 | 78 | 2 | 18521 | 49 |
ATP1A2,ATP13A4 |
1.816e-02 | -4.01 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 2 | 19454 | 49 |
SOX5,NFIA |
1.820e-02 | -4.01 | Gastric acid secretion | KEGG pathways | hsa04971 | 75 | 2 | 7161 | 20 |
CAMK2G,ATP1A2 |
1.820e-02 | -4.01 | Gastric acid secretion | KEGG pathways | ko04971 | 75 | 2 | 7161 | 20 |
CAMK2G,ATP1A2 |
1.824e-02 | -4.00 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 6 | 19108 | 48 |
NRXN1,ATP1A2,SLC1A3,BMPR1B,GPM6A,CTNND2 |
1.832e-02 | -4.00 | negative regulation of non-canonical Wnt signaling pathway | biological process | GO:2000051 | 7 | 1 | 18204 | 48 |
ZNRF3 |
1.832e-02 | -4.00 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 48 |
NFIA |
1.832e-02 | -4.00 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 48 |
RYR3 |
1.832e-02 | -4.00 | observational learning | biological process | GO:0098597 | 7 | 1 | 18204 | 48 |
NRXN1 |
1.832e-02 | -4.00 | regulation of cardiac muscle myoblast proliferation | biological process | GO:0110022 | 7 | 1 | 18204 | 48 |
MEIS2 |
1.832e-02 | -4.00 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 48 |
PTGDS |
1.832e-02 | -4.00 | S-adenosylmethionine cycle | biological process | GO:0033353 | 7 | 1 | 18204 | 48 |
AHCYL2 |
1.832e-02 | -4.00 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 48 |
CTNNA2 |
1.838e-02 | -4.00 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 49 |
CTNNA2 |
1.838e-02 | -4.00 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 49 |
CTNND2 |
1.838e-02 | -4.00 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 49 |
SPARCL1 |
1.838e-02 | -4.00 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 49 |
BMPR1B |
1.844e-02 | -3.99 | visual system development | biological process | GO:0150063 | 385 | 4 | 18204 | 48 |
NFIA,GPM6A,MEIS2,BMPR1B |
1.847e-02 | -3.99 | FBXO2 (F-box protein 2) | protein interactions | 26232 | 403 | 4 | 19454 | 49 |
PCDH9,LRIG1,NTM,FGFR3 |
1.848e-02 | -3.99 | caveola | cellular component | GO:0005901 | 83 | 2 | 19108 | 48 |
ATP1A2,SORBS1 |
1.858e-02 | -3.99 | SYT1 (synaptotagmin 1) | protein interactions | 6857 | 83 | 2 | 19454 | 49 |
NRXN1,GPM6A |
1.858e-02 | -3.99 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 49 |
FGFR3,GPM6A |
1.860e-02 | -3.98 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 49 |
GLIS3 |
1.878e-02 | -3.97 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 47 |
BMPR1B,FGFR3 |
1.894e-02 | -3.97 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 748 | 6 | 16828 | 48 |
DTNA,PARD3,SOX5,CTNND2,SLC1A3,ACSS1 |
1.912e-02 | -3.96 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 49 |
SPARCL1 |
1.912e-02 | -3.96 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 49 |
BMPR1B |
1.918e-02 | -3.95 | leg | COSMIC cancer mutations | leg | 969 | 7 | 16828 | 48 |
SLC4A4,ATP13A4,FGFR3,ZBTB20,COL5A3,HIF3A,NTM |
1.926e-02 | -3.95 | endometrium-carcinoma-serous_carcinoma | COSMIC cancer mutations | endometrium-carcinoma-serous_carcinoma | 1442 | 9 | 16828 | 48 |
NRXN1,SORBS1,SLC4A4,PARD3,LSAMP,TNIK,CTNND2,RYR3,GPC5 |
1.940e-02 | -3.94 | sensory system development | biological process | GO:0048880 | 391 | 4 | 18204 | 48 |
GPM6A,NFIA,BMPR1B,MEIS2 |
1.965e-02 | -3.93 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 48 |
SPARCL1,GPM6A,TNIK,SLC1A2 |
1.975e-02 | -3.92 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 48 |
SORBS1,ABLIM1 |
1.975e-02 | -3.92 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 48 |
ABLIM1,SORBS1 |
1.980e-02 | -3.92 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 48 |
FGFR3 |
1.980e-02 | -3.92 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 48 |
FGFR3 |
1.986e-02 | -3.92 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 49 |
SORBS1,GPM6A |
1.986e-02 | -3.92 | EGLN1 (egl-9 family hypoxia inducible factor 1) | protein interactions | 54583 | 86 | 2 | 19454 | 49 |
HIF3A,FGFR3 |
1.992e-02 | -3.92 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 48 |
SORBS1 |
1.992e-02 | -3.92 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 48 |
BMPR1B |
1.998e-02 | -3.91 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 49 |
BMPR1B |
1.998e-02 | -3.91 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 49 |
NTM |
1.998e-02 | -3.91 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 49 |
BMPR1B |
1.998e-02 | -3.91 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 49 |
SORBS1 |
1.998e-02 | -3.91 | SCT (secretin) | protein interactions | 6343 | 8 | 1 | 19454 | 49 |
MEIS2 |
1.998e-02 | -3.91 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 49 |
PTGDS |
1.998e-02 | -3.91 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 49 |
BMPR1B |
2.014e-02 | -3.91 | Ig_sub | interpro domains | IPR003599 | 394 | 4 | 18521 | 49 |
FGFR3,LRIG1,LSAMP,NTM |
2.016e-02 | -3.90 | ConA-like_dom_sf | interpro domains | IPR013320 | 219 | 3 | 18521 | 49 |
COL5A3,RYR3,NRXN1 |
2.016e-02 | -3.90 | DST (dystonin) | protein interactions | 667 | 230 | 3 | 19454 | 49 |
ATP1A2,TNIK,PARD3 |
2.025e-02 | -3.90 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 30 |
FGFR3 |
2.029e-02 | -3.90 | ZNF608 (zinc finger protein 608) | protein interactions | 57507 | 87 | 2 | 19454 | 49 |
SOX5,NFIA |
2.031e-02 | -3.90 | cell-cell signaling | biological process | GO:0007267 | 822 | 6 | 18204 | 48 |
SLC1A2,SLC1A3,CAMK2G,FGFR3,NRXN1,DTNA |
2.035e-02 | -3.89 | HAD superfamily/HAD-like | gene3d domains | 3.40.50.1000 | 74 | 2 | 14470 | 43 |
ATP13A4,ATP1A2 |
2.049e-02 | -3.89 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 18 |
BMPR1B |
2.060e-02 | -3.88 | sodium ion binding | molecular function | GO:0031402 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.060e-02 | -3.88 | P-type potassium transmembrane transporter activity | molecular function | GO:0008556 | 8 | 1 | 18094 | 47 |
ATP1A2 |
2.060e-02 | -3.88 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 47 |
BMPR1B |
2.060e-02 | -3.88 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 47 |
SLC1A3 |
2.069e-02 | -3.88 | regulation of sodium ion transport | biological process | GO:0002028 | 84 | 2 | 18204 | 48 |
NKAIN3,ATP1A2 |
2.073e-02 | -3.88 | RAP2A (RAP2A, member of RAS oncogene family) | protein interactions | 5911 | 88 | 2 | 19454 | 49 |
TNIK,BMPR1B |
2.090e-02 | -3.87 | cell proliferation in external granule layer | biological process | GO:0021924 | 8 | 1 | 18204 | 48 |
RORA |
2.090e-02 | -3.87 | cerebellar granule cell precursor proliferation | biological process | GO:0021930 | 8 | 1 | 18204 | 48 |
RORA |
2.090e-02 | -3.87 | cell proliferation in hindbrain | biological process | GO:0021534 | 8 | 1 | 18204 | 48 |
RORA |
2.090e-02 | -3.87 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 48 |
PTGDS |
2.090e-02 | -3.87 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 48 |
SLC1A3 |
2.090e-02 | -3.87 | regulation of L-glutamate import across plasma membrane | biological process | GO:0002036 | 8 | 1 | 18204 | 48 |
ATP1A2 |
2.090e-02 | -3.87 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 48 |
CTNNA2 |
2.097e-02 | -3.86 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 49 |
ABLIM1 |
2.097e-02 | -3.86 | RFX-like | interpro domains | IPR039779 | 8 | 1 | 18521 | 49 |
RFX4 |
2.097e-02 | -3.86 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 49 |
ABLIM1 |
2.099e-02 | -3.86 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 43 |
GPC5 |
2.109e-02 | -3.86 | HMG20A (high mobility group 20A) | protein interactions | 10363 | 234 | 3 | 19454 | 49 |
NFIA,SOX5,DTNA |
2.110e-02 | -3.86 | cell differentiation | biological process | GO:0030154 | 3645 | 16 | 18204 | 48 |
NTM,RORA,TNIK,MSI2,FGFR3,PARD3,BMPR1B,CAMK2G,NHSL1,NRXN1,CTNNA2,CTNND2,SLC1A3,GPM6A,SOX5,NFIA |
2.117e-02 | -3.85 | PLEKHA2 (pleckstrin homology domain containing A2) | protein interactions | 59339 | 89 | 2 | 19454 | 49 |
DTNA,AHCYL2 |
2.125e-02 | -3.85 | cellular developmental process | biological process | GO:0048869 | 3648 | 16 | 18204 | 48 |
BMPR1B,CAMK2G,NHSL1,NRXN1,CTNNA2,CTNND2,SLC1A3,GPM6A,SOX5,NFIA,RORA,NTM,TNIK,MSI2,FGFR3,PARD3 |
2.162e-02 | -3.83 | FGFR1OP2 (FGFR1 oncogene partner 2) | protein interactions | 26127 | 90 | 2 | 19454 | 49 |
TNIK,CAMK2G |
2.180e-02 | -3.83 | CAMK2A (calcium/calmodulin dependent protein kinase II alpha) | protein interactions | 815 | 237 | 3 | 19454 | 49 |
CAMK2G,GPM6A,SOX5 |
2.182e-02 | -3.82 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 49 |
ABLIM1 |
2.207e-02 | -3.81 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 49 |
NTM,GPM6A |
2.207e-02 | -3.81 | SOS1 (SOS Ras/Rac guanine nucleotide exchange factor 1) | protein interactions | 6654 | 91 | 2 | 19454 | 49 |
SORBS1,TNIK |
2.209e-02 | -3.81 | associative learning | biological process | GO:0008306 | 87 | 2 | 18204 | 48 |
ATP1A2,MEIS2 |
2.218e-02 | -3.81 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 48 |
FGFR3,SOX5,BMPR1B |
2.224e-02 | -3.81 | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-fibula-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 377 | 4 | 16828 | 48 |
NRXN1,PRODH,FGFR3,COL5A3 |
2.224e-02 | -3.81 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 10 | 19454 | 49 |
ZBTB20,PARD3,MSI2,NFIA,FGFR3,PARD3B,BMPR1B,AHCYL2,DTNA,ABLIM1 |
2.228e-02 | -3.80 | forebrain development | biological process | GO:0030900 | 408 | 4 | 18204 | 48 |
SLC1A2,PCDH9,ATP1A2,RFX4 |
2.239e-02 | -3.80 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 48 |
SORBS1 |
2.241e-02 | -3.80 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 48 |
ABLIM1,SORBS1 |
2.245e-02 | -3.80 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 49 |
CTNNA2 |
2.245e-02 | -3.80 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 49 |
FGFR3 |
2.245e-02 | -3.80 | CAMK2N1 (calcium/calmodulin dependent protein kinase II inhibitor 1) | protein interactions | 55450 | 9 | 1 | 19454 | 49 |
CAMK2G |
2.245e-02 | -3.80 | KLB (klotho beta) | protein interactions | 152831 | 9 | 1 | 19454 | 49 |
FGFR3 |
2.245e-02 | -3.80 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 49 |
BMPR1B |
2.251e-02 | -3.79 | lung-carcinoma-bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | lung-carcinoma-bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 48 |
TNIK,CTNND2,CAMK2G,SOX5,BMPR1B,FGFR3 |
2.251e-02 | -3.79 | bronchioloalveolar_adenocarcinoma | COSMIC cancer mutations | bronchioloalveolar_adenocarcinoma | 778 | 6 | 16828 | 48 |
CTNND2,TNIK,FGFR3,BMPR1B,SOX5,CAMK2G |
2.253e-02 | -3.79 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 49 |
FGFR3,DTNA |
2.253e-02 | -3.79 | FNTA (farnesyltransferase, CAAX box, subunit alpha) | protein interactions | 2339 | 92 | 2 | 19454 | 49 |
TNIK,FGFR3 |
2.260e-02 | -3.79 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 48 |
FGFR3 |
2.260e-02 | -3.79 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 48 |
FGFR3 |
2.260e-02 | -3.79 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 48 |
FGFR3 |
2.260e-02 | -3.79 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 48 |
FGFR3 |
2.260e-02 | -3.79 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 48 |
FGFR3 |
2.260e-02 | -3.79 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 48 |
FGFR3 |
2.268e-02 | -3.79 | response to organic cyclic compound | biological process | GO:0014070 | 843 | 6 | 18204 | 48 |
RORA,ATP1A2,RYR3,SLC1A2,PTGDS,SLC1A3 |
2.288e-02 | -3.78 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 9 | 16828 | 48 |
PARD3B,FGFR3,NPAS3,GPC5,RYR3,PRODH,PCDH9,SORBS1,DTNA |
2.299e-02 | -3.77 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 49 |
ABLIM1,BMPR1B |
2.299e-02 | -3.77 | ODR4 (odr-4 GPCR localization factor homolog) | protein interactions | 54953 | 93 | 2 | 19454 | 49 |
LRIG1,GPM6A |
2.299e-02 | -3.77 | MPDZ (multiple PDZ domain crumbs cell polarity complex component) | protein interactions | 8777 | 93 | 2 | 19454 | 49 |
PARD3,FGFR3 |
2.299e-02 | -3.77 | behavior | biological process | GO:0007610 | 619 | 5 | 18204 | 48 |
SLC1A3,NRXN1,ATP1A2,SLC1A2,MEIS2 |
2.302e-02 | -3.77 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 7 | 19454 | 49 |
PARD3,PITPNC1,CAMK2G,SORBS1,PARD3B,ABLIM1,NHSL1 |
2.303e-02 | -3.77 | Insulin secretion | KEGG pathways | hsa04911 | 85 | 2 | 7161 | 20 |
ATP1A2,CAMK2G |
2.305e-02 | -3.77 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 48 |
SORBS1,ZBTB20 |
2.311e-02 | -3.77 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 30 |
GPC5 |
2.314e-02 | -3.77 | L-aspartate transmembrane transporter activity | molecular function | GO:0015183 | 9 | 1 | 18094 | 47 |
SLC25A18 |
2.323e-02 | -3.76 | lipid binding | molecular function | GO:0008289 | 861 | 6 | 18094 | 47 |
PTGDS,PARD3B,ATP1A2,RORA,PARD3,PITPNC1 |
2.345e-02 | -3.75 | GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) | protein interactions | 2902 | 94 | 2 | 19454 | 49 |
CAMK2G,FGFR3 |
2.345e-02 | -3.75 | QSER1 (glutamine and serine rich 1) | protein interactions | 79832 | 94 | 2 | 19454 | 49 |
SOX5,NFIA |
2.345e-02 | -3.75 | FOXP4 (forkhead box P4) | protein interactions | 116113 | 94 | 2 | 19454 | 49 |
SOX5,NFIA |
2.345e-02 | -3.75 | WWC1 (WW and C2 domain containing 1) | protein interactions | 23286 | 94 | 2 | 19454 | 49 |
ABLIM1,TNIK |
2.349e-02 | -3.75 | positive regulation of synapse maturation | biological process | GO:0090129 | 9 | 1 | 18204 | 48 |
NRXN1 |
2.349e-02 | -3.75 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 48 |
CTNNA2 |
2.349e-02 | -3.75 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 48 |
ATP13A4 |
2.349e-02 | -3.75 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 48 |
PTGDS |
2.349e-02 | -3.75 | negative regulation of striated muscle contraction | biological process | GO:0045988 | 9 | 1 | 18204 | 48 |
ATP1A2 |
2.349e-02 | -3.75 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 48 |
CTNNA2 |
2.349e-02 | -3.75 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 48 |
RYR3 |
2.353e-02 | -3.75 | regulation of purine nucleotide metabolic process | biological process | GO:1900542 | 90 | 2 | 18204 | 48 |
ZBTB20,SLC4A4 |
2.353e-02 | -3.75 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 43 |
ABLIM1 |
2.354e-02 | -3.75 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 48 |
DTNA,NRXN1,SLC1A3,SLC1A2 |
2.354e-02 | -3.75 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 48 |
SLC1A2,DTNA,SLC1A3,NRXN1 |
2.357e-02 | -3.75 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 49 |
BMPR1B |
2.357e-02 | -3.75 | DNA-bd_RFX | interpro domains | IPR003150 | 9 | 1 | 18521 | 49 |
RFX4 |
2.357e-02 | -3.75 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 49 |
SPARCL1 |
2.357e-02 | -3.75 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 49 |
SLC4A4 |
2.378e-02 | -3.74 | double-stranded DNA binding | molecular function | GO:0003690 | 1643 | 9 | 18094 | 47 |
MEIS2,ZBTB20,RFX4,NPAS3,HIF3A,NFIA,GLIS3,RORA,SOX5 |
2.391e-02 | -3.73 | STRIP1 (striatin interacting protein 1) | protein interactions | 85369 | 95 | 2 | 19454 | 49 |
CAMK2G,TNIK |
2.402e-02 | -3.73 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 48 |
BMPR1B,NFIA |
2.402e-02 | -3.73 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 48 |
BMPR1B,NFIA |
2.402e-02 | -3.73 | regulation of nucleotide metabolic process | biological process | GO:0006140 | 91 | 2 | 18204 | 48 |
SLC4A4,ZBTB20 |
2.411e-02 | -3.73 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 49 |
FBXL7 |
2.420e-02 | -3.72 | fibula | COSMIC cancer mutations | fibula | 387 | 4 | 16828 | 48 |
COL5A3,FGFR3,PRODH,NRXN1 |
2.425e-02 | -3.72 | superpathway of L-citrulline metabolism | BIOCYC pathways | META_PWY-5004 | 11 | 1 | 902 | 2 |
PRODH |
2.426e-02 | -3.72 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 48 |
ABLIM1,SORBS1 |
2.426e-02 | -3.72 | sarcoplasm | cellular component | GO:0016528 | 96 | 2 | 19108 | 48 |
CAMK2G,RYR3 |
2.445e-02 | -3.71 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 43 |
BMPR1B |
2.447e-02 | -3.71 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 48 |
NRXN1,PARD3,CTNNA2,BMPR1B |
2.452e-02 | -3.71 | RFX_DNA_binding | pfam domains | PF02257 | 9 | 1 | 17795 | 49 |
RFX4 |
2.452e-02 | -3.71 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 49 |
SLC4A4 |
2.452e-02 | -3.71 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 49 |
BMPR1B |
2.452e-02 | -3.71 | NCOR2 (nuclear receptor corepressor 2) | protein interactions | 9612 | 248 | 3 | 19454 | 49 |
SOX5,NFIA,TNIK |
2.454e-02 | -3.71 | sequence-specific DNA binding | molecular function | GO:0043565 | 1652 | 9 | 18094 | 47 |
GLIS3,NFIA,SOX5,RORA,ZBTB20,MEIS2,HIF3A,NPAS3,RFX4 |
2.458e-02 | -3.71 | metal ion transport | biological process | GO:0030001 | 630 | 5 | 18204 | 48 |
SLC4A4,ATP1A2,GPM6A,RYR3,SLC1A3 |
2.474e-02 | -3.70 | Transmission across Chemical Synapses | REACTOME pathways | R-HSA-112315 | 217 | 3 | 10285 | 30 |
CAMK2G,SLC1A3,SLC1A2 |
2.478e-02 | -3.70 | MYO1B (myosin IB) | protein interactions | 4430 | 249 | 3 | 19454 | 49 |
CAMK2G,PARD3,FGFR3 |
2.479e-02 | -3.70 | muscle contraction | biological process | GO:0006936 | 238 | 3 | 18204 | 48 |
RYR3,ATP1A2,DTNA |
2.485e-02 | -3.70 | response to radiation | biological process | GO:0009314 | 422 | 4 | 18204 | 48 |
ATP1A2,SLC1A3,MEIS2,SLC1A2 |
2.486e-02 | -3.69 | PLCB3 (phospholipase C beta 3) | protein interactions | 5331 | 97 | 2 | 19454 | 49 |
PARD3,CAMK2G |
2.491e-02 | -3.69 | TSHZ1 (teashirt zinc finger homeobox 1) | protein interactions | 10194 | 10 | 1 | 19454 | 49 |
MEIS2 |
2.491e-02 | -3.69 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 49 |
GPM6A |
2.491e-02 | -3.69 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 49 |
GPM6A |
2.491e-02 | -3.69 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 49 |
GLIS3 |
2.491e-02 | -3.69 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 49 |
PITPNC1 |
2.491e-02 | -3.69 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 49 |
ABLIM1 |
2.495e-02 | -3.69 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 35 |
BMPR1B |
2.510e-02 | -3.68 | Protein digestion and absorption | KEGG pathways | ko04974 | 89 | 2 | 7161 | 20 |
COL5A3,ATP1A2 |
2.510e-02 | -3.68 | Protein digestion and absorption | KEGG pathways | hsa04974 | 89 | 2 | 7161 | 20 |
ATP1A2,COL5A3 |
2.534e-02 | -3.68 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 49 |
LSAMP,GPM6A |
2.539e-02 | -3.67 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 48 |
FGFR3 |
2.539e-02 | -3.67 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 48 |
FGFR3 |
2.551e-02 | -3.67 | mitochondrial transmembrane transport | biological process | GO:1990542 | 94 | 2 | 18204 | 48 |
SLC25A18,SFXN5 |
2.555e-02 | -3.67 | NCK2 (NCK adaptor protein 2) | protein interactions | 8440 | 252 | 3 | 19454 | 49 |
SORBS1,TNIK,NHSL1 |
2.563e-02 | -3.66 | Salivary secretion | KEGG pathways | ko04970 | 90 | 2 | 7161 | 20 |
RYR3,ATP1A2 |
2.563e-02 | -3.66 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 2 | 7161 | 20 |
RYR3,ATP1A2 |
2.568e-02 | -3.66 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 47 |
ATP13A4 |
2.568e-02 | -3.66 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 47 |
PITPNC1 |
2.580e-02 | -3.66 | ATPase-coupled transmembrane transporter activity | molecular function | GO:0042626 | 96 | 2 | 18094 | 47 |
ATP13A4,ATP1A2 |
2.582e-02 | -3.66 | TNKS (tankyrase) | protein interactions | 8658 | 99 | 2 | 19454 | 49 |
TNIK,PCDH9 |
2.594e-02 | -3.65 | human chr2p13.2 | chromosome location | human chr2p13.2 | 14 | 1 | 26134 | 49 |
SFXN5 |
2.594e-02 | -3.65 | human chr2p16.3 | chromosome location | human chr2p16.3 | 14 | 1 | 26134 | 49 |
NRXN1 |
2.595e-02 | -3.65 | pancreas-other-adenoma | COSMIC cancer mutations | pancreas-other-adenoma | 224 | 3 | 16828 | 48 |
BMPR1B,PCDH9,CTNND2 |
2.606e-02 | -3.65 | neuronal action potential propagation | biological process | GO:0019227 | 10 | 1 | 18204 | 48 |
ATP1A2 |
2.606e-02 | -3.65 | action potential propagation | biological process | GO:0098870 | 10 | 1 | 18204 | 48 |
ATP1A2 |
2.606e-02 | -3.65 | proline metabolic process | biological process | GO:0006560 | 10 | 1 | 18204 | 48 |
PRODH |
2.606e-02 | -3.65 | learned vocalization behavior or vocal learning | biological process | GO:0098598 | 10 | 1 | 18204 | 48 |
NRXN1 |
2.606e-02 | -3.65 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 48 |
RYR3 |
2.606e-02 | -3.65 | postsynaptic density assembly | biological process | GO:0097107 | 10 | 1 | 18204 | 48 |
NRXN1 |
2.606e-02 | -3.65 | regulation of mesenchymal stem cell differentiation | biological process | GO:2000739 | 10 | 1 | 18204 | 48 |
SOX5 |
2.606e-02 | -3.65 | otolith development | biological process | GO:0048840 | 10 | 1 | 18204 | 48 |
LRIG1 |
2.606e-02 | -3.65 | postsynaptic membrane assembly | biological process | GO:0097104 | 10 | 1 | 18204 | 48 |
NRXN1 |
2.615e-02 | -3.64 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 49 |
RYR3 |
2.615e-02 | -3.64 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 49 |
NPAS3 |
2.615e-02 | -3.64 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 49 |
SLC4A4 |
2.615e-02 | -3.64 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 49 |
RYR3 |
2.615e-02 | -3.64 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 49 |
SLC4A4 |
2.615e-02 | -3.64 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 49 |
SLC4A4 |
2.630e-02 | -3.64 | ATP4A (ATPase H+/K+ transporting subunit alpha) | protein interactions | 495 | 100 | 2 | 19454 | 49 |
ATP1A2,GPM6A |
2.630e-02 | -3.64 | APBA1 (amyloid beta precursor protein binding family A member 1) | protein interactions | 320 | 100 | 2 | 19454 | 49 |
ABLIM1,NRXN1 |
2.659e-02 | -3.63 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 4 | 18204 | 48 |
SLC1A2,DTNA,NRXN1,SLC1A3 |
2.679e-02 | -3.62 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 49 |
CTNNA2,FGFR3 |
2.698e-02 | -3.61 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 48 |
RYR3,SLC1A3,ATP13A4,ATP1A2 |
2.699e-02 | -3.61 | regulation of synapse organization | biological process | GO:0050807 | 246 | 3 | 18204 | 48 |
GPM6A,NRXN1,CTNNA2 |
2.704e-02 | -3.61 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 48 |
SLC1A3,LRIG1 |
2.711e-02 | -3.61 | Ig-like_dom | interpro domains | IPR007110 | 432 | 4 | 18521 | 49 |
NTM,LSAMP,FGFR3,LRIG1 |
2.720e-02 | -3.60 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 49 |
SLC4A4 |
2.720e-02 | -3.60 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 49 |
RYR3 |
2.720e-02 | -3.60 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 49 |
NPAS3 |
2.724e-02 | -3.60 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 18 |
PTGDS |
2.724e-02 | -3.60 | serous_carcinoma | COSMIC cancer mutations | serous_carcinoma | 10987 | 38 | 16828 | 48 |
LRIG1,ATP1A2,PARD3,BMPR1B,PAMR1,PTGDS,NHSL1,CAMK2G,COL5A3,FBXL7,GPC5,ZNRF3,CTNND2,MEIS2,SLC4A4,SOX5,FGFR3,RORA,NTM,SFXN5,ATP13A4,SORBS1,PCDH9,NRXN1,ZBTB20,MSI2,LSAMP,CDH20,GLIS3,DTNA,ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,NPAS3,SLC1A3,TNIK |
2.737e-02 | -3.60 | AQP5 (aquaporin 5) | protein interactions | 362 | 11 | 1 | 19454 | 49 |
ATP1A2 |
2.737e-02 | -3.60 | GAL3ST1 (galactose-3-O-sulfotransferase 1) | protein interactions | 9514 | 11 | 1 | 19454 | 49 |
LRIG1 |
2.737e-02 | -3.60 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 49 |
PTGDS |
2.737e-02 | -3.60 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 49 |
FGFR3 |
2.737e-02 | -3.60 | SYTL1 (synaptotagmin like 1) | protein interactions | 84958 | 11 | 1 | 19454 | 49 |
NRXN1 |
2.737e-02 | -3.60 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 49 |
ABLIM1 |
2.737e-02 | -3.60 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 49 |
NHSL1 |
2.737e-02 | -3.60 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 49 |
GPM6A |
2.742e-02 | -3.60 | MARK2 (microtubule affinity regulating kinase 2) | protein interactions | 2011 | 259 | 3 | 19454 | 49 |
PARD3,DTNA,PARD3B |
2.760e-02 | -3.59 | Methionine degradation | KEGG pathways | hsa_M00035 | 10 | 1 | 7161 | 20 |
AHCYL2 |
2.760e-02 | -3.59 | Methionine degradation | KEGG pathways | M00035 | 10 | 1 | 7161 | 20 |
AHCYL2 |
2.777e-02 | -3.58 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 49 |
NKAIN3 |
2.778e-02 | -3.58 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 49 |
BMPR1B,GPM6A |
2.789e-02 | -3.58 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 43 |
ABLIM1 |
2.808e-02 | -3.57 | bone morphogenesis | biological process | GO:0060349 | 99 | 2 | 18204 | 48 |
FGFR3,BMPR1B |
2.817e-02 | -3.57 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 48 |
FGFR3 |
2.817e-02 | -3.57 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 48 |
FGFR3 |
2.817e-02 | -3.57 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 48 |
FGFR3 |
2.817e-02 | -3.57 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 48 |
FGFR3 |
2.817e-02 | -3.57 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 48 |
FGFR3 |
2.817e-02 | -3.57 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 48 |
FGFR3 |
2.821e-02 | -3.57 | acetylcholine receptor binding | molecular function | GO:0033130 | 11 | 1 | 18094 | 47 |
NRXN1 |
2.821e-02 | -3.57 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 47 |
SLC1A2 |
2.833e-02 | -3.56 | Pancreatic secretion | KEGG pathways | ko04972 | 95 | 2 | 7161 | 20 |
ATP1A2,SLC4A4 |
2.833e-02 | -3.56 | Pancreatic secretion | KEGG pathways | hsa04972 | 95 | 2 | 7161 | 20 |
ATP1A2,SLC4A4 |
2.844e-02 | -3.56 | skin-hand-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-hand-carcinoma-squamous_cell_carcinoma | 407 | 4 | 16828 | 48 |
COL5A3,SLC4A4,FGFR3,HIF3A |
2.845e-02 | -3.56 | cell development | biological process | GO:0048468 | 2236 | 11 | 18204 | 48 |
CTNND2,CTNNA2,NRXN1,MSI2,TNIK,BMPR1B,NTM,RORA,PARD3,GPM6A,SLC1A3 |
2.846e-02 | -3.56 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 35 |
ABLIM1 |
2.849e-02 | -3.56 | protein binding | molecular function | GO:0005515 | 13983 | 42 | 18094 | 47 |
GPC5,CTNNA2,NRXN1,SLC4A4,PARD3B,ABLIM1,ATP1A2,RYR3,RFX4,PTGDS,PARD3,GLIS3,SFXN5,NTM,FGFR3,SOX5,BMPR1B,COL5A3,ZNRF3,CDH20,TNIK,LRIG1,NFIA,PITPNC1,GPM6A,SLC1A2,MEIS2,ACSS1,LSAMP,HIF3A,CAMK2G,SLC25A18,MSI2,DTNA,RORA,SPARCL1,SLC1A3,SORBS1,AHCYL2,FBXL7,CTNND2,NPAS3 |
2.863e-02 | -3.55 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 48 |
ATP13A4 |
2.863e-02 | -3.55 | lactone metabolic process | biological process | GO:1901334 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.863e-02 | -3.55 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 48 |
RYR3 |
2.863e-02 | -3.55 | establishment or maintenance of transmembrane electrochemical gradient | biological process | GO:0010248 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.863e-02 | -3.55 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 48 |
BMPR1B |
2.863e-02 | -3.55 | L-ascorbic acid metabolic process | biological process | GO:0019852 | 11 | 1 | 18204 | 48 |
ATP1A2 |
2.871e-02 | -3.55 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 3 | 18204 | 48 |
NRXN1,GPM6A,CTNNA2 |
2.873e-02 | -3.55 | Fib_collagen_C | interpro domains | IPR000885 | 11 | 1 | 18521 | 49 |
COL5A3 |
2.878e-02 | -3.55 | ANP32E (acidic nuclear phosphoprotein 32 family member E) | protein interactions | 81611 | 105 | 2 | 19454 | 49 |
PARD3,AHCYL2 |
2.880e-02 | -3.55 | Organic anion transporters | REACTOME pathways | R-HSA-428643 | 10 | 1 | 10285 | 30 |
SLC25A18 |
2.880e-02 | -3.55 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 30 |
FGFR3 |
2.889e-02 | -3.54 | Circadian entrainment | KEGG pathways | hsa04713 | 96 | 2 | 7161 | 20 |
CAMK2G,RYR3 |
2.889e-02 | -3.54 | Circadian entrainment | KEGG pathways | ko04713 | 96 | 2 | 7161 | 20 |
RYR3,CAMK2G |
2.897e-02 | -3.54 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 10 | 19108 | 48 |
FGFR3,PTGDS,RYR3,NRXN1,SPARCL1,CAMK2G,ATP1A2,COL5A3,ATP13A4,AHCYL2 |
2.914e-02 | -3.54 | regulation of glucose metabolic process | biological process | GO:0010906 | 101 | 2 | 18204 | 48 |
SORBS1,RORA |
2.927e-02 | -3.53 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 30 |
NTM,LSAMP |
2.933e-02 | -3.53 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 43 |
SLC4A4 |
2.974e-02 | -3.52 | sodium:potassium-exchanging ATPase complex | cellular component | GO:0005890 | 12 | 1 | 19108 | 48 |
ATP1A2 |
2.974e-02 | -3.52 | banded collagen fibril | cellular component | GO:0098643 | 12 | 1 | 19108 | 48 |
COL5A3 |
2.974e-02 | -3.52 | fibrillar collagen trimer | cellular component | GO:0005583 | 12 | 1 | 19108 | 48 |
COL5A3 |
2.982e-02 | -3.51 | IL15 (interleukin 15) | protein interactions | 3600 | 12 | 1 | 19454 | 49 |
LRIG1 |
2.982e-02 | -3.51 | FAM222A (family with sequence similarity 222 member A) | protein interactions | 84915 | 12 | 1 | 19454 | 49 |
MEIS2 |
2.982e-02 | -3.51 | LGR5 (leucine rich repeat containing G protein-coupled receptor 5) | protein interactions | 8549 | 12 | 1 | 19454 | 49 |
ZNRF3 |
2.982e-02 | -3.51 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 49 |
SLC4A4 |
2.982e-02 | -3.51 | Pard6b (par-6 family cell polarity regulator beta) | protein interactions | 58220 | 12 | 1 | 19454 | 49 |
PARD3 |
2.982e-02 | -3.51 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 49 |
GPM6A |
2.982e-02 | -3.51 | LMP-1 (latent membrane protein LMP-1) | protein interactions | 3783750 | 12 | 1 | 19454 | 49 |
TNIK |
2.982e-02 | -3.51 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 49 |
BMPR1B |
2.988e-02 | -3.51 | COLFI | pfam domains | PF01410 | 11 | 1 | 17795 | 49 |
COL5A3 |
2.988e-02 | -3.51 | LRRCT | pfam domains | PF01463 | 11 | 1 | 17795 | 49 |
LRIG1 |
2.988e-02 | -3.51 | PAS_11 | pfam domains | PF14598 | 11 | 1 | 17795 | 49 |
HIF3A |
3.031e-02 | -3.50 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 37 | 16828 | 48 |
NHSL1,PAMR1,PARD3,ATP1A2,LRIG1,SLC25A18,CTNND2,GPC5,FBXL7,COL5A3,CAMK2G,MEIS2,NKAIN3,RORA,GPM6A,FGFR3,RFX4,SOX5,NRXN1,PCDH9,SORBS1,PRODH,SFXN5,ATP13A4,SPARCL1,CDH20,LSAMP,ZBTB20,AHCYL2,ACSS1,ABLIM1,DTNA,TNIK,SLC1A3,NPAS3,SLC1A2,RYR3 |
3.031e-02 | -3.50 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 49 |
MSI2,RYR3 |
3.031e-02 | -3.50 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 2 | 19454 | 49 |
AHCYL2,NFIA |
3.031e-02 | -3.50 | CAMKV (CaM kinase like vesicle associated) | protein interactions | 79012 | 108 | 2 | 19454 | 49 |
AHCYL2,GPM6A |
3.033e-02 | -3.50 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 48 |
SORBS1,SLC4A4,ATP1A2,NTM,PARD3B,COL5A3,ZBTB20,NPAS3 |
3.034e-02 | -3.50 | Ethanol Degradation | SMPDB pathways | SMP0000449 | 7 | 1 | 1369 | 6 |
ACSS1 |
3.054e-02 | -3.49 | oesophagus-carcinoma-adenocarcinoma | COSMIC cancer mutations | oesophagus-carcinoma-adenocarcinoma | 13112 | 43 | 16828 | 48 |
RFX4,SOX5,GPM6A,NKAIN3,MEIS2,SLC4A4,CAMK2G,ZNRF3,CTNND2,SLC25A18,ATP1A2,LRIG1,BMPR1B,PTGDS,RYR3,SLC1A2,PARD3B,ACSS1,AHCYL2,LSAMP,SPARCL1,SFXN5,PRODH,SORBS1,FGFR3,HIF3A,RORA,NTM,COL5A3,FBXL7,GPC5,PARD3,PAMR1,NHSL1,NPAS3,SLC1A3,TNIK,ZBTB20,CDH20,GLIS3,ATP13A4,NRXN1,PCDH9 |
3.076e-02 | -3.48 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 3 | 18521 | 49 |
RYR3,SPARCL1,DTNA |
3.094e-02 | -3.48 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 48 |
FGFR3 |
3.094e-02 | -3.48 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 48 |
FGFR3 |
3.100e-02 | -3.47 | YWHAG (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma) | protein interactions | 7532 | 1211 | 7 | 19454 | 49 |
PITPNC1,PARD3,ABLIM1,NHSL1,PARD3B,SORBS1,CAMK2G |
3.120e-02 | -3.47 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 48 |
BMPR1B |
3.120e-02 | -3.47 | 4-hydroxyproline metabolic process | biological process | GO:0019471 | 12 | 1 | 18204 | 48 |
PRODH |
3.120e-02 | -3.47 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 48 |
SLC1A2 |
3.120e-02 | -3.47 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 48 |
BMPR1B |
3.121e-02 | -3.47 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 6 | 19454 | 49 |
NFIA,CTNND2,ZBTB20,ATP13A4,SLC1A3,CAMK2G |
3.130e-02 | -3.46 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 49 |
PTGDS |
3.130e-02 | -3.46 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 49 |
PTGDS |
3.130e-02 | -3.46 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 49 |
BMPR1B |
3.130e-02 | -3.46 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 49 |
NFIA |
3.132e-02 | -3.46 | RFX_DBD | prosite domains | PS51526 | 9 | 1 | 12186 | 43 |
RFX4 |
3.135e-02 | -3.46 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 49 |
BMPR1B,PARD3B |
3.139e-02 | -3.46 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 3 | 18204 | 48 |
SPARCL1,PCDH9,CDH20 |
3.139e-02 | -3.46 | calcium ion binding | molecular function | GO:0005509 | 683 | 5 | 18094 | 47 |
SPARCL1,PAMR1,NRXN1,PCDH9,RYR3 |
3.151e-02 | -3.46 | steroid binding | molecular function | GO:0005496 | 107 | 2 | 18094 | 47 |
RORA,ATP1A2 |
3.185e-02 | -3.45 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 13 | 16828 | 48 |
RYR3,FGFR3,PARD3B,NPAS3,RORA,CAMK2G,COL5A3,ZNRF3,GLIS3,CTNND2,NFIA,SPARCL1,SORBS1 |
3.185e-02 | -3.45 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 13 | 16828 | 48 |
CAMK2G,COL5A3,GLIS3,ZNRF3,NFIA,CTNND2,SPARCL1,SORBS1,RYR3,NPAS3,PARD3B,FGFR3,RORA |
3.197e-02 | -3.44 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 35 |
SPARCL1 |
3.226e-02 | -3.43 | JAM2 (junctional adhesion molecule 2) | protein interactions | 58494 | 13 | 1 | 19454 | 49 |
PARD3 |
3.226e-02 | -3.43 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 49 |
GPM6A |
3.226e-02 | -3.43 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 49 |
NFIA |
3.226e-02 | -3.43 | MYO16 (myosin XVI) | protein interactions | 23026 | 13 | 1 | 19454 | 49 |
NRXN1 |
3.226e-02 | -3.43 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 49 |
NTM |
3.226e-02 | -3.43 | CAPN11 (calpain 11) | protein interactions | 11131 | 13 | 1 | 19454 | 49 |
PRODH |
3.226e-02 | -3.43 | MAB21L1 (mab-21 like 1) | protein interactions | 4081 | 13 | 1 | 19454 | 49 |
MEIS2 |
3.226e-02 | -3.43 | NPR2 (natriuretic peptide receptor 2) | protein interactions | 4882 | 13 | 1 | 19454 | 49 |
CAMK2G |
3.226e-02 | -3.43 | PLPPR4 (phospholipid phosphatase related 4) | protein interactions | 9890 | 13 | 1 | 19454 | 49 |
ZNRF3 |
3.241e-02 | -3.43 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 2 | 19454 | 49 |
SOX5,NFIA |
3.246e-02 | -3.43 | synaptic signaling | biological process | GO:0099536 | 459 | 4 | 18204 | 48 |
DTNA,NRXN1,SLC1A3,SLC1A2 |
3.256e-02 | -3.42 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 49 |
NFIA |
3.262e-02 | -3.42 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 3 | 18204 | 48 |
CTNND2,ZNRF3,GPC5 |
3.273e-02 | -3.42 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 18 | 16828 | 48 |
RYR3,NPAS3,FGFR3,PARD3B,SLC1A3,RORA,CAMK2G,COL5A3,GLIS3,ZNRF3,CDH20,CTNND2,NFIA,SPARCL1,PARD3,SORBS1,PAMR1,NHSL1 |
3.294e-02 | -3.41 | GFI1B (growth factor independent 1B transcriptional repressor) | protein interactions | 8328 | 113 | 2 | 19454 | 49 |
DTNA,ZNRF3 |
3.323e-02 | -3.40 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 49 |
CDH20 |
3.326e-02 | -3.40 | potassium ion binding | molecular function | GO:0030955 | 13 | 1 | 18094 | 47 |
ATP1A2 |
3.326e-02 | -3.40 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 47 |
SLC4A4 |
3.326e-02 | -3.40 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 47 |
BMPR1B |
3.330e-02 | -3.40 | plasma membrane raft | cellular component | GO:0044853 | 114 | 2 | 19108 | 48 |
SORBS1,ATP1A2 |
3.347e-02 | -3.40 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 49 |
ZBTB20,PCDH9 |
3.351e-02 | -3.40 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 48 |
CTNND2,NRXN1 |
3.371e-02 | -3.39 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 48 |
FGFR3 |
3.371e-02 | -3.39 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 48 |
FGFR3 |
3.371e-02 | -3.39 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 48 |
FGFR3 |
3.373e-02 | -3.39 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 49 |
CDH20,PCDH9 |
3.375e-02 | -3.39 | cerebellar Purkinje cell differentiation | biological process | GO:0021702 | 13 | 1 | 18204 | 48 |
RORA |
3.375e-02 | -3.39 | regulation of respiratory gaseous exchange by nervous system process | biological process | GO:0002087 | 13 | 1 | 18204 | 48 |
ATP1A2 |
3.375e-02 | -3.39 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 48 |
NFIA |
3.375e-02 | -3.39 | negative regulation of cytosolic calcium ion concentration | biological process | GO:0051481 | 13 | 1 | 18204 | 48 |
ATP1A2 |
3.375e-02 | -3.39 | T-helper 17 cell differentiation | biological process | GO:0072539 | 13 | 1 | 18204 | 48 |
RORA |
3.375e-02 | -3.39 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 48 |
CTNNA2 |
3.375e-02 | -3.39 | postsynaptic specialization assembly | biological process | GO:0098698 | 13 | 1 | 18204 | 48 |
NRXN1 |
3.376e-02 | -3.39 | DNA-binding transcription activator activity, RNA polymerase II-specific | molecular function | GO:0001228 | 472 | 4 | 18094 | 47 |
RFX4,GLIS3,MEIS2,NFIA |
3.383e-02 | -3.39 | kidney-carcinoma-chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 48 |
TNIK,CAMK2G,FGFR3,BMPR1B |
3.383e-02 | -3.39 | chromophobe_renal_cell_carcinoma | COSMIC cancer mutations | chromophobe_renal_cell_carcinoma | 430 | 4 | 16828 | 48 |
TNIK,CAMK2G,BMPR1B,FGFR3 |
3.394e-02 | -3.38 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 18 |
SLC4A4 |
3.401e-02 | -3.38 | CAV1 (caveolin 1) | protein interactions | 857 | 719 | 5 | 19454 | 49 |
AHCYL2,PARD3,DTNA,TNIK,SLC1A3 |
3.401e-02 | -3.38 | CDH2 (cadherin 2) | protein interactions | 1000 | 115 | 2 | 19454 | 49 |
PARD3,CTNND2 |
3.432e-02 | -3.37 | small_intestine | COSMIC cancer mutations | small_intestine | 250 | 3 | 16828 | 48 |
ZNRF3,TNIK,FGFR3 |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Regulation of gene expression by Hypoxia-inducible Factor | REACTOME pathways | R-HSA-1234158 | 12 | 1 | 10285 | 30 |
HIF3A |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Ethanol oxidation | REACTOME pathways | R-HSA-71384 | 12 | 1 | 10285 | 30 |
ACSS1 |
3.446e-02 | -3.37 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.452e-02 | -3.37 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 3 | 18204 | 48 |
ACSS1,SLC1A3,PTGDS |
3.462e-02 | -3.36 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 6 |
FGFR3 |
3.465e-02 | -3.36 | Dppa3 (developmental pluripotency-associated 3) | protein interactions | 73708 | 284 | 3 | 19454 | 49 |
ATP1A2,CAMK2G,MSI2 |
3.470e-02 | -3.36 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 1 | 19454 | 49 |
GPM6A |
3.470e-02 | -3.36 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 49 |
SLC1A2 |
3.470e-02 | -3.36 | KRTAP22-1 (keratin associated protein 22-1) | protein interactions | 337979 | 14 | 1 | 19454 | 49 |
MEIS2 |
3.470e-02 | -3.36 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 49 |
BMPR1B |
3.470e-02 | -3.36 | SYT5 (synaptotagmin 5) | protein interactions | 6861 | 14 | 1 | 19454 | 49 |
NRXN1 |
3.470e-02 | -3.36 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 49 |
FGFR3 |
3.470e-02 | -3.36 | CHAT (choline O-acetyltransferase) | protein interactions | 1103 | 14 | 1 | 19454 | 49 |
CAMK2G |
3.470e-02 | -3.36 | VSX2 (visual system homeobox 2) | protein interactions | 338917 | 14 | 1 | 19454 | 49 |
AHCYL2 |
3.470e-02 | -3.36 | TPSAB1 (tryptase alpha/beta 1) | protein interactions | 7177 | 14 | 1 | 19454 | 49 |
CAMK2G |
3.470e-02 | -3.36 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 49 |
GLIS3 |
3.470e-02 | -3.36 | RSPO1 (R-spondin 1) | protein interactions | 284654 | 14 | 1 | 19454 | 49 |
ZNRF3 |
3.474e-02 | -3.36 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 43 |
RYR3 |
3.479e-02 | -3.36 | phosphatidylinositol binding | molecular function | GO:0035091 | 276 | 3 | 18094 | 47 |
PARD3,PARD3B,PITPNC1 |
3.504e-02 | -3.35 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 49 |
NTM |
3.504e-02 | -3.35 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 49 |
NHSL1 |
3.504e-02 | -3.35 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 49 |
CTNND2 |
3.510e-02 | -3.35 | - | gene3d domains | 3.10.450.50 | 12 | 1 | 14470 | 43 |
CAMK2G |
3.510e-02 | -3.35 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 43 |
CTNNA2 |
3.510e-02 | -3.35 | SYT6 (synaptotagmin 6) | protein interactions | 148281 | 117 | 2 | 19454 | 49 |
AHCYL2,NRXN1 |
3.512e-02 | -3.35 | DNA-binding transcription activator activity | molecular function | GO:0001216 | 478 | 4 | 18094 | 47 |
GLIS3,NFIA,MEIS2,RFX4 |
3.514e-02 | -3.35 | bile_duct | COSMIC cancer mutations | bile_duct | 15095 | 47 | 16828 | 48 |
NTM,HIF3A,RORA,FGFR3,GPC5,FBXL7,COL5A3,NHSL1,PAMR1,PARD3,TNIK,SLC1A3,NPAS3,ABLIM1,DTNA,GLIS3,CDH20,MSI2,ZBTB20,PCDH9,NRXN1,ATP13A4,GPM6A,RFX4,SOX5,SLC4A4,MEIS2,SLC25A18,CTNND2,ZNRF3,CAMK2G,PTGDS,BMPR1B,ATP1A2,LRIG1,PARD3B,SLC1A2,RYR3,AHCYL2,ACSS1,NFIA,LSAMP,PITPNC1,SORBS1,PRODH,SFXN5,SPARCL1 |
3.514e-02 | -3.35 | biliary_tract-bile_duct-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-bile_duct-carcinoma-adenocarcinoma | 15095 | 47 | 16828 | 48 |
AHCYL2,ACSS1,PARD3B,SLC1A2,RYR3,SORBS1,PRODH,SFXN5,SPARCL1,NFIA,PITPNC1,LSAMP,SLC4A4,MEIS2,GPM6A,SOX5,RFX4,PTGDS,BMPR1B,LRIG1,ATP1A2,SLC25A18,CTNND2,ZNRF3,CAMK2G,ABLIM1,DTNA,TNIK,SLC1A3,NPAS3,PCDH9,NRXN1,ATP13A4,GLIS3,CDH20,MSI2,ZBTB20,NTM,RORA,HIF3A,FGFR3,NHSL1,PAMR1,PARD3,GPC5,FBXL7,COL5A3 |
3.544e-02 | -3.34 | HLH_DNA-bd_sf | interpro domains | IPR036638 | 112 | 2 | 18521 | 49 |
HIF3A,NPAS3 |
3.544e-02 | -3.34 | bHLH_dom | interpro domains | IPR011598 | 112 | 2 | 18521 | 49 |
HIF3A,NPAS3 |
3.546e-02 | -3.34 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 35 |
RYR3 |
3.549e-02 | -3.34 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 3 | 18204 | 48 |
PTGDS,ACSS1,SLC1A3 |
3.560e-02 | -3.34 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 16 |
BMPR1B |
3.560e-02 | -3.34 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 16 |
RYR3 |
3.565e-02 | -3.33 | PLCD3 (phospholipase C delta 3) | protein interactions | 113026 | 118 | 2 | 19454 | 49 |
TNIK,AHCYL2 |
3.567e-02 | -3.33 | OCLN (occludin) | protein interactions | 100506658 | 495 | 4 | 19454 | 49 |
ABLIM1,TNIK,DTNA,PARD3 |
3.579e-02 | -3.33 | dendrite development | biological process | GO:0016358 | 113 | 2 | 18204 | 48 |
CTNNA2,CTNND2 |
3.589e-02 | -3.33 | VASP (vasodilator stimulated phosphoprotein) | protein interactions | 7408 | 288 | 3 | 19454 | 49 |
NHSL1,SORBS1,PARD3 |
3.609e-02 | -3.32 | stomach-carcinoma | COSMIC cancer mutations | stomach-carcinoma | 439 | 4 | 16828 | 48 |
BMPR1B,FGFR3,CAMK2G,TNIK |
3.611e-02 | -3.32 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 48 |
PARD3,GPC5 |
3.615e-02 | -3.32 | telencephalon development | biological process | GO:0021537 | 276 | 3 | 18204 | 48 |
RFX4,ATP1A2,SLC1A2 |
3.615e-02 | -3.32 | learning or memory | biological process | GO:0007611 | 276 | 3 | 18204 | 48 |
ATP1A2,NRXN1,MEIS2 |
3.625e-02 | -3.32 | membrane raft | cellular component | GO:0045121 | 290 | 3 | 19108 | 48 |
SLC1A2,SORBS1,ATP1A2 |
3.630e-02 | -3.32 | acetyl-CoA biosynthetic process | biological process | GO:0006085 | 14 | 1 | 18204 | 48 |
ACSS1 |
3.630e-02 | -3.32 | positive regulation of myoblast proliferation | biological process | GO:2000288 | 14 | 1 | 18204 | 48 |
MEIS2 |
3.630e-02 | -3.32 | negative regulation of sodium ion transmembrane transporter activity | biological process | GO:2000650 | 14 | 1 | 18204 | 48 |
ATP1A2 |
3.630e-02 | -3.32 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 48 |
SLC1A2 |
3.630e-02 | -3.32 | relaxation of cardiac muscle | biological process | GO:0055119 | 14 | 1 | 18204 | 48 |
ATP1A2 |
3.630e-02 | -3.32 | regulation of skeletal muscle adaptation | biological process | GO:0014733 | 14 | 1 | 18204 | 48 |
CAMK2G |
3.630e-02 | -3.32 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 48 |
RYR3 |
3.637e-02 | -3.31 | regulation of circadian rhythm | biological process | GO:0042752 | 114 | 2 | 18204 | 48 |
RORA,PTGDS |
3.638e-02 | -3.31 | extremity | COSMIC cancer mutations | extremity | 1876 | 10 | 16828 | 48 |
PCDH9,ACSS1,ATP13A4,PARD3,CDH20,PITPNC1,RYR3,FBXL7,COL5A3,FGFR3 |
3.642e-02 | -3.31 | Neurexin-like | interpro domains | IPR003585 | 14 | 1 | 18521 | 49 |
NRXN1 |
3.647e-02 | -3.31 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 48 |
FGFR3 |
3.647e-02 | -3.31 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 48 |
FGFR3 |
3.647e-02 | -3.31 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 48 |
FGFR3 |
3.647e-02 | -3.31 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 48 |
FGFR3 |
3.660e-02 | -3.31 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 49 |
CDH20,PCDH9 |
3.675e-02 | -3.30 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 7 | 16828 | 48 |
COL5A3,FGFR3,CTNND2,NTM,SLC4A4,ATP13A4,SORBS1 |
3.676e-02 | -3.30 | HOXB9 (homeobox B9) | protein interactions | 3219 | 120 | 2 | 19454 | 49 |
NFIA,AHCYL2 |
3.680e-02 | -3.30 | Neural Crest Differentiation | WikiPathways | WP2064 | 102 | 2 | 5310 | 16 |
FGFR3,SOX5 |
3.688e-02 | -3.30 | membrane microdomain | cellular component | GO:0098857 | 292 | 3 | 19108 | 48 |
SLC1A2,SORBS1,ATP1A2 |
3.695e-02 | -3.30 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 2 | 18204 | 48 |
PTGDS,ACSS1 |
3.704e-02 | -3.30 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 48 |
SLC1A2 |
3.710e-02 | -3.29 | calcium channel activity | molecular function | GO:0005262 | 117 | 2 | 18094 | 47 |
RYR3,GPM6A |
3.714e-02 | -3.29 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 49 |
FGFR3 |
3.714e-02 | -3.29 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 49 |
BMPR1B |
3.728e-02 | -3.29 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.731e-02 | -3.29 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 9 | 16828 | 48 |
DTNA,PRODH,ABLIM1,SORBS1,FGFR3,PARD3B,CDH20,RORA,CTNND2 |
3.731e-02 | -3.29 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 9 | 16828 | 48 |
ABLIM1,PRODH,SORBS1,DTNA,CDH20,CTNND2,RORA,PARD3B,FGFR3 |
3.738e-02 | -3.29 | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-humerus-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 107 | 2 | 16828 | 48 |
PARD3B,HIF3A |
3.776e-02 | -3.28 | Prot_kinase_dom | interpro domains | IPR000719 | 480 | 4 | 18521 | 49 |
FGFR3,TNIK,BMPR1B,CAMK2G |
3.778e-02 | -3.28 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 49 |
PCDH9,CDH20 |
3.779e-02 | -3.28 | KCNE3 (potassium voltage-gated channel subfamily E regulatory subunit 3) | protein interactions | 10008 | 294 | 3 | 19454 | 49 |
TNIK,PCDH9,ZNRF3 |
3.783e-02 | -3.27 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-large_cell | 1117 | 7 | 16828 | 48 |
CDH20,GPC5,RYR3,SOX5,SLC1A2,PARD3,ATP13A4 |
3.788e-02 | -3.27 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 49 |
NHSL1,DTNA |
3.788e-02 | -3.27 | SLMAP (sarcolemma associated protein) | protein interactions | 7871 | 122 | 2 | 19454 | 49 |
TNIK,CAMK2G |
3.811e-02 | -3.27 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 49 |
PCDH9,CDH20 |
3.815e-02 | -3.27 | NC1_FIB | prosite domains | PS51461 | 11 | 1 | 12186 | 43 |
COL5A3 |
3.815e-02 | -3.27 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 43 |
PTGDS |
3.828e-02 | -3.26 | C4-dicarboxylate transmembrane transporter activity | molecular function | GO:0015556 | 15 | 1 | 18094 | 47 |
SLC25A18 |
3.828e-02 | -3.26 | AMP binding | molecular function | GO:0016208 | 15 | 1 | 18094 | 47 |
ACSS1 |
3.828e-02 | -3.26 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 47 |
PITPNC1 |
3.844e-02 | -3.26 | SPSB4 (splA/ryanodine receptor domain and SOCS box containing 4) | protein interactions | 92369 | 123 | 2 | 19454 | 49 |
PCDH9,LRIG1 |
3.849e-02 | -3.26 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 3 | 18204 | 48 |
CTNND2,TNIK,ZNRF3 |
3.850e-02 | -3.26 | Ig-like_dom_sf | interpro domains | IPR036179 | 483 | 4 | 18521 | 49 |
FGFR3,LRIG1,NTM,LSAMP |
3.851e-02 | -3.26 | Cell-type Dependent Selectivity of CCK2R Signaling | WikiPathways | WP3679 | 13 | 1 | 5310 | 16 |
RYR3 |
3.866e-02 | -3.25 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 49 |
GPC5 |
3.872e-02 | -3.25 | synapse assembly | biological process | GO:0007416 | 118 | 2 | 18204 | 48 |
GPM6A,NRXN1 |
3.884e-02 | -3.25 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 48 |
NFIA |
3.884e-02 | -3.25 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 48 |
NFIA |
3.884e-02 | -3.25 | cerebellar Purkinje cell layer formation | biological process | GO:0021694 | 15 | 1 | 18204 | 48 |
RORA |
3.884e-02 | -3.25 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 48 |
RYR3 |
3.884e-02 | -3.25 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 48 |
PTGDS |
3.884e-02 | -3.25 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 48 |
FGFR3 |
3.884e-02 | -3.25 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 48 |
SLC1A2 |
3.884e-02 | -3.25 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 48 |
SORBS1 |
3.884e-02 | -3.25 | negative regulation of sodium ion transmembrane transport | biological process | GO:1902306 | 15 | 1 | 18204 | 48 |
ATP1A2 |
3.884e-02 | -3.25 | intracellular potassium ion homeostasis | biological process | GO:0030007 | 15 | 1 | 18204 | 48 |
ATP1A2 |
3.884e-02 | -3.25 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 48 |
RYR3 |
3.884e-02 | -3.25 | neuroblast division | biological process | GO:0055057 | 15 | 1 | 18204 | 48 |
SOX5 |
3.887e-02 | -3.25 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 18 | 16828 | 48 |
SLC1A3,RORA,RYR3,PARD3B,NPAS3,FGFR3,GLIS3,CDH20,ZNRF3,CTNND2,NFIA,CAMK2G,COL5A3,SORBS1,PAMR1,NHSL1,SPARCL1,PARD3 |
3.894e-02 | -3.25 | COLFI | smart domains | SM00038 | 11 | 1 | 9717 | 35 |
COL5A3 |
3.897e-02 | -3.24 | NTF2-like_dom_sf | interpro domains | IPR032710 | 15 | 1 | 18521 | 49 |
CAMK2G |
3.897e-02 | -3.24 | CNH_dom | interpro domains | IPR001180 | 15 | 1 | 18521 | 49 |
TNIK |
3.897e-02 | -3.24 | ATPase_P-typ_cation-transptr_C | interpro domains | IPR006068 | 15 | 1 | 18521 | 49 |
ATP1A2 |
3.922e-02 | -3.24 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 48 |
FGFR3 |
3.922e-02 | -3.24 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 48 |
FGFR3 |
3.922e-02 | -3.24 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 48 |
FGFR3 |
3.922e-02 | -3.24 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 48 |
FGFR3 |
3.922e-02 | -3.24 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 48 |
FGFR3 |
3.935e-02 | -3.24 | skin-acral-malignant_melanoma | COSMIC cancer mutations | skin-acral-malignant_melanoma | 264 | 3 | 16828 | 48 |
CDH20,COL5A3,PARD3 |
3.946e-02 | -3.23 | postsynaptic density, intracellular component | cellular component | GO:0099092 | 16 | 1 | 19108 | 48 |
TNIK |
3.956e-02 | -3.23 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 49 |
CTNNA2 |
3.956e-02 | -3.23 | VGLL1 (vestigial like family member 1) | protein interactions | 51442 | 16 | 1 | 19454 | 49 |
MEIS2 |
3.956e-02 | -3.23 | GALNT13 (polypeptide N-acetylgalactosaminyltransferase 13) | protein interactions | 114805 | 16 | 1 | 19454 | 49 |
TNIK |
3.956e-02 | -3.23 | SYTL2 (synaptotagmin like 2) | protein interactions | 54843 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | TWIST2 (twist family bHLH transcription factor 2) | protein interactions | 117581 | 16 | 1 | 19454 | 49 |
ZBTB20 |
3.956e-02 | -3.23 | FZD4 (frizzled class receptor 4) | protein interactions | 8322 | 16 | 1 | 19454 | 49 |
ZNRF3 |
3.956e-02 | -3.23 | CAMK1G (calcium/calmodulin dependent protein kinase IG) | protein interactions | 57172 | 16 | 1 | 19454 | 49 |
CAMK2G |
3.956e-02 | -3.23 | DUS1L (dihydrouridine synthase 1 like) | protein interactions | 64118 | 16 | 1 | 19454 | 49 |
CAMK2G |
3.956e-02 | -3.23 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 49 |
CTNNA2 |
3.956e-02 | -3.23 | NBL1 (NBL1, DAN family BMP antagonist) | protein interactions | 4681 | 16 | 1 | 19454 | 49 |
LRIG1 |
3.956e-02 | -3.23 | SYT9 (synaptotagmin 9) | protein interactions | 143425 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | SYT4 (synaptotagmin 4) | protein interactions | 6860 | 16 | 1 | 19454 | 49 |
NRXN1 |
3.956e-02 | -3.23 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 49 |
SPARCL1 |
3.956e-02 | -3.23 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 49 |
FGFR3 |
3.956e-02 | -3.23 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 49 |
FGFR3 |
3.961e-02 | -3.23 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 2 | 7161 | 20 |
SLC1A3,SLC1A2 |
3.961e-02 | -3.23 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 2 | 7161 | 20 |
SLC1A3,SLC1A2 |
3.992e-02 | -3.22 | regulation of nervous system process | biological process | GO:0031644 | 120 | 2 | 18204 | 48 |
PARD3,NRXN1 |
3.995e-02 | -3.22 | bicellular tight junction | cellular component | GO:0005923 | 126 | 2 | 19108 | 48 |
PARD3B,PARD3 |
4.010e-02 | -3.22 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 30 |
ABLIM1 |
4.010e-02 | -3.22 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 3 | 16828 | 48 |
RYR3,SOX5,CDH20 |
4.016e-02 | -3.21 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 49 |
GPM6A,PITPNC1 |
4.017e-02 | -3.21 | ovary-carcinoma-clear_cell_carcinoma | COSMIC cancer mutations | ovary-carcinoma-clear_cell_carcinoma | 665 | 5 | 16828 | 48 |
TNIK,BMPR1B,FGFR3,CAMK2G,SPARCL1 |
4.053e-02 | -3.21 | CNH | pfam domains | PF00780 | 15 | 1 | 17795 | 49 |
TNIK |
4.053e-02 | -3.21 | Cation_ATPase_C | pfam domains | PF00689 | 15 | 1 | 17795 | 49 |
ATP1A2 |
4.059e-02 | -3.20 | ovary-carcinoma-mucinous_carcinoma | COSMIC cancer mutations | ovary-carcinoma-mucinous_carcinoma | 456 | 4 | 16828 | 48 |
FGFR3,BMPR1B,CAMK2G,TNIK |
4.067e-02 | -3.20 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 18 | 19454 | 49 |
ACSS1,PARD3,ATP1A2,CTNNA2,MSI2,CTNND2,NTM,PITPNC1,TNIK,SLC25A18,SLC1A3,CAMK2G,SLC4A4,LRIG1,AHCYL2,GPM6A,LSAMP,DTNA |
4.077e-02 | -3.20 | non_small_cell_carcinoma | COSMIC cancer mutations | non_small_cell_carcinoma | 5198 | 21 | 16828 | 48 |
MSI2,FBXL7,COL5A3,CAMK2G,CTNND2,PITPNC1,LSAMP,BMPR1B,PARD3,ATP13A4,LRIG1,SPARCL1,PRODH,FGFR3,NPAS3,SOX5,HIF3A,RORA,TNIK,SLC1A3,ABLIM1 |
4.077e-02 | -3.20 | lung-carcinoma-non_small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-non_small_cell_carcinoma | 5198 | 21 | 16828 | 48 |
FGFR3,NPAS3,SOX5,RORA,HIF3A,TNIK,SLC1A3,ABLIM1,MSI2,FBXL7,COL5A3,CAMK2G,CTNND2,PITPNC1,LSAMP,BMPR1B,PARD3,ATP13A4,LRIG1,SPARCL1,PRODH |
4.078e-02 | -3.20 | oxysterol binding | molecular function | GO:0008142 | 16 | 1 | 18094 | 47 |
RORA |
4.079e-02 | -3.20 | cellular response to growth factor stimulus | biological process | GO:0071363 | 494 | 4 | 18204 | 48 |
NFIA,SOX5,FGFR3,BMPR1B |
4.085e-02 | -3.20 | acral | COSMIC cancer mutations | acral | 268 | 3 | 16828 | 48 |
CDH20,COL5A3,PARD3 |
4.105e-02 | -3.19 | clear_cell_carcinoma | COSMIC cancer mutations | clear_cell_carcinoma | 669 | 5 | 16828 | 48 |
FGFR3,BMPR1B,SPARCL1,CAMK2G,TNIK |
4.108e-02 | -3.19 | CARM1 (coactivator associated arginine methyltransferase 1) | protein interactions | 10498 | 304 | 3 | 19454 | 49 |
DTNA,CAMK2G,RORA |
4.114e-02 | -3.19 | mucinous_carcinoma | COSMIC cancer mutations | mucinous_carcinoma | 458 | 4 | 16828 | 48 |
TNIK,FGFR3,BMPR1B,CAMK2G |
4.124e-02 | -3.19 | cation binding | molecular function | GO:0043169 | 4341 | 17 | 18094 | 47 |
NRXN1,PCDH9,PAMR1,SLC1A2,ABLIM1,ATP1A2,ACSS1,ZBTB20,RYR3,ATP13A4,GLIS3,SPARCL1,RORA,DTNA,BMPR1B,SLC1A3,ZNRF3 |
4.132e-02 | -3.19 | SYT2 (synaptotagmin 2) | protein interactions | 127833 | 128 | 2 | 19454 | 49 |
NRXN1,AHCYL2 |
4.138e-02 | -3.18 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 48 |
SLC1A3 |
4.138e-02 | -3.18 | neuron cell-cell adhesion | biological process | GO:0007158 | 16 | 1 | 18204 | 48 |
NRXN1 |
4.138e-02 | -3.18 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | S-adenosylmethionine metabolic process | biological process | GO:0046500 | 16 | 1 | 18204 | 48 |
AHCYL2 |
4.138e-02 | -3.18 | regulation of Wnt signaling pathway, planar cell polarity pathway | biological process | GO:2000095 | 16 | 1 | 18204 | 48 |
ZNRF3 |
4.138e-02 | -3.18 | regulation of amino acid transmembrane transport | biological process | GO:1903789 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | regulation of amino acid import across plasma membrane | biological process | GO:0010958 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | short-chain fatty acid metabolic process | biological process | GO:0046459 | 16 | 1 | 18204 | 48 |
ACSS1 |
4.138e-02 | -3.18 | regulation of respiratory system process | biological process | GO:0044065 | 16 | 1 | 18204 | 48 |
ATP1A2 |
4.138e-02 | -3.18 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 48 |
SLC1A2 |
4.154e-02 | -3.18 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 48 |
RORA,ZNRF3,SOX5,FGFR3,NFIA |
4.190e-02 | -3.17 | Lima1 (LIM domain and actin binding 1) | protein interactions | 65970 | 129 | 2 | 19454 | 49 |
ABLIM1,ZBTB20 |
4.190e-02 | -3.17 | CHD7 (chromodomain helicase DNA binding protein 7) | protein interactions | 55636 | 129 | 2 | 19454 | 49 |
ZBTB20,SOX5 |
4.196e-02 | -3.17 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 48 |
FGFR3 |
4.198e-02 | -3.17 | KRTAP19-3 (keratin associated protein 19-3) | protein interactions | 337970 | 17 | 1 | 19454 | 49 |
CAMK2G |
4.198e-02 | -3.17 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 49 |
GPC5 |
4.198e-02 | -3.17 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 49 |
NTM |
4.198e-02 | -3.17 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 49 |
BMPR1B |
4.198e-02 | -3.17 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 49 |
BMPR1B |
4.198e-02 | -3.17 | FAM163B (family with sequence similarity 163 member B) | protein interactions | 642968 | 17 | 1 | 19454 | 49 |
CAMK2G |
4.198e-02 | -3.17 | MSANTD2 (Myb/SANT DNA binding domain containing 2) | protein interactions | 79684 | 17 | 1 | 19454 | 49 |
SOX5 |
4.198e-02 | -3.17 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 49 |
ABLIM1 |
4.198e-02 | -3.17 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 49 |
GPM6A |
4.198e-02 | -3.17 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 49 |
DTNA |
4.203e-02 | -3.17 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 11 | 16828 | 48 |
PARD3B,FGFR3,SOX5,TNIK,DTNA,SLC4A4,CAMK2G,SLC25A18,NFIA,BMPR1B,ATP1A2 |
4.233e-02 | -3.16 | skeletal system development | biological process | GO:0001501 | 500 | 4 | 18204 | 48 |
NFIA,SOX5,FGFR3,BMPR1B |
4.236e-02 | -3.16 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 48 |
ZBTB20,SORBS1 |
4.240e-02 | -3.16 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 35 |
NFIA |
4.249e-02 | -3.16 | DVL1 (dishevelled segment polarity protein 1) | protein interactions | 1855 | 130 | 2 | 19454 | 49 |
PARD3,ZNRF3 |
4.282e-02 | -3.15 | ovary-carcinoma-endometrioid_carcinoma | COSMIC cancer mutations | ovary-carcinoma-endometrioid_carcinoma | 464 | 4 | 16828 | 48 |
FGFR3,BMPR1B,CAMK2G,TNIK |
4.286e-02 | -3.15 | tight junction | cellular component | GO:0070160 | 131 | 2 | 19108 | 48 |
PARD3B,PARD3 |
4.290e-02 | -3.15 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 30 |
PTGDS |
4.294e-02 | -3.15 | Helix-loop-helix DNA-binding domain | gene3d domains | 4.10.280.10 | 111 | 2 | 14470 | 43 |
HIF3A,NPAS3 |
4.308e-02 | -3.14 | ZNF609 (zinc finger protein 609) | protein interactions | 23060 | 131 | 2 | 19454 | 49 |
SOX5,NFIA |
4.308e-02 | -3.14 | TRPS1 (transcriptional repressor GATA binding 1) | protein interactions | 7227 | 131 | 2 | 19454 | 49 |
SOX5,NFIA |
4.308e-02 | -3.14 | NCOA2 (nuclear receptor coactivator 2) | protein interactions | 10499 | 131 | 2 | 19454 | 49 |
NFIA,RORA |
4.315e-02 | -3.14 | PROTEIN_KINASE_ATP | prosite domains | PS00107 | 377 | 4 | 12186 | 43 |
CAMK2G,BMPR1B,FGFR3,TNIK |
4.339e-02 | -3.14 | signaling | biological process | GO:0023052 | 4968 | 19 | 18204 | 48 |
RORA,TNIK,ATP1A2,DTNA,FGFR3,RYR3,PITPNC1,ZNRF3,SLC1A2,PARD3,CAMK2G,BMPR1B,SORBS1,PRODH,CTNND2,NRXN1,SPARCL1,NFIA,SLC1A3 |
4.340e-02 | -3.14 | muscle system process | biological process | GO:0003012 | 297 | 3 | 18204 | 48 |
ATP1A2,DTNA,RYR3 |
4.364e-02 | -3.13 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 48 |
SLC1A2,SORBS1,SLC1A3,RYR3 |
4.367e-02 | -3.13 | STRN (striatin) | protein interactions | 6801 | 132 | 2 | 19454 | 49 |
CAMK2G,TNIK |
4.391e-02 | -3.13 | cGMP metabolic process | biological process | GO:0046068 | 17 | 1 | 18204 | 48 |
RORA |
4.391e-02 | -3.13 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 48 |
SLC1A2 |
4.391e-02 | -3.13 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 48 |
SORBS1 |
4.391e-02 | -3.13 | membrane depolarization during cardiac muscle cell action potential | biological process | GO:0086012 | 17 | 1 | 18204 | 48 |
ATP1A2 |
4.391e-02 | -3.13 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 48 |
NFIA |
4.391e-02 | -3.13 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 48 |
CTNNA2 |
4.391e-02 | -3.13 | T-helper 17 type immune response | biological process | GO:0072538 | 17 | 1 | 18204 | 48 |
RORA |
4.391e-02 | -3.13 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 48 |
RYR3 |
4.391e-02 | -3.13 | microvillus assembly | biological process | GO:0030033 | 17 | 1 | 18204 | 48 |
TNIK |
4.391e-02 | -3.13 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 48 |
NFIA |
4.391e-02 | -3.13 | cell communication by electrical coupling involved in cardiac conduction | biological process | GO:0086064 | 17 | 1 | 18204 | 48 |
ATP1A2 |
4.406e-02 | -3.12 | PAC | interpro domains | IPR001610 | 17 | 1 | 18521 | 49 |
HIF3A |
4.406e-02 | -3.12 | AMP-bd_C | interpro domains | IPR025110 | 17 | 1 | 18521 | 49 |
ACSS1 |
4.422e-02 | -3.12 | cell-cell junction assembly | biological process | GO:0007043 | 127 | 2 | 18204 | 48 |
CDH20,PARD3 |
4.440e-02 | -3.11 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 49 |
BMPR1B |
4.440e-02 | -3.11 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 49 |
NTM |
4.440e-02 | -3.11 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 49 |
BMPR1B |
4.440e-02 | -3.11 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 49 |
BMPR1B |
4.440e-02 | -3.11 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 49 |
PTGDS |
4.444e-02 | -3.11 | circulatory system process | biological process | GO:0003013 | 508 | 4 | 18204 | 48 |
ATP1A2,SLC1A3,SLC1A2,SLC4A4 |
4.448e-02 | -3.11 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 49 |
PARD3,PARD3B |
4.469e-02 | -3.11 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 48 |
FGFR3 |
4.469e-02 | -3.11 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 48 |
FGFR3 |
4.469e-02 | -3.11 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 48 |
FGFR3 |
4.469e-02 | -3.11 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 48 |
FGFR3 |
4.487e-02 | -3.10 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 2 | 19454 | 49 |
GPM6A,NTM |
4.506e-02 | -3.10 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 43 |
PCDH9,CDH20 |
4.547e-02 | -3.09 | FOXP1 (forkhead box P1) | protein interactions | 27086 | 135 | 2 | 19454 | 49 |
SOX5,NFIA |
4.547e-02 | -3.09 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 49 |
CAMK2G,ABLIM1 |
4.576e-02 | -3.08 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 47 |
PITPNC1 |
4.576e-02 | -3.08 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 47 |
RYR3 |
4.581e-02 | -3.08 | AMP-binding_C | pfam domains | PF13193 | 17 | 1 | 17795 | 49 |
ACSS1 |
4.581e-02 | -3.08 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 49 |
DTNA |
4.629e-02 | -3.07 | Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | Pathway Interaction DB | hif1apathway | 15 | 1 | 2226 | 7 |
HIF3A |
4.629e-02 | -3.07 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 4 | 16828 | 48 |
RYR3,GPC5,GPM6A,PAMR1 |
4.643e-02 | -3.07 | positive regulation of myelination | biological process | GO:0031643 | 18 | 1 | 18204 | 48 |
PARD3 |
4.643e-02 | -3.07 | non-proteinogenic amino acid catabolic process | biological process | GO:0170044 | 18 | 1 | 18204 | 48 |
PRODH |
4.643e-02 | -3.07 | positive regulation of circadian rhythm | biological process | GO:0042753 | 18 | 1 | 18204 | 48 |
RORA |
4.643e-02 | -3.07 | receptor catabolic process | biological process | GO:0032801 | 18 | 1 | 18204 | 48 |
ZNRF3 |
4.643e-02 | -3.07 | negative regulation of sodium ion transport | biological process | GO:0010766 | 18 | 1 | 18204 | 48 |
ATP1A2 |
4.643e-02 | -3.07 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 48 |
CTNND2 |
4.659e-02 | -3.07 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 49 |
FBXL7 |
4.659e-02 | -3.07 | Leu-rich_rpt_4 | interpro domains | IPR025875 | 18 | 1 | 18521 | 49 |
LRIG1 |
4.661e-02 | -3.07 | cell division | biological process | GO:0051301 | 516 | 4 | 18204 | 48 |
FBXL7,SOX5,PARD3,PARD3B |
4.669e-02 | -3.06 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 48 |
GPM6A |
4.669e-02 | -3.06 | postsynaptic specialization, intracellular component | cellular component | GO:0099091 | 19 | 1 | 19108 | 48 |
TNIK |
4.669e-02 | -3.06 | cation-transporting ATPase complex | cellular component | GO:0090533 | 19 | 1 | 19108 | 48 |
ATP1A2 |
4.669e-02 | -3.06 | astrocyte projection | cellular component | GO:0097449 | 19 | 1 | 19108 | 48 |
SLC1A2 |
4.669e-02 | -3.06 | TBL1X (transducin beta like 1 X-linked) | protein interactions | 6907 | 137 | 2 | 19454 | 49 |
SOX5,NFIA |
4.671e-02 | -3.06 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 3 | 14470 | 43 |
RYR3,DTNA,SPARCL1 |
4.681e-02 | -3.06 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 49 |
GPM6A |
4.681e-02 | -3.06 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | INKA1 (inka box actin regulator 1) | protein interactions | 389119 | 19 | 1 | 19454 | 49 |
ZBTB20 |
4.681e-02 | -3.06 | NLGN1 (neuroligin 1) | protein interactions | 22871 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.681e-02 | -3.06 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 49 |
DTNA |
4.681e-02 | -3.06 | C3orf62 (chromosome 3 open reading frame 62) | protein interactions | 375341 | 19 | 1 | 19454 | 49 |
ATP1A2 |
4.681e-02 | -3.06 | RRAD (RRAD, Ras related glycolysis inhibitor and calcium channel regulator) | protein interactions | 6236 | 19 | 1 | 19454 | 49 |
CAMK2G |
4.681e-02 | -3.06 | Mtx1 (metaxin 1) | protein interactions | 17827 | 19 | 1 | 19454 | 49 |
CAMK2G |
4.681e-02 | -3.06 | LTC4S (leukotriene C4 synthase) | protein interactions | 4056 | 19 | 1 | 19454 | 49 |
CAMK2G |
4.681e-02 | -3.06 | SYT7 (synaptotagmin 7) | protein interactions | 9066 | 19 | 1 | 19454 | 49 |
NRXN1 |
4.695e-02 | -3.06 | cell communication | biological process | GO:0007154 | 5010 | 19 | 18204 | 48 |
RORA,TNIK,DTNA,ATP1A2,FGFR3,RYR3,PITPNC1,ZNRF3,SLC1A2,PARD3,CAMK2G,BMPR1B,PRODH,SORBS1,CTNND2,NRXN1,SPARCL1,NFIA,SLC1A3 |
4.730e-02 | -3.05 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 2 | 19454 | 49 |
NFIA,SOX5 |
4.734e-02 | -3.05 | NAD+ Signalling and Aging | SMPDB pathways | SMP0084271 | 11 | 1 | 1369 | 6 |
RORA |
4.742e-02 | -3.05 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 48 |
FGFR3 |
4.742e-02 | -3.05 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 48 |
FGFR3 |
4.765e-02 | -3.04 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 49 |
DTNA |
4.789e-02 | -3.04 | Ser/Thr_kinase_AS | interpro domains | IPR008271 | 308 | 3 | 18521 | 49 |
CAMK2G,BMPR1B,TNIK |
4.792e-02 | -3.04 | KRTAP9-3 (keratin associated protein 9-3) | protein interactions | 83900 | 139 | 2 | 19454 | 49 |
NTM,SLC25A18 |
4.802e-02 | -3.04 | ductal_carcinoma | COSMIC cancer mutations | ductal_carcinoma | 15798 | 48 | 16828 | 48 |
ACSS1,AHCYL2,RYR3,SLC1A2,PARD3B,PRODH,SORBS1,SPARCL1,SFXN5,LSAMP,PITPNC1,NFIA,NKAIN3,MEIS2,SLC4A4,GPM6A,SOX5,RFX4,PTGDS,ATP1A2,LRIG1,BMPR1B,ZNRF3,CTNND2,SLC25A18,CAMK2G,ABLIM1,DTNA,SLC1A3,TNIK,NPAS3,PCDH9,NRXN1,ATP13A4,CDH20,GLIS3,ZBTB20,MSI2,HIF3A,RORA,NTM,FGFR3,PAMR1,NHSL1,PARD3,COL5A3,GPC5,FBXL7 |
4.804e-02 | -3.04 | regulation of sequestering of calcium ion | biological process | GO:0051282 | 133 | 2 | 18204 | 48 |
ATP1A2,RYR3 |
4.824e-02 | -3.03 | alkali metal ion binding | molecular function | GO:0031420 | 19 | 1 | 18094 | 47 |
ATP1A2 |
4.824e-02 | -3.03 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 47 |
BMPR1B |
4.834e-02 | -3.03 | Ser-Thr/Tyr_kinase_cat_dom | interpro domains | IPR001245 | 133 | 2 | 18521 | 49 |
BMPR1B,FGFR3 |
4.844e-02 | -3.03 | LRR_4 | pfam domains | PF12799 | 18 | 1 | 17795 | 49 |
LRIG1 |
4.848e-02 | -3.03 | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | REACTOME pathways | R-HSA-2173791 | 17 | 1 | 10285 | 30 |
PARD3 |
4.848e-02 | -3.03 | Unblocking of NMDA receptor, glutamate binding and activation | REACTOME pathways | R-HSA-438066 | 17 | 1 | 10285 | 30 |
CAMK2G |
4.848e-02 | -3.03 | CREB phosphorylation through the activation of CaMKII | REACTOME pathways | R-HSA-442729 | 17 | 1 | 10285 | 30 |
CAMK2G |
4.853e-02 | -3.03 | CEP89 (centrosomal protein 89) | protein interactions | 84902 | 140 | 2 | 19454 | 49 |
ABLIM1,PARD3 |
4.853e-02 | -3.03 | KIF7 (kinesin family member 7) | protein interactions | 374654 | 140 | 2 | 19454 | 49 |
PARD3,TNIK |
4.853e-02 | -3.03 | WDR48 (WD repeat domain 48) | protein interactions | 57599 | 140 | 2 | 19454 | 49 |
AHCYL2,FBXL7 |
4.853e-02 | -3.03 | SATB2 (SATB homeobox 2) | protein interactions | 23314 | 140 | 2 | 19454 | 49 |
SOX5,NFIA |
4.860e-02 | -3.02 | sulfur compound metabolic process | biological process | GO:0006790 | 311 | 3 | 18204 | 48 |
AHCYL2,ACSS1,SLC1A2 |
4.866e-02 | -3.02 | calcium ion transmembrane transporter activity | molecular function | GO:0015085 | 136 | 2 | 18094 | 47 |
GPM6A,RYR3 |
4.869e-02 | -3.02 | establishment of cell polarity | biological process | GO:0030010 | 134 | 2 | 18204 | 48 |
PARD3,PARD3B |
4.895e-02 | -3.02 | negative regulation of peptidyl-threonine phosphorylation | biological process | GO:0010801 | 19 | 1 | 18204 | 48 |
PARD3 |
4.895e-02 | -3.02 | cerebellar Purkinje cell layer morphogenesis | biological process | GO:0021692 | 19 | 1 | 18204 | 48 |
RORA |
4.895e-02 | -3.02 | response to potassium ion | biological process | GO:0035864 | 19 | 1 | 18204 | 48 |
ATP1A2 |
4.895e-02 | -3.02 | regulation of circadian sleep/wake cycle | biological process | GO:0042749 | 19 | 1 | 18204 | 48 |
PTGDS |
4.895e-02 | -3.02 | microvillus organization | biological process | GO:0032528 | 19 | 1 | 18204 | 48 |
TNIK |
4.895e-02 | -3.02 | excitatory synapse assembly | biological process | GO:1904861 | 19 | 1 | 18204 | 48 |
NRXN1 |
4.895e-02 | -3.02 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 48 |
NRXN1 |
4.895e-02 | -3.02 | regulation of neurotransmitter uptake | biological process | GO:0051580 | 19 | 1 | 18204 | 48 |
ATP1A2 |
4.910e-02 | -3.01 | Kinase-like_dom_sf | interpro domains | IPR011009 | 523 | 4 | 18521 | 49 |
TNIK,CAMK2G,BMPR1B,FGFR3 |
4.911e-02 | -3.01 | Znf_ZZ | interpro domains | IPR000433 | 19 | 1 | 18521 | 49 |
DTNA |
4.911e-02 | -3.01 | Znf_ZZ_sf | interpro domains | IPR043145 | 19 | 1 | 18521 | 49 |
DTNA |
4.916e-02 | -3.01 | SNTB2 (syntrophin beta 2) | protein interactions | 6645 | 141 | 2 | 19454 | 49 |
FGFR3,DTNA |
4.916e-02 | -3.01 | UPK2 (uroplakin 2) | protein interactions | 7379 | 141 | 2 | 19454 | 49 |
PCDH9,CTNNA2 |
4.916e-02 | -3.01 | MAB21L2 (mab-21 like 2) | protein interactions | 10586 | 141 | 2 | 19454 | 49 |
MEIS2,CTNNA2 |
4.921e-02 | -3.01 | OXT (oxytocin/neurophysin I prepropeptide) | protein interactions | 5020 | 20 | 1 | 19454 | 49 |
FGFR3 |
4.921e-02 | -3.01 | ZNF488 (zinc finger protein 488) | protein interactions | 118738 | 20 | 1 | 19454 | 49 |
CAMK2G |
4.921e-02 | -3.01 | BMP6 (bone morphogenetic protein 6) | protein interactions | 654 | 20 | 1 | 19454 | 49 |
BMPR1B |
4.921e-02 | -3.01 | HOXA13 (homeobox A13) | protein interactions | 3209 | 20 | 1 | 19454 | 49 |
MEIS2 |
4.921e-02 | -3.01 | ANXA13 (annexin A13) | protein interactions | 312 | 20 | 1 | 19454 | 49 |
MSI2 |
4.921e-02 | -3.01 | CCKBR (cholecystokinin B receptor) | protein interactions | 887 | 20 | 1 | 19454 | 49 |
NTM |
4.921e-02 | -3.01 | Kif1c (kinesin family member 1C) | protein interactions | 16562 | 20 | 1 | 19454 | 49 |
ABLIM1 |
4.921e-02 | -3.01 | NCAM2 (neural cell adhesion molecule 2) | protein interactions | 4685 | 20 | 1 | 19454 | 49 |
CTNND2 |
4.921e-02 | -3.01 | RNF183 (ring finger protein 183) | protein interactions | 138065 | 20 | 1 | 19454 | 49 |
PTGDS |
4.921e-02 | -3.01 | MLC1 (modulator of VRAC current 1) | protein interactions | 23209 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | ADRA1D (adrenoceptor alpha 1D) | protein interactions | 146 | 20 | 1 | 19454 | 49 |
DTNA |
4.921e-02 | -3.01 | FAM13C (family with sequence similarity 13 member C) | protein interactions | 220965 | 20 | 1 | 19454 | 49 |
AHCYL2 |
4.921e-02 | -3.01 | ADRA2C (adrenoceptor alpha 2C) | protein interactions | 152 | 20 | 1 | 19454 | 49 |
MEIS2 |
4.921e-02 | -3.01 | CACFD1 (calcium channel flower domain containing 1) | protein interactions | 11094 | 20 | 1 | 19454 | 49 |
PITPNC1 |
4.921e-02 | -3.01 | SNX20 (sorting nexin 20) | protein interactions | 124460 | 20 | 1 | 19454 | 49 |
AHCYL2 |
4.921e-02 | -3.01 | PON1 (paraoxonase 1) | protein interactions | 5444 | 20 | 1 | 19454 | 49 |
SFXN5 |
4.930e-02 | -3.01 | CNH | smart domains | SM00036 | 14 | 1 | 9717 | 35 |
TNIK |
4.930e-02 | -3.01 | 4.1m | smart domains | SM00294 | 14 | 1 | 9717 | 35 |
NRXN1 |
4.936e-02 | -3.01 | - | gene3d domains | 2.60.120.1000 | 17 | 1 | 14470 | 43 |
COL5A3 |
4.943e-02 | -3.01 | human chr2p12 | chromosome location | human chr2p12 | 27 | 1 | 26134 | 49 |
CTNNA2 |
4.952e-02 | -3.01 | adrenal_cortical_carcinoma | COSMIC cancer mutations | adrenal_cortical_carcinoma | 2256 | 11 | 16828 | 48 |
SOX5,RFX4,SLC1A2,MEIS2,ZNRF3,CTNND2,ZBTB20,PCDH9,NHSL1,ATP1A2,LRIG1 |
4.954e-02 | -3.01 | DCAF7 (DDB1 and CUL4 associated factor 7) | protein interactions | 10238 | 328 | 3 | 19454 | 49 |
SOX5,BMPR1B,PARD3 |
4.961e-02 | -3.00 | testis-germ_cell_tumour-non_seminoma | COSMIC cancer mutations | testis-germ_cell_tumour-non_seminoma | 487 | 4 | 16828 | 48 |
TNIK,CAMK2G,BMPR1B,FGFR3 |
4.963e-02 | -3.00 | medullary_carcinoma | COSMIC cancer mutations | medullary_carcinoma | 290 | 3 | 16828 | 48 |
SLC1A2,PARD3B,FGFR3 |
4.963e-02 | -3.00 | thyroid-carcinoma-medullary_carcinoma | COSMIC cancer mutations | thyroid-carcinoma-medullary_carcinoma | 290 | 3 | 16828 | 48 |
SLC1A2,PARD3B,FGFR3 |
4.978e-02 | -3.00 | STRN3 (striatin 3) | protein interactions | 29966 | 142 | 2 | 19454 | 49 |
CAMK2G,TNIK |
4.983e-02 | -3.00 | PK_Tyr_Ser-Thr | pfam domains | PF07714 | 130 | 2 | 17795 | 49 |
BMPR1B,FGFR3 |
4.999e-02 | -3.00 | proton transmembrane transport | biological process | GO:1902600 | 136 | 2 | 18204 | 48 |
SLC25A18,ATP1A2 |
4.999e-02 | -3.00 | cell-matrix adhesion | biological process | GO:0007160 | 136 | 2 | 18204 | 48 |
COL5A3,SORBS1 |